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CHAPTER 1
Introduction
The activity research done during this Ph.D., was born as an overview of phar-
maceutical compounds (PhCs) in wastewaters (WWs). In particular, the aim of
this work was evaluate the occurrence of these emerging pollutants in the hospital’s
wastewaters (HWWs), considered one of the main sources of these contaminants in
the public sewage and in the environment. To do this, many water samples (with-
drawn from different kind of waters: groundwaters, surface waters, drinking waters,
urban wastewaters, hospital wastewaters, bottle waters) were analyzed in order to
investigate the problem and have more data to compare HWWs with urban ones.
The chemical’s analysis includes conventional macropollutants like BOD5, COD, SS,
N compounds. . . as well as pharmaceuticals (till 73 compounds were monitored).
Currently, in Italy and in many other countries, HWWs are assimilated to urban
eﬄuents: they are discharged into public sewage, where they are mixed with urban
wastewaters (UWWs) and then, they are conveyed to the municipal wastewater
treatment plant (WWTP), where they are co-treated.
This practice is acceptable when the eﬄuents of a small hospital discharge in a
large WWTP. In this case the dilution from the UWWs decreases the pollution load.
But if a large hospital discharges in a small WWTP and so HWWs represent a
high percentage of the total water treated, this could represent a problem. In this
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new case is important to guarantee an adequate treatment to remove all the macro
and micro pollutants that characterize HWWs.
The aim of this thesis was also to focus the attention on the appropriate treatment
in function of the eﬄuent’s kind, the flow rate and the environmental final conditions.
This is because, in general, existing WWTP was built to remove mainly conventional
pollutants, like carbon or nitrogen fraction, and not specifically for PhCs.
In Italy the only required pretreatment for HWWs is a mild chlorination, with the
objective of decrease of the bacteriological load. This came from a sanitary aspect.
In fact, in the first part of last century, there was supposed that these WWs were
really dangerous from a bacteriological point of view. Currently, in HWWs, the
concentration of bacteria and viruses (excluded infectious diseases department that
requires a specific account) are in the same order of magnitude of the urban ones.
For this reason, a chlorination of a raw WW (with all the problems facing in this
practice, it can cause during the formation of secondary compounds substances like
trihalomethane THM and other) is a useless practice if the hospital eﬄuent have to
be discharged in a public sewage or co-treated in a biological WWTP.
On the basis of our studies, the local sanitary authority stopped the chlorination of
raw HWWs to the health structures of Ferrara’s Province. All the Emilia-Romagna
Region is discussing about this, in order to stop this expensive and environmental
dangerous practice.
1.1. Topic and aims
An important aspect of this thesis is about the building of the new Ferrara’s Hospital.
It is a structure designed for 900 beds, 5 km far from the town. At this moment The
hospital of Ferrara is located in the center of the town, and the WWs deriving from
this structure are mixed with the UWWs and discharged in the Ferrara WWTP,
designed for 130 000 inhabitants equivalents (i.e.) for the urban line and for 100 000
i.e. for the industrial line (see figure 1.1 for more details).
It is easy to understand that, at present configuration, the town hospital is not
a relevant problem, because it represents only a small percentage of the total WWs
conveyed to the WWTP and it is correct to consider the Ferrara WWTP a plant
4
1.1. Topic and aims
FerraraWWTP
Po river
Ferrara
OldHospital
WWTP
New Hospital
Gualdo
Surface Water Network
Roads
2 km
N
Figure 1.1.: Map of the Ferrara zone with the old and new hospital under
construction
treating only UWWs.
But, in the configuration of the new hospital, the WWTP will work with a mixed
WWs deriving from a small town, and the contribution of the hospital will increase
in a variable percentage: from 16% to 70%.
In this circumstance it is correct to consider the WWTP a dedicated plant for
the hospital. For this reason it is important to adopt all the possible technologies
to limit the final environmental impact of this particular eﬄuent.
The new Hospital is under construction and, for this reason, the research about
the characterization of the HWWs was made in Ferrara Hospital and in another new
hospital in Lagosanto, 30 km far from Ferrara, with a capacity of 300 beds, that
discharge his WWs in a WWTP mixed with UWWs.
For these reasons this thesis does not focus the attention on the new Hospital, it
tries instead to create different backgrounds in the managements of its WWs.
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1.2. Structure of this thesis
This work is divided into 6 chapters (including this introduction and the conclusions)
and 5 appendixes. To the end of the topic, there is a complete Bibliography with
almost 300 citations.
All the chapters are divided, where possible, in two parts: the first one is on the
literature aspects of the treated argument, and the second one is on the (original)
experimental investigations performed about the specific topic treated in that chap-
ter. In fact, more than 6 experimental investigations were carried out in these years
of study.
Chapter 2 explains the diffusion of PhCs into the environment. It starts from a
literature’s basis that explains the occurrence, fate of PhCs, the health risk and the
consequent ecotoxicological effects; the experimental investigation regards different
samples taken from surface waters of Po River, groundwaters (GW) from the first
aquifer below the Po River and drinking waters (DW) at different steps of the
Ferrara’s waters work.
The aim of this chapter is investigate the occurrence of PhCs in the environment
(by comparing our conclusions to the literature results) and verify if the treatments
adopted at water works of Ferrara, could guarantee a sufficient removal of the in-
vestigated compounds.
Chapter 3 represents the central chapter (the core chapter) of this work. It refers
to hospital and urban eﬄuents, it compares these two kinds of WWs in terms of flow
rates and concentration and loads of conventional macroparameters (mainly BOD5,
COD, SS). It also discusses edges and disadvantages of the practice consisting in
the direct discharge of the raw hospital eﬄuents in public sewage and subsequent
co-treatment.
All these treated aspects are about the basis of literature and they compare them
data with the data that we will find in our experimental investigations. The final
part of the chapter show the analytical results done on PhCs in two real hospital
eﬄuents that have been studied (Lagosanto and Ferrara).
In this chapter are also analysed the different water consumption in the hospital
structures because for a single user (the typical user in the hospital is normally the
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patient, expressed in terms of bed) the water consumption is really different from
the usual inhabitant equivalent.
Chapter 4 explains all the experimental investigation carried out in these research
years. The chapter is divided in 6 sections.
Each section takes in consideration a different experimental investigation.
The first section regards the raw hospital eﬄuents disinfection. This kind of
treatment should not be the only and the first one but in some developing countries,
where WWTPs are not presents, hospital’s eﬄuents should be at least pre-treated by
sedimentation and disinfection before they will be discharged into the environment.
The aim of the research was evaluate the correct dose of disinfectant (peracetic
acid or hypochlorite) used for direct discharge of raw eﬄuent into the environment,
in order to avoid health and environmental risks.
The second experimental campaign was about the treatment of the raw hospi-
tal eﬄuent of Lagosanto (near Ferrara, 300 beds) where two different MBR pilot
plants (with equipped microfiltration and ultrafiltration membranes) were tested by
analysing macroparameters and some PhCs. This experimental section had the pur-
pose to compare the MBR performance with the CAS, one with respect to macro
and micro parameters.
Also the experimental campaign performed in La Spezia WWTP (north west of
Italy, see figure 1.2 to see the geografical position) compared the difference between
conventional treatments (CAS) and MBR performances, but in this case, the feed
to the plant was the UWWs. In the final part of this investigation was also tested
a final treatment with ozone.
A further investigation was done at Ferrara’s WWTP, in order to evaluate the
contribution in the removal of 73 PhCs by a CAS and a polishing treatment, that
consist in a horizontal subsurface flow system.
During this investigation in Ferrara’s WWTP, two different study steps were devel-
oped. The first one using the eﬄuent of the WWTP as influent of the CW, in order
to evaluate the final efficiency by removing the 73 studied compounds. The second
one add a mixture solution of Ciprofloxacin, Sulphametoxazole and Trimethoprin at
the influent of the natural system, with the aim of verify the efficiency of the natural
treatment with high concentration of the spiked compounds.
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Figure 1.2.: Italy map with Ferrara and La Spezia geographical position
The final section of this chapter discusses and compares the different tested tech-
nologies, with particular attention to the natural systems and to the concept of the
multibarrier system able to remove a great number of PhCs from WWs.
Chapter 5 is mainly focused about the different technologies that are able to re-
move the PhCs on the basis of a deeper literature’s research. The chapter deals the
physico-chemical treatments, the conventional and advanced biological treatments,
the nanofiltration technology, the reverse osmosis, the chlorination, a rapid overview
about ozonation and AOPs treatment, the natural polishing treatment and, to con-
clude, the photodegradation.
In the last part, the chapter presents and deals the treatment sequence adopted on
the eﬄuent of the new hospital under construction near Ferrara (900 beds), which
was also defined on the basis of the experimental investigation carried out at the
Department of Engineering of the University of Ferrara to which I took part.
In the final chapter conclusion, recommendation and suggestions are reported.
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1.3. Pharmaceutical and Personal Care Products
(PPCPs)
Pharmaceutical and Personal Care Products (PPCPs) are a set of chemical pollu-
tants resulting from pharmaceutical and products for personal hygiene. They include
a wide and diverse range of chemicals, including prescription drugs and medicines,
perfumes, cosmetics, sunscreens, cleansers, shower gel, shampoo, deodorant and
other.
Figure 1.3 shown an example of the chemical structure for some PhCs.
Figure 1.3.: Structure of some PhCs
Many drugs and cosmetic products containing substances and chemicals that are
not easily degradable, which remain biologically active, even when they are placed in
sewer networks. Among the main causes of the overload of PPCPs include hospitals,
nursing homes, veterinary clinics, farms, and not least common housing.
Residues of pharmaceuticals have been found as contaminants in wastewater, sur-
face water, groundwater and drinking water. Residues resulting from use of thera-
peutic drugs in medical care, are discharged into bodies of surface water, through
discharges of different WWTP, which acts as a source of contamination.
9
1. Introduction
Until now, the environmental assessment, for this new class of contaminants, is
not yet clear or regulated.
It is reasonable to assume that their presence in waters is not a new phenomenon,
it has become in recent decades thanks to the continuous evolution and improvement
of methods for chemical analysis that led to a lowering of detection limits for a large
number of xenobiotic compounds in environmental matrices.
Identification, analysis, and characterization of the risks posed by the presence
of PhCs in the environment, are important issues to concern within the scientific
community. Many studies have demonstrated that UWWs are the major pathway
for aquatic contamination by pharmaceuticals, since conventional WWTPs are not
able to efficiently remove some of these substances, and consequently, they are able
to enter surface and drinking waters.
1.4. Regulation
The only Italian legal requirements before the release of this WWs into public sewage
is a mild disinfection with sodium ipochloride. In some countries, disinfection was
required for the treatment of infectious diseases ward, and then all the hospital
eﬄuents were subjected to it. In Italy, Local Sewage Codes quite always require:
• a disinfection step before release into a public sewage,
• a minimum hydraulic retention time in the contact time equal to 30 mins,
• a maximum concentration of active chlorine equal to 0.3 mg L−1 in the eﬄuent
release into the sewage.
In France, in force law recommends:
• a separated sewage for HWWs,
• a screening for black WWs before release,
• a disinfection for WWs from infectious diseases wards.
Beier et al. (2011) report that in German the Ministry for the environment and
the International Association of Waterworks in the Rhine catchment area and its
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members (IAWR (2008)) set the value of 100 ng L−1 for each micropollutant in case
of direct recharge of the aquifer, and also to the recommendation of the German
Ministry for the environment. It should be considered that the mentioned target
value applies to water systems, which are part of drinking water supplies. In the
context of HWWs treatment, this target value is of interest and the treated water
is to be directly discharged into waterways, without going through the municipal
WWTP.
Moreover, depending on the daily load discharged into the public sewer, there are
limits for the hospital eﬄuent for the following:
• macropollutants: SS, BOD5, COD, total N, Total P,
• micropollutants: phenol, chromium (VI), copper and its compounds, chro-
mium and its compounds, lead, nickel, zinc, manganese, tin, iron, aluminium,
adsorbable organic alogens AOX, total hydrocarbons, fluorine.
Over the last few years, the label emerging has been applied to pollutants with
such increasing frequency that its meaning is becoming diluted. In reality, those
pollutants that are truly emerging (those that have just gained entry to the envi-
ronment - for example, because they are new to commerce) are sometimes confused
with those, whose presence has just been elucidated, but which have long been
present.
PhCs are not yet included in any priority list either in the US or in Europe. Yet
US EPA has made some progress on the lists of potential new DW contaminants
by considering herbicide degradates, e.g. atrazine-desethyl, alachlor ESA and other
acetanilide degradation products Richardson and Ternes (2005).
Daughton (2004) reports that as the power of analytical chemistry increases, the
types of chemicals that can be detected increase, and the limits of concentration
at which they can be measured are continually lowered; analytical chemistry plays
a key role in expanding and refining our ever-changing perspective of water purity.
These chemicals comprise the broad spectrum of anthropogenic chemicals (those
purposefully synthesized and indirectly produced by human activities - drinking
water disinfection byproducts are one example) as well as natural products (those
created both by natural physicochemical or biological processes an example being
geosmin, the off-flavor bicyclic alcohol produced by certain algae and fungi).
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Anthropogenic pollutants gain entry to surface and GWs as a result of manu-
facturing emissions, waste disposal (e.g., incineration, landfills), accidental releases
(e.g., spills), purposeful introduction (e.g., pesticides, groundwater recharge, sewage
sludge application to land), and consumer activity (which includes both the excretion
and purposeful disposal of a wide range of naturally occurring and anthropogenic
chemicals such as PPCPs). All of these sources but the last has long been recog-
nized as major potential routes of pollutant release. Consumer activities have only
recently been recognized as a potentially major, long-standing source of uncontrolled
nonpoint, disperse pollution.
Figure 1.4.: Some PhCs compounds
To get an idea to understand the numbers of distinct organic chemical entities
that could hypothetically be synthesized and added to a limitless, ever-expanding
known chemical universe, we consider the back-of-the-envelope calculations of Bo-
hacek et al. (1996), which yielded over 1060 distinct structures are possible with a
total of merely 30 atoms of just C, N, O, or S! Far more than 1060 structures would
be possible if the wide spectrum of other heteroatoms (including common ones such
as P or the halogens) was included, or even larger numbers of C, N, O, and S.
Clearly, there are essentially no limits to the types of possible organic chemicals.
The possibilities are only beginning to emerge from the efforts of synthetic organic
chemists or combinatorial chemistry.
Fuerhacker (2008) explains that there is an increasing threat to human health
from exposure to new forms of invisible, time-delayed and more systemic pollu-
12
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tion and chemicals. Especially effects such as cancerogenic, mutagenic and toxic
to reproduction (CMR), endocrine disrupting effects or neuro-toxicity are not yet
considered in adequate way trough assessment methods and regulatory standards
and the application of abatement technologies.
Within Europe, progress in dealing with environmental pressures has been ev-
ident in several areas; including substantial reductions in point source emissions
to water through the application of abatement technologies and through resource
substitution. Nevertheless, to meet the goals of recreational, bathing water and
drinking water use, the directives would need to be harmonized with the Water
Frame Directive (WFD) also consider microbiological substances.
Despite an explosion of published studies on occurrence, fate, and effects, emerging
contaminants discharges to surface waters, are not yet covered by WWTP regula-
tions. Especially, where water is scarce and reuse of WWs is high, treatment of
European Commission needs sufficient attention.
Fuerhacker (2008) concludes that, to answer the question if the WFD (2000/60/EC)
could reach the target, it provides a very valuable frame to approach the targets,
but there is some way to go to reach them on the EU level.
Also in Fuerhacker (2009) these arguments are treated explained that new and
existing substances threaten human health and the environment by new forms of in-
visible and time which are not yet considered in an adequate way through assessment
methods and regulatory standards and the application of abatement technologies.
One appropriate tool is REACH (Registration, Evaluation, and Authorisation of
Chemicals), which helps to control the sources. Nevertheless, to meet the goals
of recreational, bathing water and drinking water use, but also that of WFD and
the Stockholm Convention (UNEP 2008, Stockholm Convention. Available at http:
//chm.pops.int/) need to be harmonised and a continuous flexible revision process
should react on new developments after appropriate assessment of the hazard or the
risk and best available technologies (BAT) need to be developed for the application
in the Urban Wastewater Treatment Directive (UWWTD).
In substance watching the European recent legislation and the international agree-
ments there are still some gaps and also the PhCs are among excluded.
13
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Voogt et al. (2009) propose a list of 10 hight priority compounds that was extracted
from the literature review work. These compounds represent the minimum that
should be considered in any study on pharmaceuticals in water management. This
list is only based on compounds already monitored in the literature. This list include:
1. Carbamazepin
2. Sulfamethoxazole
3. Diclofenac
4. Ibuprofen
5. Naproxen
6. Bezafibrate
7. Atenolol
8. Ciprofloxacin
9. Erythromycin
10. Gemfibrozil
14
CHAPTER 2
PPCPs in the environment
This chapter, as each other, is divided in two main parts, from the section 2.1 to
the section 2.4. It describes the presence and the risks of the Pharmaceuticals and
personal care products (PPCPs) into the environment. To do this a lot of literature
data are reported in order to understand the problem and the diffusion of these
compounds.
The second part (section 2.5 and 2.6) will present the experimental investigation
results done in different water samples. In particular the analysed waters in these
sections were: surface water derived from Po river, Groundwaters (GWs) derived
from different wells and from 3 sampling point at different depth level, drinking
waters (DWs) derived from different step of the Ferrara’s water works.
The aim of this general analysis is compare the diffusion of PPCPs into the envi-
ronment (mainly surface waters and GWs) and also to discuss about the efficiency
of the drinking water treatment in Ferrara.
2.1. Background
The acronym PPCPs was coined in a review article by Daughton and Ternes (1999).
Its original intent was merely to serve as a shortcut to refer to Pharmaceuticals
and personal care products. The term was subsequently assimilated into the en-
15
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vironmental science literature, presumably for convenience. This broad collection
of substances includes any products consumed by individuals or domestic animals
for any number of countless reasons pertinent to health, performance, cognitive and
phisical function, or appearance (Petrovic and Barcelo (2007)).
The occurrence of Pharmaceuticals compounds (PhCs) in the aquatic environment
serves as a timely reminder that not only those substances traditionally target, or
those that occur on priority lists for monitoring programs, contaminate the aquatic
environment. PhCs are used by man in quantity similar to those of many pesti-
cides. It is therefore hardly surprising that once the analytical instrumentation was
established to accurately and specifically analyze for pharmaceuticals in complex
environmental matrices they have been detected.
Some of first reports on the presence of pharmaceuticals compounds in the envi-
ronment were published in 1977 in Hignite and Azarnoff (1977) and 1985 in Richard-
son and Bowron (1985), whereas the first systematic study on their occurrence in
WWTPs and rivers was conducted in Germany from Ternes (1998).
However, research efforts have to be focused on the organic pollutants with the
highest hazardous impact rather than on a blanket monitoring. There have been
several attempts to prioritize PhACs as environmental contaminants. In the United
States (US) Kolpin et al. (2002) selected 95 organic wastewater contaminants (OWCs)
among which human and veterinary PhACs, based on their wastewater entry routes
into the environment, usage quantities, human or environmental health implications,
indication of certain contamination sources or classes of compounds, and availability
of analytical methods.
The limited quantity of unpolluted water available for future use as a resource
for DW production, is one of the major challenges faced around the world, includ-
ing Europe. For instance in Mediterranean countries, limited water resources and
therefore water quality, is an important economic factor. Indirect reuse can increase
the water supply in areas in which the growth of urbanized population has exceeded
the quantity of available natural water sources (Ternes and Joss (2006)).
Currently, many communities in Europe and world - wide, use water resources for
drinking water production that contain a significant portion of wastewater. So far,
strategies for municipal WW treatment have hardly been focused on the elimination
16
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of organic trace pollutants, although for instance prescription and non - prescription
pharmaceuticals and personal care products (PPCPs) are produced and used by
humans in quantities that exceed thousands of metric tons annually.
Approximately 3000 different pharmaceuticals ingredients are used in the EU
today, including painkillers, antibiotics, β-blockers, contraceptives, lipid regula-
tors, antidepressants, antineoplastics, tranquilizers, impotence drugs and cytostatic
agents.
As these compounds are frequently transformed in the body, a combination of
unchanged pharmaceuticals and metabolites are excreted by humans. Human - use
pharmaceuticals enter raw sewage via urine and feces and by improper disposal.
These pharmaceuticals are discharged from private households and from hospitals
and eventually reach municipal wastewater treatment plants (WWTPs). If PPCPs
are only partially eliminated, residual quantities enter ambient waters or ground-
water. However, direct inputs into natural waters are also possible through storm
water overflow and leaks in the sewer system.
Personal care products include the ingredients of shampoos, liquid bath admix-
tures, skin care products, dental care products, soaps, sun screen agents, hair styling
products etc., which are used in enormous quantities throughout the world. In
the early 1990s their annual production exceeded 550 000 t for Germany alone
(Daughton and Ternes (1999)). Fragrances such as nitro and polycyclic musks
as well as UV blockers (e.g. methylbenzyliden camphor) and preservatives (e.g.
parabens and isothiazolin derivatives) are also included Ternes et al. (2003). In
contrast to pharmaceuticals, personal care products do not have to pass through
the human body. They enter the WWs via their regular use during showering or
bathing. Frequently they are used as components of cosmetics which mainly consist
of lipids or oils (e.g. sun creams) so that a higher lipophilicity is crucial for them.
Figure 2.1 shows the different dimension of the main pollutant parameters into
the environment.
The precautionary principle with regard to DW supply and WW treatment, how-
ever, implies an efficient removal of all potential harmful constituents. PPCPs are
frequently polar and persistent organic compounds, and furthermore possess ex-
tremely high biological potency (i.e. estrogens). However, these chemicals recently
17
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Figure 2.1.: Dimensions of the main pollutant parameters
detected in surface water and drinking water are not considered in the Drinking Wa-
ter Directive 98/83/EC. The indirect drinking water reuse (unplanned or planned) of
municipal WWTP discharges leads to an exposure of the environment and ultimately
of drinking water to these chemicals. The removal efficiency of existing wastewater
treatment must be optimized and new technologies need to be developed.
PhCs in the environment lately have been acknowledged to constitute a major
health risk for humans and members of terrestrial and aquatic ecosystems (Bendz
et al. (2005)). Human and veterinary applications are the main sources of PhCs in
the environment that are introduced primarily through excretion and the subsequent
transport in sewage, whereas direct disposal of unwanted or expired drugs in the
sewage is believed to be of minor importance Heberer (2002a).
In the comprehensive reviews (Heberer (2002a), Daughton and Ternes (1999),
Halling-Sorensen et al. (1998), Kolpin et al. (2002)), the available data on the oc-
currence of PhCs in sewage, sludge, sediments, oceans, rivers, and landfill leachate
(Holm et al. (1995)) are compiled.
In comparison with conventional priority pollutants, these substances are designed
to have specific pharmacological and physiological functions and thus are inherently
potent, often with unintended health outcomes in wildlife. Many PhCs do not
exhibit an acute aquatic toxicity but have a significant cumulative effect on the
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metabolism of nontarget organisms (Halling-Sorensen et al. (1998)) and the ecosys-
tem as a whole Daughton and Ternes (1999). Paramount among these are com-
pounds that interfere with natural hormones, i.e. endocrine disruptors, in nontarget
species that act either by design or unintended effect. Many endocrine disruptors in-
duce serious effects in low concentrations (Heberer (2002a), Halling-Sorensen et al.
(1998) and Jorgensen and Halling-Sorensen (2000)) but also individual PhCs oc-
curring in low concentrations may exhibit synergistic and cumulative effects. In
addition, the development of antibiotic resistance may be stimulated in bacteria
from exposure to low concentrations (Jorgensen and Halling-Sorensen (2000)).
2.2. Occurrence and Fate
Profound knowledge of the degradation and fate of PPCPs is important to evaluate
the elimination processes in WWTPs and to assess environmental and health risks.
Methods should be developed to enable the quantification of PPCPs in wastewa-
ter and sludge as well as the partitioning between the aqueous phase and sludge.
Furthermore, degradation of PPCPs and information on their metabolites in wastew-
ater and oxidative drinking water treatment are directly related to the efficiency of
treatment technologies.
In recent years several studies in Europe and North America were reported which
exhibited the occurrence of pharmaceuticals and estrogens in wastewater and ambi-
ent waters (Kolpin et al. (2002), Daughton and Ternes (1999), Heberer (2002a)).
In general, the concentrations of PPCPs in WWTP eﬄuents ranged from the ng
L−1 to the low µg L−1 range. In surface waters the concentrations of these com-
pounds ranged mainly between 10-500 ng L−1. Even in ground water and drinking
water PPCP residues were detected up to the µg L−1 level (Ternes and Joss (2006)).
The question arises whether these residues pose risks for aquatic ecosystems or hu-
mans.
For this reason in general pharmacologically active compounds that include both
legally used pharmaceuticals and illicit drugs, are a group of emerging environmental
contaminants, potentially hazardous compounds, that have been receiving steadily
growing attention over the last decade Kasprzyk-Hordern (2010).
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Surprisingly, there are limited data and minimal understanding of the environ-
mental occurrence, transport, fate and exposure for many pharmaceuticals and
their metabolites, despite their frequently high annual usage (Daughton and Ternes
(1999), Fent et al. (2006), Carlsson et al. (2006a), Carlsson et al. (2006b)).
Some of the most commonly used pharmaceuticals are sold in the UK in hundreds
of tonnes per year. Usage of drugs is going to increase in the future, due to the
ageing population in western countries and an increase in consumption levels in the
developing world. Illicit drugs, belonging to the same group of biologically active
compounds, have however hardly been studied in the environment (Zuccato et al.
(2008), Kasprzyk-Hordern et al. (2008)).
Pharmaceuticals and illicit drugs enter the aquatic environment, mainly through
treated (or raw) sewage from domestic households and hospitals, waste eﬄuents
from manufacturing processes and runoff. Domestic animals are the main direct
source of the environmental disposal of many veterinary pharmaceuticals (antibi-
otics, anaesthetics, etc.), as manure is very often applied to agricultural fields as a
fertiliser. Sludge from wastewater plants containing human pharmaceuticals (espe-
cially those of more hydrophobic nature) is also used as a fertiliser in agricultural
fields or transported to landfill.
Figure 2.2 shows the different concentration of the main pollutant parameters
into the environment, from the WWTPs eﬄuents to the natural rivers. The figure
includes the macroparameters as BOD5, COD, SS and microparameters as heavy
metals or PPCPs.
A huge percentage of antibiotics such as doxycycline, oxytetracycline and levo-
floxacin is excreted by the human body unchanged.
The behavior and fate of pharmaceuticals and their metabolites in the aquatic
environment is not well known. The low volatility of pharmaceuticals indicates that
distribution in the environment will occur primarily through aqueous transport, but
also via food chain dispersal. In WW treatment, two elimination processes are gener-
ally important: adsorption to suspended solids (sewage sludge) and biodegradation
(Fent et al. (2006)).
Adsorption is dependent on both hydrophobic and electrostatic interactions of the
pharmaceutical with particulates and microorganisms. Acidic pharmaceutical such
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Figure 2.2.: Concentrations of the main pollutant parameters
as the acetylsalicylic acid, ibuprofen, fenoprofen, ketoprofen, naproxen, diclofenac
and indomethacin having pKa values ranging from 4.9 to 4.1, as well as clofibric
acid, bezafibrate (pKa 3.6) and gemfibrozil occur as ion at neutral pH, and have
small tendency of adsorption to the sludge. But adsorption increases with lower pH.
At neutral pH, these negatively charged pharmaceuticals therefore occur mainly in
the dissolved phase in the WW. For these compounds and the antitumor agent ifos-
famide sorption by non-specific interactions seems not to be relevant (Kummerer
et al. (1997), Buser et al. (1998)). In general, sorption of acidic pharmaceuticals to
sludge is suggested to be not very important for the elimination of pharmaceuticals
from wastewater and surface water. Therefore, levels of pharmaceuticals in digested
sludge and sediments, are suggested to be relatively low, as was demonstrated in
several monitoring studies (Ternes et al. (2004a), Urase and Kikuta (2005)). How-
ever, basic pharmaceuticals can adsorb to sludge to a significant extent, as has been
shown for fluoroquinolone antibiotics (Golet et al. (2002)). For the hydrophobic
EE2 (logKow = 4.0) sorption to sludge is likely to play a role in the removal from
WWs (Fent et al. (2006)).
Degradation in sludge seems not significant. As a consequence, EE2 occurs in
digested sludge, where concentrations of 17 ng g−1 were reported (Ternes et al.
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(2002a)). In case a pharmaceutical is occurring mainly in the dissolved phase,
biodegradation is suggested to be the most important elimination process in WWTP.
It can occur either in aerobic (and anaerobic) zones in activated sludge treatment,
or anaerobically in sewage sludge digestion. In general, biological decomposition
of micro-pollutants, including pharmaceuticals increases with increase in hydraulic
retention time and with age of the sludge in the activated sludge treatment.
For example, diclofenac was shown to be significantly biodegraded only when the
sludge retention time was at least 8 days (Kreuzinger et al. (2004)). In contrast,
data from Metcalfe et al. (2003a) and Metcalfe et al. (2003b) indicate that the neu-
tral drug carbamazepine, which is hardly biodegradable, is only poorly eliminated
(normally less than 10%), independent from hydraulic retention times. Pharmaceu-
ticals are often excreted mainly as nonconjugated and conjugated polar metabolites.
Conjugates can, however, be cleaved in sewage treatment plants (STP), resulting in
the release of active parent compound as shown for estradiol (Ternes et al. (1999)),
and the steroid hormone in the contraceptive pill, 17α-ethinylestradiol (D’Ascenzio
et al. (2003)).
Studies on the elimination rates during the STP process, are mainly based on mea-
surements of influent and eﬄuent concentrations in STPs, and they vary, according
to the construction and treatment technology, hydraulic retention time, season and
performance of the STP. Some studies (Ternes (1998), Carballa et al. (2004)) indi-
cate elimination efficiencies of pharmaceuticals to span a large range (0-99%). The
average elimination for specific pharmaceuticals varied from only 7 to 8% for car-
bamazepine (Ternes (1998), Heberer (2002a), Clara et al. (2004)) up to 81% for
acetylsalicylic acid, 96% for propranolol, and 99% for salicylic acid (Ternes (1998),
Ternes et al. (1999), Heberer (2002a)).
Lowest average removal rates were found for diclofenac (26%), the removal of
bezafibrate was 51%, but varied significantly between STPs, and high removal rates
were found for naproxen (81%) (Lindqvist et al. (2005)). Very high total elimi-
nation of 94-100% of ibuprofen, naproxen, ketoprofen and diclofenac was found in
three STPs in the U.S.A. (Thomas and Foster (2004)). Efficient removal took place
mainly in the secondary treatment step (51-99% removal), whereas in the primary
treatment only 0-44% were removed. X-ray contrast media (diatrizoate, iopamidol,
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iopromide, iomeprol), to the contrary, were not significantly eliminated (Ternes and
Hirsch (2000)). This variation in elimination rates is not surprising, since pharma-
ceuticals form a heterogeneous group consisting of compounds with diverse chemical
properties. Independent from the chemical characteristics of the compounds, the ef-
ficiencies of various STPs also vary for the same compound due to their equipment
and treatment steps but also to other factors such as temperature and weather. For
instance, diclofenac showed largely different elimination rates between 17% (Heberer
(2002a)) and 69% (Ternes (1998)), and 100% (Thomas and Foster (2004)).
Once in surface waters, biotransformation through biodegradation occurs, but
abiotic transformation reactions are probably more important. Whereas hydrolysis
is generally negligible for environmentally relevant human drugs, photodegradation
sometimes plays an important role at the water surface. Photolysis has been shown
to be the main removal process for diclofenac in surface water (Buser et al. (1998)).
For additional pharmaceuticals (sulfamethoxazole, ofloxacin and propranolol) labo-
ratory experiments indicate direct and indirect photolysis as an important removal
process (Andreozzi et al. (2003)). Carbamazepine and clofibric acid, both com-
pounds that are marginally processed in STP, have been shown to undergo slow
photodegradation in salt- and organicfree water with estimated half-lives in the range
of 100 days at latitudes of 50 N in winter (Andreozzi et al. (2003)). The efficiency
of photodegradation depends, besides substance properties, on the strength of the
solar irradiation, and therefore on latitude and season, and on constituents present
in the water that may act as photosensitizers generating hydroxyl radicals and sin-
glet oxygen (i.e. nitrates, humic acids). Some adsorption to particles may occur.
Laboratory batch studies to characterize the sorption behavior of carbamazepine,
diclofenac and ibuprofen in sandy sediments show that sorption coefficients were
generally quite low (Scheytt et al. (2005)). Diclofenac and ibuprofen are carboxylic
acids with pKa values of 4.16 and 4.52 and these weak acids are negatively charged
at pH of ambient water and sediment.
There is no information about the bioaccumulation potential of pharmaceuticals
in biota or food webs with the exception of diclofenac, accumulating in the prey of
vultures (Oaks et al. (2004)), fluoxetine, sertraline and the SSRI metabolites norflu-
oxetine and desmethylsertraline detected in fish. Diclofenac bioconcentration factors
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were 10-2700 in the liver of fish and 5-1000 in the kidney, depending on exposure
concentrations (Brooks et al. (2005)). A few cases were reported, where pharma-
ceuticals were detected in drinking water and groundwater (Holm et al. (1995)).
Ozonation, granulated activated carbon, and advanced oxidation have been shown
as efficient removal processes. In drinking water, this has been shown for diclofenac,
while clofibric acid and ibuprofen were oxidized in laboratory experiments mainly by
ozone/H2O2 (Zwiener and Frimmel (2000)). The elimination of selected compounds
(bezafibrate, clofibric acid, carbamazepine, diclofenac) during drinking water treat-
ment, was investigated in laboratory experiments and waterworks (Ternes et al.
(2002b)). No significant removal was observed in batch experiments with sand, indi-
cating low sorption properties and persistence. Flocculation using iron(III) chloride
was ineffective, but ozonation was in some cases very effective in eliminating these
polar pharmaceuticals. However, clofibric acid was stable and not eliminated, even
with filtration using granular activated carbon, which was effective for the other
compounds. The removal of pharmaceuticals and other polar micro-pollutants, can
therefore only be assured, using more advanced techniques such as ozonation, acti-
vated carbon or membrane filtration (Ternes et al. (2002b)). However, the economic
consequences have to be evaluated carefully, before investing into these advanced
treatment technologies on a larger scale.
The drugs that have a low proportion of the parent compound excreted also
display a higher concentration in the aquatic environment, suggesting that the low
excretion proportions may represent higher recalcitrance in the environment. The
data base on PPCP concentrations in the environment is still small, but it is apparent
that the concentrations are typically low. Physico - chemical characteristics such as
solubility, logKow, and pKa are used in pharmacokinetic studies in clinical settings
and their use has been transplanted, seemingly wholesale, in predicting the behavior
of PPCPs in environmental (Jjemba (2006)).
2.3. Health Risks
The aim of this thesis is not focusing this interesting theme but I think that it is
important to speak slowly about this topic.
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Lin (2007) defines human health risk, like the probability that a given exposure
or a series of exposures may have or will damage the health of individuals exposed.
Risk is the potential for realization of unwanted adverse consequences or events.
In general terms, human health risk is the probability of injury, disease, or death
under a given chemical or biological exposure or under series of exposures.
Risk may be expressed in quantitative term (zero to one). In many cases, it can
only be described as high, low or trivial.
An important concept is that we do not live in a risk-free world, but in a chemical
world. There are more than 65 000 chemicals produced, and they are increasing
their number every year. Through use and abuse, many of those chemical products
will end up in our environment - water, air and land. These chemicals include or-
ganics and inorganics that are used in industries (including water treatment plants),
pharmaceuticals, agriculture (insecticides), home, personal cosmic purposes, etc.
Escher et al. (2011) report that, despite limitations of the toxicity estimation
model, his study gives a comprehensive picture on the risk posed by HWWs. It
allows setting priorities for further experimental testing. Interestingly (but dis-
turbingly), the PhCs likely to pose the highest environmental risk, have rarely been
investigated previously. No one, or very few experimental data, are available for
the physicochemical properties or ecotoxicity of amiodarone, ritonavir, and clotri-
mazole, the three top-risk compounds in the general hospital. In the psychiatric
center, diclofenac was among the three top-risk compounds, together with ritonavir
and clotrimazole. Diclofenac is the only one of these pharmaceuticals that is well
researched in ecotoxicology and risk assessment.
As this analysis has demonstrated, the predicted no-effect concentration (PNEC)
is generally the more important driver for the risk quotient (RQ). The reason is that
the variability in the PNEC among all pharmaceuticals investigated is more than
seven orders of magnitude, while the predicted environmental concentration (PEC)
values cover only three to four orders of magnitude among the group of 100 most
used pharmaceuticals. This means that if PhCs are selected only according to their
usage pattern and occurrence, one might miss relevant ones that could pose an envi-
ronmental risk. Therefore, consumption data are less suited to guide prioritization,
but often the only available source for compound identification. Thus hazard iden-
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tification should precede risk assessment to prioritize according to intrinsic hazard
properties such as potential for persistence, bioaccumulation, and toxicity (PBT).
The regulation for industrial chemicals in Europe, REACH, has exactly taken
this step by using a PBT assessment to identify chemicals to be prioritized for
further testing and risk assessment (EC (2006)). Following this recommendation,
the European Medicines Agency’s guideline also advises to include PBT assessment
in the prescreening phase of risk assessment of pharmaceuticals for pharmaceuticals
exceeding a logKow of 4.5 complementing the exposure estimate as trigger for refined
risk assessment (EMEA (2006)).
The ecotoxicological risk assessment is a subset of the ecological risk assessment
and can, for this reason, be treated according to an approach of the same type. Eco-
logical risk assessment is a process that evaluates the likelihood of one or more stres-
sors (EPA (1992)). This process is based on two major elements: characterization
of effects and characterization of exposure, these provide the focus for conducting
the three phases of risk assessment: problem formulation, analysis phase and risk
characterization phase (EPA (1998)).
2.3.1. Risk management
Risk management is the identification, assessment, and prioritization of risks fol-
lowed by coordinated and economical application of resources to minimize, monitor,
and control the probability and/or impact of unfortunate events or to maximize the
realization of opportunities. Risks can come from uncertainty in financial markets,
project failures, legal liabilities, credit risk, accidents, natural causes and disasters
as well as deliberate attacks from an adversary. Several risk management standards
have been developed including the Project Management Institute, the National In-
stitute of Science and Technology, actuarial societies, and ISO standards. Meth-
ods, definitions and goals, vary widely according to whether the risk management
method, are in the context of project management, security, engineering, industrial
processes, financial portfolios, actuarial assessments, or public health and safety.
The strategies to manage risk include transferring the risk to another party, avoid-
ing the risk, reducing the negative effect of the risk, and accepting some or all of
the consequences of a particular risk. Certain aspects of many risk is management
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standards have come under criticism for having no measurable improvement on risk
even though the confidence in estimates and decisions increase.
In other words, it is the process of deciding what to do about the problems.
2.3.2. Risk assessment
Risk assessment is a step in a risk management procedure. Risk assessment is
the determination of quantitative or qualitative value of risk related to a concrete
situation and a recognized threat (also called hazard). Quantitative risk assessment
requires calculations of two components of risk: R, the magnitude of the potential
loss L, and the probability p, that the loss will occur.
In other words, risk assessment is a quantitative evaluation process of health or
environmental risks determining the potential risks, associated with exposure to a
type of human hazard-physical, chemical or biological.
2.3.3. Environmental risk of PPCPs
Wells et al. (2009) shown an interesting review about all the different reports of
water quality research and management pertaining to emerging pollutants, either
chemical or biological, for which discussion of occurrence surveys, fate investigations,
treatment methodologies, modeling, and/or toxicity/risk assessment appearing in
the peer-reviewed literature during 2008, are presented.
As reported Eriksson et al. (2008) published a literature review, demonstrat-
ing that 541 xenobiotic organic compounds (XOCs) potentially could be present
in sewage sludge, due to their presence in construction materials: pharmaceuticals,
personal care products, etc.; 192 compounds have been quantified in sewage sludge,
which indicated that, although many XOCs have been measured in sludge, there
are potentially a vast number of compounds present that have not been analyzed to
date. In a hazard identification of the quantified compounds, using their inherent
properties and environmental fate, it was shown that 99 XOCs could be classified
as being hazardous with regard to the solid phase and 23 were found to be priority
pollutants in the subsequent hazard assessment.
Cooper et al. (2008) provided information on pharmaceutical threats to the en-
vironment. A preliminary risk assessment database for common pharmaceuticals,
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was created and put into a web-accessible database named Pharmaceuticals in the
Environment, Information for Assessing Risk (PEIAR) to help others evaluate po-
tential risks of pharmaceutical contaminants in the environment. Information from
PEIAR was used to prioritize compounds that may threaten the environment, with
a focus on marine and estuarine environments.
Fawell (2008) provided a commentary on determining the health risks of microcon-
stituents. He highlighted the inappropriateness of currently accepted risk assessment
methods. The author also suggested that an emerging method, the threshold of tox-
icological concern (TTC) be considered as an alternate method for dealing with
prioritization of problems associated with low level contaminants in the diet. In
addition, the importance of understanding how to deal with complex mixtures and
evaluating catchment control options as part of a holistic approach to addressing risk
priorities. The ecotoxicological hazard potential of pharmaceuticals and their hu-
man metabolites and of nanomaterials in the aquatic environment, were reviewed by
Farre et al. (2008). This work focused particularly on the metabolites and transfor-
mation products of emerging pollutants. Ecotoxicological studies of carbamazepine
and diclofenac (frequently detected in the aquatic environment) implied that acute
toxic effects are not a concern at environmental concentrations, but their chronic
and synergistic effects with other compounds need more study, also because sludge
retention time did not influence removal efficiencies of either compound.
Life cycle impact assessment (LCIA) was conducted by Munoz et al. (2008) for
98 frequently detected priority and emerging pollutants. The approach was used to
study influent and eﬄuent from a WWTP in Spain. Impact scores for two scenarios-
discharging wastewater to the aquatic environment and its use for crop irrigation-
were evaluated. The data indicated substantial reduction in ecotoxicity and human
toxicity, following treatment (42 to 85%). The pollutants causing the greatest share
of the impacts were prioritized. Ciprofloxacin, fluoxetine, and nicotine were the
primary PPCPs of concern while 2,3,7,8-TCDD, nickel, and hexachlorobenzene were
the priority pollutants of greatest impact.
Occurrence of the antibiotics roxithromycin, trimethoprim, and chloramphenicol
were studied in STP eﬄuents and surface waters of the Han River, Korea, by Choi
et al. (2008). Concentration and frequency of detection of the antibiotics were
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greater in eﬄuent samples and in samples collected during the low-flow season.
Acute standard aquatic ecotoxicity tests indicated minimal risks to aquatic systems.
Dussault et al. (2008) examined the toxicity of atorvastin (ATO), carbamazepine
(CBZ), 17α- ethinylestradiol (EE2), and triclosan (TCS) toward benthic inverte-
brate species. The toxicity data were applied in a hazard quotient approach. They
concluded that potential risks existed toward benthic invertebrates for TCS and
CBZ, however, considering low environmental concentrations, ATO and EE2 posted
negligible risk to benthic invertebrates.
Safety threshold values for pharmaceutical compounds are limited and often re-
lated to single compound-single organism toxicity studies. Many pharmaceutical
compounds have not yet been studied as extensively as others and reliable toxic-
ity data are limited to acute effects only. Cleuvers (2003) studied the toxicity of a
number of compounds to Daphnia magna including diclofenac, carbamazepine and
propranolol. The EC50 values were found to be 68, 72 and 7.5 mgL−1 respectively,
which are substantially higher in comparison to the concentrations measured in this
study at ng L−1 range. Nevertheless, it must be noted that the impact of a mixture
of these chemicals could prove more toxic than the individual compounds alone.
For example, Flaherty and Dodson (2005) found that pharmaceutical mixtures be-
haved unpredictably and caused serious side effects such as deformities and increased
mortality in D. magna.
Due to low pharmaceutical concentrations found in natural waters, their impact
in causing chronic toxicity to aquatic populations close to sewage eﬄuents is of more
importance. Recently when studying cytological effects of pharmaceuticals in rain-
bow trout (Oncorhynchus mykiss) and common carp (Cyprinus carpio), Triebskorn
et al. (2007) determined that the lowest observed effect concentrations (LOEC) for
carbamazepine and diclofenac were 1 µg L−1. Although the highest pharmaceutical
concentration (334 ng L−1 of carbamazepine) in the river Ouse is still lower than
its LOEC, the safety margin becomes relatively constrained. Furthermore, due to
the more significant impacts from mixtures of pollutants and potential persistence
of such chemicals, it is prudent that these chemicals should be monitored regularly.
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2.4. Ecotoxicological effects
Hospitals are the main sources of PhCs in a concentrated area and, together with
households and industries, can be seen as significant urban area hotspots for dis-
charging these contaminants into the sewer network and surface waters, with a po-
tential impact on human health (Kummerer (2001); Pauwels and Verstraete (2006);
Weissbrodt et al. (2008)). Many drugs used in hospitals (for instance antibiotics
and cytostatic drugs) are designed to show signs of DNA damage toward bacte-
ria or eukaryotic cells, raising concern about the human and ecological hazard of
hospital eﬄuents (Giuliani et al. (1996), Hartmann et al. (1999)). The contact
of hospital contaminants with aquatic ecosystems leads to a risk directly related
to the existence of hazardous substances (mainly disinfectants, excreted pharma-
ceuticals or their metabolites) which could have potential negative effects on the
biological balance of natural environments. This risk is defined as the probability
of appearance of toxic effects after an organism’s exposure to hazardous substances
(Rivière (1998)). The fate of pharmaceuticals in the aquatic environment has been
reported in different studies (Kummerer et al. (1997); Halling-Sorensen et al. (1998);
Heberer (2002b); Golet et al. (2002); Bendz et al. (2005); Bartels and von Tumpling
(2008)), and an ecological risk assessment has been carried out for specific com-
pounds: glutaraldehyde, a dialdehyde usually recommended as the disinfectant of
choice for reusable fiber-optic endoscopes (Jolibois et al. (2002)), specific antibiotics
(Hartmann et al. (1999); Golet et al. (2002), Kummerer and Henninger (2003)),
carmamazepine, ibuprofen, ketoprofen and naproxen (Santos et al. (2007)). How-
ever, few studies deal with the total risk resulting from simultaneous exposure to
the various pollutants present in hospital eﬄuents.
Emmanuel et al. (2005b) describes a proposal framework for the ecotoxicological
risk assessment of hospital wastewaters, and the European Medicine Agency (EMEA
(2006)) issued guidelines for the environmental risk assessment of medicinal products
for human use according to the directive EC (2003) on risk assessment for new
notified substances.
Pharmaceuticals are designed to target specific metabolic and molecular pathways
in humans and animals, but they often have important side effects too. When
introduced into the environment they may affect the same pathways in animals
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having identical or similar target organs, tissues, cells or biomolecules. Certain
receptors in lower animals resemble those in humans, others however, are different
or lacking, which means that dissimilar modes of actions may occur in lower animals.
It is important in this respect to recognize that for many drugs, their specific modes
of actions are not well known and often not only one, but many different modes of
actions occur. Among other reasons, this makes specific toxicity analysis in lower
animals difficult to perform. Despite this, toxicity experiments should be targeted
and designed for specific targets of the pharmaceutical even in lower vertebrates and
invertebrates, based on the hypothesis of similarity of modes of actions. However,
current toxicity testing is not designed in this way, rather general and established
test systems and traditional organisms according to guidelines are being used and
traditional end points such as mortality are assessed.
The current literature (Jones et al. (2002), Carlsson et al. (2006a), Carlsson et al.
(2006b), Emmanuel et al. (2005b)) about ecotoxicological effects of human pharma-
ceutical deals mainly with the acute toxicity in standardized tests and it is generally
focused on aquatic organisms. The influence of environmental parameters such as
pH on toxicity has only rarely, or not yet been investigated. Such studies would be
important for instance of acidic pharmaceuticals, that may induce different toxicities
depending on speciation at different ambient pH. Moreover, effects of drug metabo-
lites have rarely been investigated. Phototransformation products of naproxen, for
instance, showed higher toxicities than the parent compound, while genotoxicity was
not found (Isidori et al. (2005)). At contaminated sites, aquatic life is exposed over
the entire life cycle to these compounds. Chronic effects are less investigated and
often even related to relative short-term exposures. However, long-term exposures
are needed for an accurate environmental risk assessment (Fent et al. (2006)).
2.5. Experimental investigations on ground,
surface and drinking water
Starting from this section the attention is focused on the experimental analysis done
during this Ph.D. research. All the samples were analysed with the help of the CSIC
of Barcelona with the methods reported in appendix A and in Gros et al. (2009).
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In the first phase of the experimental investigation the goal was to verify the
diffusion of the different PhCs in the environment. In particular different kind
of waters were analysed, in order to completely understand the diffusion into the
surface water or into the GWs of these compounds. Moreover another important
objective of these investigations was to see the abatement capacity of the drinking
step in Ferrara water works.
The different analysed samples were:
• surface waters from Po River
• GWs down and near the Po River. The samples were taken at different depth
with specific perforation and from existing wells,
• drinking waters in different section of the Ferrara water works
All the investigated compound are reported in table 2.1. Not all the compounds
were found in all the different kinds of waters. In appendix A (from table A.1 to table
A.7) are also reported the physico-chemical properties of the 73 investigated PhCs.
Moreover in table A.11 and A.12 are reported all the compounds and their optimized
QqLIT-MS/MS Parameters by SRM negative and positive ionization mode.
Table 2.1.: Investigated pharmaceutical compounds: CAS number and formula. In paren-
thesis the number of analyzed compounds
Class Compound CAS Number Formula
Analgesics or Acetaminophen 103-90-2 C8H9NO2
anti-inflam. (12) Codeine 76-57-3 C18H21NO3
Diclofenac 15307-86-5 C14H11Cl2NO2
Ibuprofen 15687-27-1 C13H18O2
Indomethacin 53-86-1 C19H16ClNO4
Ketoprofen 22071-15-4 C16H14O3
Mefenamic acid 61-68-7 C15H15NO2
Naproxen 22204-53-1 C14H14O3
Phenazone 60-80-0 C11H12N2O
Phenylbutazone 50-33-9 C19H20N2O2
Propyphenazone 479-92-5 C14H18N2O
Salicylic acid 69-72-7 C7H6O3
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Antibiotics (25) Azithromycin 83905-01-5 C38H72N2O12
Chloramphenicol 56-75-7 C11H12Cl2N2O5
Chlortetracycline 57-62-5 C22H23ClN2O8
Ciprofloxacin 85721-33-1 C17H18FN3O3
Clarithromycin 81103-11-9 C38H69NO13
Danofloxacin 112398-08-0 C19H20FN3O3
Doxycycline 564-25-0 C22H24N2O8
Enoxacin 74011-58-8 C15H17FN4O3
Enrofloxacin 93106-60-6 C19H22FN3O3
Erithromycin 114-07-08 C37H67NO13
Josamycin 1684-24-5 C42H69NO15
Metronidazole 443-48-1 C6H9N3O3
Nifuroxazide 965-52-6 C12H9N3O5
Norfloxacin 70458-96-7 C16H18FN3O3
Ofloxacin 82419-36-1 C18H20FN3O4
Oxytetracyclin 79-57-2 C22H24N2O9
Roxithromycin 80214-83-1 C41H76N2O15
Spiramycin 8025-81-8 C43H74N2O14
Sulfadiazine 68-35-9 C10H10N4O2S
Sulfamethazine 57-68-1 C12H14N4O2S
Sulfamethoxazole 723-46-6 C10H11N3O3S
Tetracycline 60-54-8 C22H24N2O8
Tilmicosin 108050-54-0 C46H80N2O13
Trimethoprim 738-70-5 C14H18N4O3
Tylosin A 1401-69-0 C46H77NO17
Antidiabetic (1) Glibenclamide 10238-21-8 C23H28ClN3O5S
Anti-hypertensive (3) Enalapril 75847-73-3 C20H28N2O5
Hydro-chlorothiazide 58-93-5 C7H8ClN3O4S2
Lisinopril 83915-83-7 C21H31N3O5
Barbiturates (3) Butalbital 77-27-9 C11H16N2O3
Pentobarbital 76-74-4 C11H18N2O3
Phenobarbital 50-06-6 C12H12N2O3
Beta-agonists (2) Clenbuterol 037148-27-9 C12H18Cl2N2O
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Salbutamol 35763-26-9 C13H21NO3
Beta-blockers (9) Atenolol 29133-68-7 C14H22N2O3
Betaxolol 63659-18-7 C18H29NO3
Carazolol 57775-29-8 C18H22N2O2
Metoprolol 37350-58-6 C15H25NO3
Nadolol 42200-33-9 C17H27NO4
Pindolol 13523-86-9 C14H20N2O2
Propranolol 525-66-6 C16H21NO2
Sotalol 3930-20-9 C12H20N2O3S
Timolol 26839-75-8 C13H24N4O3S
Diuretic (1) Furosemide 54-31-9 C12H11ClN2O5S
Lipid regulators (7) Atorvastatin 134523-00-5 C33H35FN2O5
Bezafibrate 41859-67-0 C19H20ClNO4
Clofibric acid 882-09-7 C10H11O3
Fenofibrate 49562-28-9 C20H21ClO4
Gemfibrozil 25812-30-0 C15H2203
Mevastatin 73573-88-3 C23H34O5
Pravastatin 81093-37-0 C23H36O7
Psychiatric drugs (5) Carbamazepine 298-46-4 C15H12N2O
Diazepam 439-14-5 C16H13ClN2O
Fluoxetine 54910-89-3 C17H18F3NO
Lorazepam 846-49-1 C15H10Cl2N2O2
Paroxetine 61869-08-7 C19H20FNO3
Receptor antagonists (4) Cimetidine 51481-61-9 C10H16N6S
Famotidine 76824-35-6 C8H15N7O2S3
Loratadine 79794-75-5 C22H23ClN2O2
Ranitidine 66357-35-5 C13H22N4O3S
Antineoplastic (1) Tamoxifen 10540-29-1 C26H29NO
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2.5.1. Po River
Literature data
Greater amounts of data are available for surface waters. The number of PhCs that
have been targeted and the number of locations samples are significantly greater.
Much of these data are of North America and Europe. For example, of 18 antibi-
otics targeted in German study of river waters as reported in Hirsch et al. (1999),
a degradation product of erythromicin was detected in the highest concentration
(maximum 1.7 µg L−1), whilst four other compounds were also detected at lower
concentrations. Buser et al. (1999) reports that Ibuprofen has also been detected
in several lakes and rivers in Swizzerland at concentrations up to 7.8 ng L−1 but he
did not report the metabolites. The concentration of ibuprofen in this study were
low in comparison to studies in other countries like, for example in Ternes (1998)
where concentration of over 2000 ng L−1 have been reported.
Dilution effects are an important consideration when measuring the concentration
of pharmaceutical compounds in rivers and streams. Lipid regulators, bezafibrate
and gemfibrozil, demonstrated at 5 - 10 times dilution in rivers receiving WWTP
eﬄuent compared to the eﬄuent discharged (Ternes (1998)). Elsewhere, elevated
concentrations of drugs detected in a small tributary receiving a large contribution
of eﬄuent were rapidly diluted to near detection limits when they flowed into a large
volume river (Metcalfe et al. (2003b)) and most pharmaceuticals were only detected
in freshwater sites receiving WWTP eﬄuents. However, in the low flow system of
a smaller river, virtually no dilution was shown to occur. The hydrology of the
receiving water therefore plays an important role in the dilution of any pharmaceu-
tical substances that may be present and is specific to a given location Petrovic and
Barcelo (2007). In addition to ibuprofen, other pharmaceutical metabolites have
been detected in receiving waters. Clofibrate was not detected in rivers and streams
in a German study whereas its metabolite, clofibric acid was present in the ng L−1
range as explained in Ternes (1998). Uptake of pharmaceuticals by aquatic or-
ganisms is an important consequence of elevated pharmaceuticals concentrations in
receiving waters such as eﬄuent dominated rivers and streams. Fish in US streams
have demonstrated uptake of the antidepressant, fluoxetine, norfluoxetine, sertraline
and desmethylsertraline (Brooks et al. (2005)).
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Experimental data
The analysis about the surface water of the Po River were made on March, 23 (1st
sample), 24 (2nd sample) and 25 (3th sample), 2010. The sampling point was just in
front of Ferrara water works in order to take out some significant samples from the
inlet of this plant.
Particular attention was made to the weather condition because it was important
that the samples were taken in dry days in order to decrease the rain dilution.
These instantaneous samples were collected in 1 L plastic bottle, they were imme-
diately filtered with a 0.45 µmmembrane and refrigerated at -20 oC till the transport
and the preparation for the HPLC-MS/MS analysis in Barcelona.
Only 27 compounds (from the 73 reported in table 2.1) were detected in Po River
surface waters and the analytical results are reported in figure 2.3 and showed in
table C.2. A lot of compounds were never detected probably due to they lowest
concentration in surface waters or due to the more rapid degradation when they are
release into the environment. An important aspect of the PhCs degradation into the
environment certainly is represented from natural photo-degradation (see subsection
5.1.9 for more details about this topic).
Then, a lot of searched compounds were not detected. This is a key for the
next drinking water step. It is also very important to underline that the detected
concentration were very low, in effect the highest measured concentrations were for
the antihypertensive Hydrochlorothiazide that in the three analyzed samples was
detected with a maximum value of 118 ng L−1 (average value of 96 ng L−1). The
second highest compound detected in this waters was the β-blockers Sotalol find
with a maximum value of 84 ng L−1 and with an average of 78 ng L−1.
The average values (calculated independent from the kind of compound) of all
the detected compounds, as reported in table C.2, are quite constant in the three
samples (29, 28, 29 ng L−1) and are really very low. Moreover the sum concentration
vary from 593 ng L−1 to 756 ng L−1, so with values always lower than 1 µg L−1.
For this reason it is possible to say that the concentration of PhCs in Po River
does not represent an environmental problem. Certainly this is due to the highest
dilution of this large River that on march present an average flow rate of 1000-1200
m3 s−1.
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Figure 2.3.: Average values of the analytical results (n=3) of the experimental cam-
paign on Po River waters
2.5.2. Groundwaters
Literature data
Since the mid-1990s there have been reports of the occurrence of PhCs in groundwa-
ter. This waters can become contaminated from a number of sources, for example,
historic contamination from sites of production, runoff from agricultural land, land-
fill and wastewater eﬄuent (Heberer (2002a), Heberer et al. (1997), Holm et al.
(1995)). The disposal of industrial waste in a landfill site in Denmark has been
shown to be the source of PhCs in leachate-contaminated groundwater adjacent to
the site (Holm et al. (1995)).
A number of sulphonamide antibiotics (sulphadiazine, sulphamethiozole) were
present in groundwater samples collected at concentrations of up to 0.5 µg L−1.
The pharmaceutical contamination of groundwater around the city of Berlin in Ger-
many has been extensively investigated (Heberer (2002a), Heberer et al. (1997)).
Heberer et al. (1997) and his co-workers have reported the occurrence of clofibric
acid, phenazone, propylpenazone, carbamazepine, diclofenac, ibuprofen and fenofi-
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brate in Berlin groundwater with wastewater eﬄuent contamination being identified
as the source via surface water. In another study conducted in Germany, a number
of antibiotics compounds were identified as present in groundwater with application
of animal slurry to fields being the likely source due to runoff (Hirsch et al. (1999)).
Sulfamethoxazole was determined at a maximum concentration of 0.47 µg L−1
along with sulfamethazine that was detected at a maximum concentration of 0.16
µg L−1. However, these two compounds were only detected in 2 of the 59 samples
collected, whilst another 16 targeted antibiotics were below the detection limits of
the methods used indicating that the load of antibiotics from livestock treatment to
groundwater was small (Petrovic and Barcelo (2007)).
Experimental data
Another goal of this work was the research of the 73 PhCs reported in table 2.1 in
GWs. In particular GW derived from three different sampling points at different
levels depth were analysed. For major information about the geographical situation
and for the sampling depth see figure 2.4 and table 2.2. Figure 2.4 shows the Po
river, few km far from Ferrara, the Ferrara WWTP (north-east of the town) and
the town water works in the north of the town.
All these samples were taken in september 2009 in the middle of the Po River with
a specific perforation instrument, in order to take out water just down the river. In
this way all the samples present almost 10 m of natural sand filter.
In these samples, 36 compounds were found and the concentration were variable
from ng L−1 to µg L−1.
Table 2.2.: Sample date, name and level in GW analytical campaign
Date Sample Name Level, m
September 2, 2009 S1A 18
S1B 30
September 4, 2009 S2A 18
S2B 30
September 9, 2009 S3A 9
S3B 23
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Po River
Ferrara
0 2
km
N
Ferrara 
WWTP
44°83'N
11°62'E
Legend:
      Urban area
      Agricultural area
      Industrial area
Ferrara
Water works
To the sea
S1
S3 S2Wells
Figure 2.4.: Ferrara scheme with the three sampling point (S1, S2, S3) for the GW
analysis
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Table 2.3.: GW average and standard deviation in ng L−1 with n=6
Compounds Average Standard deviation
Acetaminophen 45 13
Atenolol 67 63
Butalbital 42 –
Carbamazepine 34 –
Chloramphenicol 20 –
Chlortetracycline 26 15
Ciprofloxacin 21 –
Diclofenac 13 –
Doxycycline 133 42
Enoxacin 12 1
Erithromycin 27 20
Fluoxetine 20 8
Indomethacine 739 662
Ketoprofen 475 232
Lorazepam 20 8
Mefenamic acid 99 45
Metoprolol 26 16
Metronidazole 39 21
Mevastatin 204 60
Naproxen 92 53
Nifuroxazide 40 31
Norfloxacin 10 1
Ofloxacin 16 5
Oxytetracycline 45 31
Pentobarbital 27 11
Phenobarbital 32 24
Phenylbutazone 26 18
Pravastatin 31 20
Propyphenazone 13 –
Salicylic acid 36 4
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Sotalol 15 –
Sulfadiazine 13 –
Sulfamethazine 71 6
Sulfamethoxazole 11 1
Tetracycline 50 43
Timolol 16 6
Table 2.3 shows the average values and the standard deviation values for the
detected compounds in these water sample. For all the analytical results in the
different sampling point see table C.3.
Watching the results it is possible to find an accumulation of some substances like
for example Indomethacine. Probably this substance find, at 18 m depth, particular
aerobic or anaerobic characteristics that cause her accumulation.
Indomethacine is detected at large concentration if compared with the other PhCs.
In fact the concentration of this compound vary from 120 ng L−1 in S2, at 30 m
depth, to 1983 ng L−1 in S1, at 18 m.
The hight presence of this and other substances may be due to the punctual and
statical sampling extraction. In fact, in order to compare a continuous sampling
extraction, water derived from a mixture of wells continuously used to produce
drinking waters were analysed. This sample were taken on march 23, 2010 in an
instantaneous sample.
Comparing table C.3 with table C.4 it is clear that a continuous sampling of the
GWs can improve the water quality due to the fact that there are not point of
accumulation.
Paying the attention in the table C.4 and in figure 2.5 it is possible to see tat
only 10 compounds were detected and that the concentrations were really slow if
compared with those in S1, S2 and S3. In this case the PhCs concentration in wells
waters are completely comparable with those in surface waters.
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Figure 2.5.: Results of the analysis on the PhCs in the Ferrara wells
2.5.3. Drinking waters
Literature data
In summer 2004, the Observer newspaper in the UK incorrectly reported the alarm-
ing news that prozac (fluoxetine) had been detected in UK drinking water (Petrovic
and Barcelo (2007)). Alarming as this headline may sound, there have been reports
of the occurrence of pharmaceuticals in water intended for human consumption (Ta-
ble 2.4). Again, occurrence alone may not be a problem since the doses may be well
below those required to exert any effect. Potable water treatment is also important
since the presence of any contaminant in source water does not mean that it will be
present in potable water supplies. It is therefore the effectiveness of any treatment
process, if present, that is key to the presence of PhCs in drinking water.
In the early 1990s, clofibric acid, the pharmacologically active metabolite of blood
lipid-regulating drugs used in human medical care, was detected in ground- and
drinking water samples collected in Berlin, Germany (Heberer and Stan (1997)).
This initial discovery was due to the structural similarity between clofibric acid and
the herbicide mecoprop. In Berlin, concentrations of up to 165 ng L−1 have been
reported, whilst concentrations of between 25 and 100 ng L−1 have been reported in
drinking water collected from The Netherlands (see table 2.4 in wich the data refers
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to: Heberer and Stan (1997), Heberer et al. (2002),Stackelberg et al. (2004), Stolker
et al. (2004), Reddersen et al. (2002)). Finding clofibric acid in the drinking water
of Berlin promted further investigation into the groundwater wells and how PhCs
were entering them (Heberer et al. (1997)). Additional work focused on whether
other PhCs were occurring in Berlin groundwater and present in drinking water
following treatment (Heberer (2002b)). In addition to clofibric acid, carbamazepine,
primidone, phenadazone, propylphenadazone and diclofenac have been detected in
samples of Berlin drinking water as reported in table 2.4. Elsewhere in Germany,
17-α-ethynylestradiol has been detected at < 1 ng L−1 concentrations, whilst also in
Berlin, phenazone drugs and their metabolites have been detected in drinking water
samples at concentrations of up to 900 ng L−1.
Outside of Germany, carbamazepine has also been detected in drinking water
samples collected from the US and the Netherlands. In the US, dehydronifedipine
has also been reported to occur in drinking water samples, whilst in the Netherlands
the occurrence of acetyl(salicyclic acid), the widely used non-prescription analgesic
commonly known as aspirin, and the antibiotic, sulfamethoxazole, have been re-
ported.
Table 2.4.: Examples of PhCs that have been shown to occur in drinking water
Substance Highest Location
concentration
(ng L−1)
Carbamazepine 258 USA
20 Germany
< 25 The Netherlands
Dehydronifedipine 4 USA
Clofibric Acid 165 Germany
25-100 The Netherlands
Primidone 15 Germany
Phenadazone 400 Germany
AMDOPH* 900 Germany
Diclofenac < 10 Germany
Acetyl(salicyclic acid) 25-100 The Netherlands
Sulfamethoxazole < 25 The Netherlands
* 1-acetyl-1-methyl-2-dimethyl-oxamoyl-2-phenylhydrazide
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Experimental data
The Ferrara water works is located in the north zone of the town and it takes water
from the Po River as reported in figure 2.4. It presents a maximum water production
capacity of 1.2 m3 s−1. In general the average load is approximately 0.9 m3 s−1 and
the water is taken for the 80% from surface Po River and for the other 20% from
different wells near the plant.
The DW is obtained with different step of treatment and the treatment is different
for waters derived from Po River and water taken out from the wells.
Figure 2.6 shows the treatment step used in Ferrara water works to produce DW
from two different kind of waters.
surface water Wells mixture
↓ ↓
Pumping Pumping
↓ ↓
↓ Oxidation
↓ ↓
Sedimentation Sedimentation
↓ ↓
Lagooning ↓
↓ ↓
Clariflocculation ↓
↓ ↓
Sand filtration Sand filtration
↓ ↓
Ozonization ↓
↓ ↓
AC filtration AC filtration
↓ ↓
Chlorination Chlorination
↓ ↓
Distribution
Figure 2.6.: Water works step in Ferrara
In order to understand the abatement capacity of the step used in the Ferrara wa-
ter works, some samples were taken after lagooning, clariflocculation, ozonization,
Activated Carbon (AC) filtration, and chlorination (this samples represent the ef-
fective tap water distributed in Ferrara). Only one instantaneous sample was taken
for each sampling point attending the respect of the hydraulic retention time of each
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step. The samples were taken on March 23, 2010.
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Figure 2.7.: Analysis of the different samples in Ferrara water works
Table C.5 and figure 2.7 shown the analytical results of all the samples taken on
march 2010 after all the main water works step. In particular 21 compounds were
detected with a maximum concentration of 173 ng L−1 (for the receptor antagonist
Ranitidine) and the passage through the potable treatment plant of Ferrara guaran-
tee a high removal rate of all compounds. In fact, if all the detected compounds are
added the concentration pass from 694 ng L−1 after the lagooning step to 42 ng L−1
for the potable water where only 2 compounds were detected (the antidepressant
Paroxetine and the analgesic Salicylic acid, commonly known as aspirin). It is also
interesting to underline that, as reported from a lot of literature data (Broseus et al.
(2009), Hua et al. (2006), Ikehata et al. (2006)), the conjugation from ozone and
AC can rapidly degrade, transform and remove the PhCs from the water.
An important aspect to point out is about the increasing of the concentration
of some compounds after the passage through the water works step. For example
results about Ranitidine (report in table C.5, or in figure 2.7) shown that a clar-
iflocculation may decrease the concentration of this substance from 173 to 21 ng
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L−1 and ozonization till 12 ng L−1 but a passage through AC filtration cause an
increase till 18 ng L−1. This is probably due to the uncorrect calculation or the not
exactly respect of the HRT but we are really talking about very small concentration
of difference.
Analysis on bottle waters were made but in these samples PhCs were never de-
tected.
2.6. Discussion
It is really difficult to discuss and compare all this different kind of waters, both for
the different detected compounds and for the different water quality. In reality it is
uncorrect to compare this different water matrix, but in order to understand what
happens in the environment all the results are here reported.
Table 2.5.: Average and sum concentration of each sampling point (ng L−1)
Compounds GW Po Wells Lag. Clarifl. Ozon. AC filtr. DW
Detected, n 36 27 10 21 15 6 3 2
Average 106 28 34 33 23 24 25 21
Sum 2194 754 344 694 339 145 76 42
Table 2.5 try to compare the analytical results and to explain that the drinking
water processes improve the water quality also towards PhCs. Table shows that
GWs samples present a hight concentration of the detected PhCs. This is not a
really problem because, comparing these results with the wells results it is clear,
that a stationary situation, cause an accumulation of the pollutants in the GW. The
continuous withdrawal of water, may decrease the concentration of the pollutant,
as happened in the wells. Moreover, referring to the GW analysis (table C.3), it
is clear, that all the concentration of these PhCs, is due to only 4 different com-
pounds Indomethacine, Ketoprofen, Mevastatin and Doxycycline that, if summed,
represents more than 70% of the total concentration. Perhaps in these particular
points it is present a particular accumulation of these substances due to specific
circumstances like stability, aerobic or anaerobic conditions.
The detected compounds decrease, passing from the GWs (36 compounds) to the
Po River waters (27 compounds) until the wells waters (10 compound detected).
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This means that, in general, the accumulation of the PhCs in GWs is possible but
the aerobic, anoxic or anaerobic conditions in this particular sites can differ a lot
and can vary from point to point.
Ying et al. (2008) for example conclude that PhCs are not likely to persist in an
aerobic sand aquifer. The analyzed compounds in Ying et al. (2008) study were
all degraded by GW microorganisms present in the aquifer tested under aerobic
conditions. Contrasts between attenuation in GW or in a synthetic eﬄuent and
GW mixture were not consistent between PhCs. Some PhCs degraded the slowest
in both aerobic microcosms and it appeared that exponential decay was inhibited
beyond day 21. Under anoxic conditions, other PhCs were persistent over the time of
the experiments, indicating that these compounds would not be likely to be removed
into an aquifer where reduced redox conditions prevail within the storage zone.
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CHAPTER 3
Hospital and Urban wastewaters
This chapter will present the real aim of this work, the hospital wastewaters, HWWs.
Starting from a literature basis it will explain the problem connected with this kind of
WWs compared with the typical UWWs, in order to understand the real differences
between these two kind of eﬄuents. Moreover, it will present the analytical results
obtained in an experimental investigation carried out in two real hospital eﬄuents.
The studied hospital structures were:
1. Lagosanto Hospital, a 300 beds hospital located near the town of Ferrara (30
km far)
2. Ferrara Hospital, the largest hospital in Ferrara, located near the town center
and with a capacity of 900 beds
Normally HWWs are assimilated to UWWs in many countries where they are dis-
charged into municipal sewage and collected to a WWTP where they are co-treated
with urban or/and industrial eﬄuents. This practice, considers that hospital and
urban WWs are similar in terms of pollutants, concentrations and loads. Probably,
this is not a correct assumption, because these WWs are really different.
Since 1980, this assumption has been often objected and rejected (Muylle (1980),
Vanini and Gilli (1983), Pauwels and Verstraete (2006)), and analytical campaign
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have been demonstrated that the two kinds of WWs presents really different quali-
tative and quantitative characteristics (Altin et al. (2003), Kosma et al. (2010), Liu
et al. (2010), Verlicchi et al. (2010a), Verlicchi et al. (2010b)).
In fact daily HWWs flow rates range between 600-900 L bed−1 d−1 and so they
are 2-5 times higher than urban flow rates which refer to one inhabitant equivalent
(typically included in the interval 120-250 L i.e.−1 d−1).
Moreover, in hospital eﬄuents, conventional pollutant (among them BOD5, COD,
SS) are in general higher than in UWWs, as well as micropollutants contents, such
as PhCs, surfactants, mercury and others.
3.1. Sewage network in hospital structures
HWW is normally discharged directly, without pre-treatment, to sewers. Despite
mostly being only a small fraction of the total WW volume in the influent of a
WWTP, HWW has gained increasing scientific and public attention in the last
decade. This is, in part due to the observation and expectation that HWW is
a source for undesirable constituents, such as (multi-)antibiotic-resistant bacteria
(Baquero et al. (2008), Kummerer (2004)). In other publications, the emission from
hospitals was estimated for antibiotics, anaesthetics, disinfectants, heavy metals,
AOX (Adsorbable Organic Halogens), iodised X-ray contrast media and cytostatic
agents (e.g. Kummerer (2001)). The latter were also investigated in detail by Lenz
et al. (2007b). Furthermore, a number of toxicity assays were performed (Boillot
et al. (2008), Ort et al. (2010)). As a result, it has been suggested in some studies
that pre-treatment of HWW prior to discharge into the sewers provides a reason-
able solution (Gautam et al. (2007), Lenz et al. (2007b), Pauwels and Verstraete
(2006)). However, this view is not unanimously supported. The separate treatment
of HWW to reduce the development of resistant bacteria, was questioned (Kum-
merer (2009)): the substantial amount of antibiotics used outside of hospitals (in
Germany more than 75%) seems to be a plausible reason, that resistant bacteria are
also abundant in WW not receiving any HWW. Additionally, Boillot et al. (2008)
found quantitatively far fewer microorganisms in the eﬄuents of hospitals than in
UWWs, which is consistent with other studies. With regard to pharmaceuticals,
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Lenz et al. (2007b) report that 1) for some pharmaceuticals merely a small fraction
of the amounts administered in the hospital were actually found in its eﬄuent (i.e.
0.1-0.2% for doxorubicin, 0.5- 4.5% for 5-fluorouracil and 27-34% for total platinum)
and 2) a complete onsite WWTP is needed to significantly remove targeted phar-
maceuticals. This includes full physical and biological treatment steps, not only
advanced processes. Capturing all sources within a hospital (wards, laboratories)
may be further complicated by the fact, that different facilities discharge through
different pipes to the common sewer. This particularly holds true for large existing
hospital complexes.
Therefore, local circumstances need to be considered and the contribution of an
individual hospital needs to be assessed in relation to the total load in a WWTP
catchment. To our knowledge, only a few publications explicitly quantify phar-
maceutical residues (subsequently referred to as pharmaceuticals) excreted within
hospitals compared to the total pharmaceutical load in the corresponding STP influ-
ents (Feldmann et al. (2008), Heberer and Feldmann (2005), Thomas et al. (2007)).
However, these studies are limited to a small number of pharmaceuticals, or make
an assumption on the water flow instead of measuring the WWs flow, onsite to
determine actual loads.
In general, a lot of hospital structures also in Italy are very old and many subse-
quent development of these structures made a situation with old sewage, different
discharge point and unclear water flux. This involves that, for the oldest structures,
a lot of discharge point may occurs in the local sewage network and mainly a lot of
losses, due to the old hospital sewage, may cause a diffusion and a contamination of
dangerous pollutant into the environment.
Old structures in Italy are made in the town center, where may be that also the
local sewage are old and with a lot of losses. This situation can really represent
an environmental problem for the local diffusion of a lot of pollutant and a lot of
bacteria in the GWs.
These problems are overcome in those situation where hospital are built in new
town, and in general in new context, where the local network are up-to-date and
does not present any kind of losses. In general, in these context rain water are
divided from WWs. This is an important aspect in order to avoid excessive dilution
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of the WWs conveyed in public sewage and then at the WWTP.
For instance the two hospital structure studied in this research activities represent
specific example of these concept. In fact, Ferrara Hospital is an old hospital built
in the town center and this hospital presents different discharge point (at least 3)
and it does not present a separate sewage for rain and for the specific producted
WWs.
At the contrary, the new Lagosanto Hospital, built in recent years, has a new
sewage and only one discharge point. Moreover, it presents a separate sewage for
rain and for the produced WWs. In this case the management of the hospital
eﬄuents are really more easy than in the previous case, because the WWTP will
treat only WWs and not rain waters, so the biological processes will be done with
the correct concentration of biomass avoid dilution or washing with rain waters.
3.2. Nature of HWWs
It seems established that the microbial composition of the WWs produced by hos-
pitals is similar to that of urban sewage with regard to bacterial contamination of
fecal origin (Salmonella, E. coli), while differing in the presence of a greater number
of micro-organisms responsible for hospital specific infections (Pseudomonas and
Staphylococcus aureus).
With regard to the contamination of chemical and physical nature, HWWs are
certainly different from UWWs (table 3.1).
Table 3.1.: Different content of HWWs compared with UWWs (Mersi et al. (1993))
Chemical Fisical Biological
Medicines Radioactive marker Bacterial load
Chemical reactives Temperature Antibiotic-resistant bacteria
Heavy metals Pathogens
Disinfectants
Sterilizing
From a chemical point of view in a HWWs are certainly present:
• antibiotics, derived from the patient excretion
• chemical reactive, derived from the washing waters for the different wards
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• disinfectants, derived from the cleaning for hygienic purposes of the wards
The physical contamination (mainly radioactive) may derived from the physiologic
elimination from the patient treated with these compounds with therapeutic and
diagnostic purposes.
Kummerer and Henninger (2003) explain that the majority of antibiotics used are
only partially metabolized after administration, and are released via patient excreta
into the municipal sewage system. Kummerer and Henninger (2003) say that the
volume of antibiotics used in hospital and private households and released into the
municipal sewage indicate a selection pressure on bacteria. In particular resistant
bacteria could be selected by antibiotic substances present in the WWs. Steps should
be taken to reduce the risk by proper handling of antibiotics and their residues both
in hospitals and by private users.
Liu et al. (2010) speak about the SARS problem in China and explain that the
presence of pathogenic microorganisms and viruses in HWWs is a major environ-
mental and public health concern, especially following the outbreak of severe acute
respiratory syndrome (SARS) in 2003.
3.3. Common management of HWWs, effects on
public sewage
Hospital discharges represent a particular type of waste, due to the nature of the
pollutants that are present in them: the active principles of drugs or metabolites,
chemical reagents, heavy metals, disinfectants and sterilizing agents, radioactive
markers, pathogens, antibiotic-resistant strains and viruses.
Antibiotics, cytostatic agents, anesthetics, disinfectants, heavy metals (platinum
and mercury), rare elements (gadolinium, indium and osmium) have higher con-
centrations of a few orders of magnitude compared to those found in a UWWs
(Kummerer (2001)), always in a range between the ng L−1 and µg L−1.
From microbiological point of view, HWWs are similar to the urbans one for
bacterial contamination of fecal type (Salmonella, Shigella, E. coli, etc.). A difference
is about the major number of microrganisms responsable of the typical hospital
infections (Pseudomonas sup., Staphylococcus aureus) and organisms with increased
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resistance to antibiotics (from 2 to 10 times that found in UWWs) as reported in
Pauwels and Verstraete (2006). Also the viral load is a quite different parameter
from a quali-quantitative point of view. HWWs present a great number and wider
range of species, especially where there is a department of infectious diseases.
Usually these discharges are treated as UWWs (Mersi et al. (1993)). After mild
chlorination within the hospital, they are placed on public sewer and treated in
combination with the urban and/or industrial WWs, made in accordance with cur-
rent legislation, mainly in order to remove organic compounds of carbon, nitrogen
and phosphorus: substances that come regularly and in large amounts (order of
magnitudo of mg L−1) to the system.
PhCs are present in concentrations lower than the conventional macropollutants.
They include a wide range of compounds with different physical-chemical character-
istics and therefore different behaviour and fate in the WWTP.
Solubility, volatility, molecular weight, biodegradability, polarity (lipophilicity or
hydrophilicity), stability, life-time and persistence are the characteristics that deter-
mine the specific behaviour.
There are few studies that relate only to HWWs (Kummerer et al. (1997), Kum-
merer (2001), Emmanuel et al. (2001), Altin et al. (2003), Chiang et al. (2003),
Wen et al. (2004), Pauwels and Verstraete (2006), Pauwels et al. (2006), Gautam
et al. (2007)). These studies usually investigate the removal efficiency of the dif-
ferent systems regarding only a small group of pharmaceuticals compounds (only
to name a few: Heberer (2002b), Ternes et al. (2004a), Andreozzi et al. (2005),
Jones et al. (2005a), Castiglioni et al. (2006), Ternes and Joss (2006), Vieno et al.
(2007a), Heberer and Feldmann (2005)). The substances under study are frequently
dissolved, lipophilic, degradation and low volatility subsatnces.
Hospital discharges are the major source of pharmaceuticals or their metabolites in
the WWTP, although for some drugs has been found that the urban contribution is
similar or even greater than hospital one (Clara et al. (2004), Pauwels and Verstraete
(2006) and Pauwels et al. (2006)). In addition, hospital may be a diffusion source
for other dangerous substances like heavy metals. Kummerer et al. (1999) and
Kummerer and Helmers (2000) for example talk about the diffusion in the aquatic
environment of platinum and gadolinium deriving from hospital structures.
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The strategies to reduce the presence of these substances are basically three:
1. optimize existing treatments,
2. implement measures for upgrading of existing facilities through new processes
of ageing (end-of-pipe process),
3. separating the eﬄuent at the source.
This approach is based on the idea of being able to obtain an eﬄuent composition
appropriate for a specific treatment and subsequent disposal (waste design). This
involves the separation of the WWs at the source (source separation) and, where
possible, a collaboration with the manufacturing industry (source control) to reduce
(to zero) the release in the water cycle (initial contamination) (Larsen et al. (2004)).
Moreoever, the approach takes into considerations the concept that a lot of PhCs
present a hight solubility, due to their chemical characteristics and, for this reason,
they have the propensity to stay in the liquid phase (urine) and not in the solud
one (faeces) (Ternes et al. (2004b), Ternes et al. (2003), Larsen and Gujer (1996),
Lienert et al. (2007a), Lienert et al. (2007b)). For this reason, a source separation
can improve the removal efficiency of a treatment, because the concentration of
micropollutants can be higher. For more details about the source separation see
paragraph 5.3.
The studies, that have been done on hospital wastes so far, have mostly focused
on solid wastes. There have been quite detailed studies, especially on the collection,
characteristics, determination of characteristics and disposal of infectious wastes.
But only a limited number of detailed studies about complete WW treatment have
been found. The studies done on HWWs dealed mostly with the treatability of
the chemical materials used for the sterilization in these institutions. For instance,
Matsushima (1988) has proved that these WW include a lot of disinfectants such
as cresols, triclosan, chlorhexidine and benzalkonium, and pointed out that these
substances have toxic effects in active sludge systems Altin et al. (2003).
As reported, the aim of this work is to study the HWWs characteristics and their
different probable pollution impact on the environment. After a general study about
the diffusion of PPCPs in the environment, in particular in surface waters and GWs,
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but also in DWs, the attention is posed in the HWWs and in UWWs in order to
compare their characteristics.
Leprat (1998) explains that the most frequent contaminants in HWWs are viruses
and pathogenic bacteria (some of them are antibacterial resistant characters), mole-
cules from unused and excreted non-metabolized pharmaceuticals (Halling-Sorensen
et al. (1998)), organohalogen compounds, such as the halogenated organic com-
pounds adsorbable on activated carbon (AOX) (Kummerer (2001)), radioisotopes
(Erlandsson and Matsson (1978)).
Results on the microbiological characterization of HWWs (Leprat (1998)) reports
that these eﬄuents present a bacteria concentrations lower than the 108/100 mL
generally present in the municipal sewage system (Metcalfe and Eddy (1991)). The
low most probable number (MPN) detected for fecal bacteria in hospital is probably
due to the presence of disinfectants and antibiotics. Markers of viral pollution of
water, such as enterovirus and other viruses have been identified in the hospital
eﬄuents.
Studies on the bacteria flora of hospital wastewater into WWTP have shown that
bacteria acquired resistant character. Antibacterial resistancy is a threat to the ef-
ficacy of antibacterial substances. The development of resistance to antimicrobial
agents by many bacterial pathogens has compromised traditional therapeutic regi-
mens, making treatment of infections more difficult (Halling-Sorensen et al. (1998)).
Three factors have contributed to the development and spread of resistance: mu-
tation in common genes that extend their spectrum of resistance, transfer of resis-
tance genes among diverse microorganisms, and increase in selective pressures that
enhance the development of resistant organisms (Halling-Sorensen et al. (1998),
Davidson (1999), Schwartz et al. (2002)). Emmanuel et al. (2005b) explaned that
hospitals use a variety of chemical substances such as pharmaceuticals, radionuclides,
solvents and disinfectants for medical purposes as diagnostics, disinfections and re-
search (Erlandsson and Matsson (1978), Richardson and Bowron (1985), Kummerer
and Al-Ahmad (1997)). After application, some of these substances and excreted
non-metabolized drugs by the patients enter into the hospital eﬄuents (Halling-
Sorensen et al. (1998), Kummerer (2001)), which generally reach, as well as the
UWWs (see Figure 3.1), the municipal sewer network without preliminary treat-
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ment as reported in Leprat (1998).
Effluents from diagnostic and medical research activities(pharmaceuticals, radionuclides, disinfectants,detergents solvents, ...)
Domestic&industrialHospitalwastewater
Hospital sewer network
Urban sewer network
WWTP
Urbanwastewater
Surface water
Groundwater
Figure 3.1.: Problems of hospital eﬄuents, their impacts on WWTP and on natural
environments (adapted from Emmanuel et al. (2005b))
The chemical substances used in hospitals for care activities and medical research
are generally found in the WWs. Even if the high volume of generated WWs by
these establishments, ensures an important dilution of the pollutants, the discharge
of these eﬄuents in the urban sewer network or in the natural environment generates
risks for human health, and represents a significant contribution to the general con-
tamination of the environment, and more particularly of the aquatic environments.
The most important pollutants present in HWWs are pathogenic microorganism,
organohalogen compounds, such as the AOX (halogenated organic compounds ad-
sorbable on activated carbon), radioisotopes , detergents and pharmaceuticals.
In Italy (but also in other part of the world) for HWWs are not prescribed partic-
ular and specific treatment. These waters are completely assimilated to the UWWs
and in some cases this may represent a big environmental problem.
The main problem is about the dilution of the contaminants. If an hospital
discharge his eﬄuent in a public sewage all the WWs are collected in a WWTP.
In this site the treatment is generally a biological treatment as activated sludge,
designed for the removal of BOD5 and SS, but not for pathogens (Liu et al. (2010),
Koivunen et al. (2003), Chitnis et al. (2004)). In this case the dilution play an
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important role. If a large hospital with 1000 beds, discharge in a large WWTP
(with more than 100 000 i.e.), the diffusion of PhCs into the environment due to the
low biological efficiency does not represent a relevant problem.
In Ferrara the largest hospital of the town (about 900 beds) discharge in the
municipal WWTP where are collected all the WWs from the town and from the
near industrial site for a treatment capacity of more or less 240 000 i.e. In this
case HWWs are a small percentage (more or less 1%) of the total WWs presents in
the WWTP and a biological treatment designed for the urban or industrial WWs is
sufficient to minimize the hospital environmental impact.
In other cases where hospitals discharge in a small WWTP treated only UWWs the
percentage of HWWs may be higher and the environmental impact is very different.
For example if we consider Lagosanto Hospital, a small hospital with 300 beds that
discharge in a small WWTP (about 5000 i.e.), in this case the percentage of HWWs
varies from 10% to 15%.
HWWs contain a variety of toxic or persistent substances such as pharmaceuticals,
radionuclides, solvents and disinfectants for medical purposes in a wide range of
concentrations due to laboratory and research activities or medicine excretion. Most
of these compounds belong to the so called emerging contaminants; quite often
unregulated pollutants which may be candidates for future regulation depending
on research on their potential health effects and monitoring of their occurrence.
They include surfactants, PPCPs, EDC, illicit drugs, gasoline additives and many
other groups of compounds. Their main characteristic is that they do not need to
persist in the environment to cause negative effects, since their high transformation
or removal rates can be compensated for, by their continuous introduction into the
environment (Barcelo (2003)).
In recent years, increasing attention has been paid to the presence of emerging
pollutants in WWs, surface waters and ground waters (Daughton and Ternes (1999),
Heberer (2002a), Barcelo (2003), Daughton (2004), Petrovic et al. (2009)). Referring
to PhCs, large amounts of different compounds are used worldwide and, in the last
decade, their sales have been continuously increasing (Kummerer (2001), Ternes and
Joss (2006), Jjemba (2006); Lienert et al. (2007a); USEPA (2009)).
After administration, the active substances of medicaments are metabolized, but
58
3.3. Common management of HWWs, effects on public sewage
only to some extent. The unmetabolized active substances are excreted, largely in
urine and partially in faeces, as unchanged substances, as a mixture of metabolites
or conjugated with an inactivating compound attached to the molecule (Halling-
Sorensen et al. (1998), Lienert et al. (2007a)), thus entering the water cycle.
Hospitals are important sources of these compounds, but they are not the only
source: residues of pharmaceuticals can be found in all WWTP eﬄuents, due to
their inefficient removal by conventional systems (Kummerer (2001), Petrovic et al.
(2003), Carballa et al. (2004), Onesios et al. (2009)). Despite their specific nature,
quite often hospital eﬄuents are considered to be of the same pollutant load as
UWWs and are discharged into public sewer networks, collected to a WWTP and
co-treated with UWWs.
The difficulties in removing micropollutants, especially PhCs, from WWs are due
to the fact that their concentrations are in the range 10−3-10−6 mg L−1, which is
much smaller than those of conventional macropollutants (BOD5, COD, nitrogen
and phosphorus compounds. . . ). Moreover, they include a broad spectrum of com-
pounds with great differences in their main properties which affect their behavior
and fate in the WWTP: solubility, volatility, adsorbability, absorbability, biodegrad-
ability, polarity and stability. In addition, municipal WWTPs were first built, then
upgraded, with the principal aim of removing carbon, nitrogen and phosphorus com-
pounds, as well as microbiological organisms: pollutants which regularly arrive at
the WWTP in concentrations to the order of mg L−1 and at least 106 MPN/100
mL. Conventional treatments are not designed to be able to greatly remove micro-
contaminants as well.
Other Ph.D. thesis studies about hospital structures. For example in her Ph.D.
thesis Wangsaatmaja (1997) studied a general medical hospital with 538 beds.
Some interesting data are the daily average water consumption (1034 m3 d−1)
divided in hospital use with 1589 L bed−1 d−1 and dormitory purposes with a pro-
capita consume of 517 L head−1 d−1. For the water consumption in Italy and the
comments about this topic in my thesis see section 3.4.
Hazardous and Toxic Materials (HTM) Office Board of Public Works, Los Angles
(1995) estimated that around 15 percent of hospital waste is contaminated with
infectious agents potentially hazardous to human health such as hepatitis and human
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immunodeficiency virus (HIV) and to the environment.
In Thailand, the characteristics of HWWs from 21 provinces was found to be that
BOD5, SS and pH were 113 mg L−1, 103 mg L−1 and 7.17 respectively.
Wangsaatmaja’s thesis reported a comparison between the WWs of two different
hospital, the first in Indonesia and the second one in Thailand. She also reported all
the analysis done about the principals macro parameter on the water. In particular,
interesting dates are about COD, BOD5, SS, P and N.
Figure 3.2reports the different water activities as reported inWangsaatmaja (1997).
Figure 3.2.: Estimation of water uses in each activity (Wangsaatmaja (1997))
Water uses in each activity of the hospital treated in Wangsaatmaja (1997) has
been calculated by different methods. It is possible to conclude that water consump-
tion in the wards including the laboratories is the highest (331 m3 d−1) compared
with other activities. It was surprisingly known that the attendants of this hospital
have also consumed significant amount of water (156 m3 d−1) which is mainly for
toilet purposes. Total number of attendants during observation were 2600 in a day.
This is a unique case especially for a typical children’s hospital where the patients
are always accompanied by their parents during examination. Moreover, most of
inpatient parents also stay in the hospital for 24 hours. Number of attendants are
totally influenced by the number of patients.
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For several, widely applied pharmaceuticals, an individual hospital seems to be a
small additional point source in the catchment of a WWTP. In Ort et al. (2010) a
hospital with 4.4 hospital beds per 1000 i.e. contributed less than 15% to the total
load in the influent of the sewage treatment plant for 28 substances, detected in both
hospital eﬄuent and WWTP influent, which is in good agreement with estimates
from other studies. Considering a conservative worst case uncertainty estimation,
the hospital contribution only exceeded 15% for two substances, roxithromycin (max.
56%) and trimethoprim (max. 18%).
3.3.1. THM in WWs
Before entering into the municipal sewer, a chlorination is sometimes required for
the whole HWWs flow rate, sometimes only for the eﬄuent, from infectious disease
wards (Emmanuel (2004)). The common practice of co-treatment of hospital and
urban WWs, at a municipal WWTP is not considered an adequate solution by
many authors (among them: Altin et al. (2003), Pauwels and Verstraete (2006),
Vieno et al. (2007b)) because it is based on dilution of different discharges and does
not provide a segregation or separation of pollutants, and in particular of emerging
contaminants and toxic substances from the liquid phase which, is then discharged
into the environment.
The widespread medical use of chlorine disinfection is due to its very broad spec-
trum of biocide activity against bacteria, virus and fungi and simple operation.
However, this method is capable of producing undesirable disinfection by-products
(DBPs), its efficacy depends much upon the quality of the feed water and in partic-
ular low efficiency of virus removal.
There is an increasing concern about the formation of mutagenic or carcinogenic
and toxic disinfection by-products, that are potentially harmful to humans and
aquatic organisms (Monarca et al. (2000)). Chlorine-containing disinfectant for virus
removal, depends much upon the quality of the feed water. The results of study,
indicate that viruses still can be detected, despite the lower than 50 PFU/100 mL
number of E. coli, which accorded with the HWWs discharging standard (Emmanuel
et al. (2004), Sun et al. (2006)) because of their much higher tolerance, compared
to coliform or enteric pathogenic bacteria Wu et al. (1991).
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Moreover, the presence of suspended solids and organic compounds in WWs, often
makes disinfectants’ efficiency to decrease drastically (Emmanuel et al. (2005a),
Emmanuel et al. (2005b)). Therefore, many hospitals use excessive disinfectants to
ensure thorough sterilization. In the investigation conducted in China by Liu et al.
(2010), the highest residual chloride level in eﬄuent was 128 mg L−1 and the second
highest value was 103.50 mg L−1 (Cheng et al. (2004)). Statistical study showed
that the overall emission of residual chlorine of these hospitals, was about 14 400 kg
yr−1 in Jinan city, the capital of Shandong province (Cheng et al. (2004)).
Excessive residual chlorine not only increased the treatment costs of hospital
wastewater, but also caused the serious second pollution to aquatic environment
(Liu et al. (2010)).
A particular problem in HWWs treatment is the disinfection phase. The italian
regulations prescribe a disinfection of the raw HWWs, before the discharge in public
sewage. For this reason all the hospital need a chlorination plant, that have to
guarantee a contact time of 30 mins, to respect the normative.
This prescription derives from an old law that considered the hospital liquid ef-
fluent dangerous for the human health for his hight presence of bacterials and virus.
This law, in these years, is under study with the objective, to delete it because a
chlorination of a raw WW may have a high impact in the future treatments step.
In particular, if the chlorination objective is to kill all the bacterial and the virus
presents in this WW, the quantitative of this disinfectant may be very hight (more
or less 10 times more than the ammonium concentration).
An important aspect correlated with this treatment is the formation, in the WWs,
of many sub products derived from the chlorine, the trihalomethane (THM).
A lot of author are studying this important problem and an interesting study
about the formation of THM in WWs after the chlorination is Matamoros et al.
(2007b). In this work the authors compare three different chlorinated eﬄuents
adding different concentrations of chlorine dosage (2-5-16 mg L−1 of Cl2). An im-
portant conclusion is that THM concentrations observed during the 2 year study
period never exceeded quality standards applicable to drinking water.
Another important conclusion is about the role of ammonia in WWs to limit
the presence of THM, in particular Ammonia nitrogen is a key factor in achieving
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breakpoint chlorination, as its reaction with chlorine. Chlorine could react with
organic compounds present in WWs, such as amino acids from complex organic
matter, leasing to low THM formation.
In conclusion the presence of significant concentrations of ammonia nitrogen (in
the absence of nitrification processes, so in a raw WWs) ensures that the risk of
THM formation is significantly prevented.
3.3.2. The water body receptor
Another problem is about the final dilution in the environment. When a WWTP
discharge in a large river the bioaccumulation of the PhCs does not represent a
relevant problem.
For example Ferrara WWTP discharge in Volano river (an aﬄuent of the Po
River) that presents an average flow rate of 50 m3 s−1. The dilution is guarantee
from this hight difference in the flow rate between the Volano river and the eﬄuent
of the WWTP (80-100 times lower).
This hight difference in the flow rate is not so important in a small WWTP that
discharge in a small channel or river.
In the case of Lagosanto Hospital, this 300 beds hospital, convey its WWs in a
WWTP treating 5000 i.e. and finally all the treated WWs are discharged in a small
channel used in summer for irrigational uses, the dilution is not really guarantee.
In the winter season, when agriculture does not need water, this channel is dry and
the only water in this season comes from the WWTP.
This particular aspect is really important for the diffusion of PPCPs and other
pollutants in the environment and in the food chain. In this case the aspect of
bioaccumulation, not only in the animals, but also in the sludge or in the ground
near the discharge is more relevant that in the first case and the environmental
consequence will be monitored as also reported in Emmanuel et al. (2005b), EPA
(1992), Fawell (2008).
An important parameter to greatly understand the diffusion in the environment
of the emerging contaminants is the time of half life of each compound. If this time
is short the environmental accumulation is not a big problem because the compound
will degrade in a few time, but, if the half life is long the bioaccumulation and the
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persistence in the environment could be a problem (Zuccato et al. (2008), Zuccato
et al. (2010)).
Nevertheless the persistence of PhCs in the environment is a known aspect and
biologists and other scientists will study this phenomenon.
3.4. Water consumption in Hospital structures
Hospitals require a significant quantity of water per day for the different purposes
and services depending on the activities, which take place within the structure.
The quantity of WWs produced in a hospital depends on different factors: bed
numbers, hospital age, accessibility to water, general services present inside the
structure (kitchen, laundry and air conditioning), number and type of wards and
units, institution management policies and awareness in managing the structure in
safeguarding the environment, climate and cultural and geographical factors. Not all
the hospital presents all the specific uses listed above. For example, in the last years,
kitchen and laundry are not presents in all the hospital structures, that outsource
these services.
It is possible to divide the hospital water requirements in:
• production of steam for heating
• sterilization of reusable principals
• humidity environments
• use technology (eg cooling towers)
• civilian use (ie catering and sanitary)
There is not a clear correlation between specific hospital consumption (expressed
as L bed−1 d−1) and hospital size (that is bed numbers), as shown by the data
reported in figure 3.3, which refers to hospitals in different countries around the
world (C.T.C. (1994); Wangsaatmaja (1997); Laber et al. (1999); Chawathe and
Fellow (2002); Altin et al. (2003); Mohee (2005); Rezaee et al. (2005); Sarafraz
et al. (2007); Duong et al. (2008); Suarez et al. (2009); Emilia-Romagna (2009);
Mesdaghinia et al. (2009)). In this graph, data are spread between 200 and 1200
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Figure 3.3.: Water consumption per day and per bed with respect to hospital size
L bed−1 d−1 with the highest values coming from industrialized countries and the
lowest ones from developing countries, where the consumption keeps around 0.2-0.4
m3 per bed and day.
Water consumption varies during the day: with respect to the daily average flow
rate, increasing by up to +20% between 8 a.m. and 4 p.m. and decreasing to -30%
between 1 a.m. and 8 a.m. Further differences occur during the year, with higher
average values during hotter months (Joss et al. (2005); Mohee (2005); Boillot et al.
(2008); Verlicchi et al. (2008)) in part due to irrigation. Peaking coefficients for
hospital flow rates are quite similar to those generally assumed for the influent to a
small WWTP (< 10 000 population equivalent, p.e.) as reported in Tab. 3.2 (Mersi
et al. (1993); Frangipane and Pastorelli (1997)).
Table 3.2.: Peaking coefficient for hospital and urban eﬄuents
Peaking coefficient Hospital eﬄuent Urban eﬄuent
Monthly 1.5-1.8 1.2-2
Daily 2-2.8 2-5
Hourly 3.5-4 3-4
Commonly adopted values for water consumption in urban centres are in the range
of 150-300 L i.e−1 d−1 for industrialized areas, and 50-100 L i.e.−1 d−1 for developing
countries. Further literature data for specific water consumption (L pro capita−1
d−1) for commercial, institutional and recreational sources show that the rate for
hospitals is much greater than other specific consumption and that it ranges over a
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wider interval (Metcalfe and Eddy (1991)).
In case of co-treatment, hospital eﬄuent flow rate represents a percentage of the
total WWTP influent flow rate whose value depends on hospital size (small with
< 300 beds, medium with 300-700 beds and large with > 700 beds) and resident
population in the urban centre. The situation is depicted in Figure 3.4, where the
curves of hospital flow rate and urban one are drawn versus number of beds or
population equivalent.
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Figure 3.4.: Flow rates for hospital and urban centres of different size
These flow rates are based on a specific water consumption of 700 L bed−1 d−1 for
hospitals and 150 L i.e.−1 d−1 for resident populations. A large hospital of 900 beds,
producing a daily flow rate equal to 630 m3 d−1, has the same hydraulic load as an
urban centre of 4200 i.e. If this hospital is placed in a large town (for instance 100
000 i.e., 15 000 m3 d−1) and its eﬄuent is co-treated at the sameWWTP, the hospital
flow rate corresponds to 630
630+15000
· 100 = 4% of the total WWTP influent. Instead,
if the same hospital eﬄuent is collected to a small WWTP receiving UWWs from
a 2000 i.e. urban centre (300 m3 d−1), its percentage on the total WWTP influent
flow rate increases to 630
630+300
· 100 = 68%.
Figure 3.5 shows the hospital monthly consumption expressed in L bed−1 day−1,
for the Rimini Hospital, a structure that present 464 bed plus 83 day hospital bed
(in total 547 bed). The monthly water consumption in m3 month−1 are reported in
table 3.3 for the 2008.
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Figure 3.5.: Monthly Rimini Hospital water consumption L bed−1 day−1
Table 3.3.: Monthly Rimini Hospital water consumption in m3 month−1
Month m3 month−1
Jan 9887
Feb 8335
Mar 5557
Apr 10335
May 8129
Jun 13151
Jul 16153
Aug 11400
Sep 8864
Oct 6702
Nov 5698
Dec 8676
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3.5. Characteristics of HWWs and UWWs
This section will describe the characteristics and the differences between the two
kind of studied eﬄuents, hospital and urban. All the results here reported made
from a literature review. For the the experimental results about this topic see section
3.6.
3.5.1. Macropollutants
An in-depth literature review has been conducted on conventional pollutants of
WWs from hospitals of different sizes (60-900 beds), different wards and of the
following countries: France, Turkey, India, Iran, Italy, Thailand, Canada and Greece
(Nardi et al. (1995); Kummerer et al. (1997); Wangsaatmaja (1997); Laber et al.
(1999); Emmanuel et al. (2001); Altin et al. (2003); Chiang et al. (2003); Emmanuel
(2004); Brown et al. (2006); Pauwels and Verstraete (2006); Kajitvichyanukul and
Suntronvipart (2006); Gautam et al. (2007); Machado et al. (2007); Sarafraz et al.
(2007); Tsakona et al. (2007); Verlicchi et al. (2008); Mesdaghinia et al. (2009)).
Collected data for BOD5, COD and SS have been elaborated, resulting in the curves
of cumulative frequencies of occurrence (see figures 3.6, 3.7, 3.8). The grey bands
in the three graphs represent the variability ranges for each cumulative frequency
curve. Corresponding average values for BOD5, COD and SS in HWWs and medium
strength UWWs are reported in table 3.4, along with the resulting ratios. Referring
to these three parameters, and by considering their usual concentrations in the
influents to municipal WWTPs, it can be observed that in HWWs BOD5, COD and
SS keep 2-3 times higher than in UWWs.
The specific contributions for each patient are reported in table 3.4 where are com-
pared with the typical inhabitant equivalent (Metcalfe and Eddy (1991)). Hospital
values corresponding to about 2-3 times urban values.
Table 3.4.: Average values in HWWs and UWWs. Data expressed in g i.e.−1 day−1
Parameter HWWs UWWs Ratio
BOD5 160-200 60 2.6-3.3
COD, 260-300 100-120 2.5-3
SS 120-150 70-90 1.8-2.3
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Figure 3.6.: BOD5 cumulative frequency curves in HWWs and UWWs
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Figure 3.7.: COD cumulative frequency curves in HWWs and UWWs
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Figure 3.8.: SS cumulative frequency curves in HWWs and UWWs
As for other common macropollutants, typical ranges of variability as well as
average concentrations in HWWs and UWWs as derived from an analysis of the
literature data are reported in table 3.5, (Metcalfe and Eddy (1991); Nardi et al.
(1995); Laber et al. (1999); Altin et al. (2003); Emmanuel (2004); Wen et al. (2004);
Rezaee et al. (2005); Gautam et al. (2007); Sun et al. (2008); Boillot et al. (2008);
Verlicchi et al. (2008)). The ratio between the average concentrations in HWWs and
UWWs is reported in the last column. It is less than 1 for all the parameters with
the exception of chlorides, which are found in higher concentrations in HWWs than
UWWs.
3.5.2. Micropollutants
A great variety of chemical substances are commonly used in hospitals for laboratory
and research activities, in particular surgery. These not only include pharmaceuti-
cals, but also diagnostic agents and disinfectants. Consumption, use and application
of pharmaceuticals may vary considerably with time. Annually, changes in quantity
and quality of medicaments may result due to new legislation, the introduction of
new active pharmaceutical ingredients or the disappearance of others following med-
ical progress. Consumption may also differ from country to country (Schuster and
Hadrich (2008)). The main classes of compounds used in hospitals are reported in
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Table 3.5.: Other macropollutants with their typical values in HWWs and UWWs
Parameter HWW UWWRanges Average Ranges Average
pH 7.7-8.1 8 7.5-8.5 7.5
Redox pot. 850-920 890 100
mV
TKN 5-80 33 20-70
mg L−1
Total P 0.2-13 4 4-10 7
mg L−1
Fat and oil 5-60 25 50-100 75
mg L−1
Chlorides 65-360 200 30-90 50
mg L−1
Surfactantsa 3-7.2 4.5 4-8 5
mg L−1
E. coli 103-106 104 106-107 105
MPN/100 mL
FCb 103-107 105 106-108 107
MPN/100 mL
TCc 105-108 106 107-1010 108
MPN/100 mL
aTotal Surfactants; bFecal Coliforms; cTotal Coliforms
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table 3.6 (Kummerer (2001); Ternes and Joss (2006); Schuster and Hadrich (2008)),
other groups of compounds are listed in table 3.7.
Table 3.6.: Main classes of compounds used in hospitals
Class Examples
Antibiotics cefazolin, chlortetracycline, ciprofloxacin, co-
profloxacin, doxycycline, erythromycin, lin-
comycin, norfloxacin, ofloxacin, oxytetracy-
cline, penicillin, sulfamethoxazole, tetracycline,
trimethoprim
Analgesics and antinflam-
matories
codeine, diclofenac, dipyrone, ibuprofen, in-
domethacin, ketoprofen, mefenamic acid,
naproxen, paracetamol, propyphenazone, salycilic
acid
Cytostatics 5-fluorouracil, ifosfamide
Anaesthetics propofol
Disinfectants triclosan, glutaraldehyde
Rare earth elements gadolinium
Heavy metals platinum, mercury
Iodized contrast media
(ICM)
iopromide, iopamidol
The type and amount of pharmaceuticals in HWWs reflect the substances and
quantities of the particular drugs being administrated there. In the case of out-
patients, unmetabolized pharmaceuticals excretion will partially occur inside the
hospital with the remainder elsewhere, depending on the specific therapy and the
time spent at the hospital. For example, cytostatics are administrated at high
percentages in out-patients’ treatment wards, but relevant amounts of them can
also be found in the wastewater of in-patient treatment wards (Kummerer and Al-
Ahmad (1997); Kummerer et al. (1999); Lenz et al. (2007a)). Gadolinium, which
is used in magnetic resonance imaging (MRI), is 90% excreted during the hospital
stay (Kummerer and Helmers (2000)). For total invasive anaesthesia, alkylphenol
compounds are the most used, propofol in particular. These are characterized by a
high rate of excretion, on average 90% (Kummerer (2001)).
Disinfectants are used in large quantities for the disinfection of surfaces, instru-
ments and skin, in glue and size production and use, and in food processing. They
are often highly complex products or mixtures of active substances: alcohols and
aldehydes as well as chlorine-containing compounds such as recalcitrant chlorophe-
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Table 3.7.: Other classes of compounds used in hospitals
Class Examples
Psychiatric drugs, antide-
pressants, anticonvulsants
carbamazepine, gabapentin, phenytoin, valproic
acid
Antihistamines ranitidine, cimetidine
Antihypertensives diltiazem
Antidiabetics glibenclamide
β-blockers atenolol, metroprolol, propranolol, solatolol
Hormones 17-β-estradiol, estriol, estrone, ethinylestradiol
Diuretics furosemide, hydrochlorothiazide
Lipid regulators atorvastatina, bezafibrate, clofibric acid, gemfi-
brozil, pravastatin
Stimulants caffeine
Musks and fragrances tonalide, galoxolide
nols which are used as active compounds. Solutions containing glutaraldehyde are
still used in some hospital departments to disinfect reusable fiber-optic endoscopes,
however, in general there is a tendency to substitute it with other compounds with
a lower environmental impact.
The main heavy metals found in HWWs are platinum, due to excretions by on-
cological patients treated with cis-platinum and carboplatinum or other cytostatic
agents; mercury, usually found in diagnostic agents, active ingredients of disinfec-
tants as well as in diuretic agents and gadolinium, which is used in MRI due to its
high magnetic moment. Following administration, the organic complexes are very
quickly excreted unchanged. ICM exhibit a high biochemical stability and, hence,
are excreted mainly unmetabolized (above 90%). They derive from X-ray exami-
nations and radiological practices and consequently, their occurrence increases on
weekdays (Ternes and Hirsch (2000)).
Finally, adsorbable organic compounds (commonly called AOX) are compounds
which are the most persistent in the environment, and which tend to accumulate
in the food chain; often they are toxic to humans and aquatic organisms. Some
pharmaceuticals and their metabolites, may contain organic bound halogens and,
therefore, contribute to AOX emissions. In clinical wastewaters, the main contrib-
utors to the burden of total AOX are ICM. Furthermore, the release of solvents
used in laboratories, disinfectants, cleaning products and drugs containing chlorine,
contribute to a lesser extent (Gartiser et al. (1996); Kummerer et al. (1998)).
73
3. Hospital and Urban wastewaters
Figures 3.9 (data from: Ohlsen et al. (2003); Gomez et al. (2006); Thomas et al.
(2007); Foster (2007); Duong et al. (2008); Seifrtova et al. (2008); Lin and Tsai
(2009); Suarez et al. (2009)) and 3.10 (data from: Kummerer et al. (1997); Kum-
merer et al. (1998); Kummerer et al. (1999); Kummerer (2001); Mahnik et al. (2007);
Thomas et al. (2007); Foster (2007); Lenz et al. (2007b); Lenz et al. (2007a); Pauwels
et al. (2008); Verlicchi et al. (2008); Weissbrodt et al. (2008); Suarez et al. (2009))
report literature data of pharmaceuticals concentrations and other emerging pollu-
tants in hospital eﬄuents, while figures 3.11 (data from: Golet et al. (2002); Golet
et al. (2003); D’Ascenzio et al. (2003); Carballa et al. (2004); Joss et al. (2005);
Khan and Ongerth (2005); Lindqvist et al. (2005); Xia et al. (2005); Nakada et al.
(2006); Yu et al. (2006); Foster (2007); Gomez et al. (2007); Kim and Aga (2007);
Matamoros and Bayona (2006); Matamoros et al. (2007c); Matamoros et al. (2007a);
Matamoros et al. (2008); Radjenovic et al. (2007); Radjenovic et al. (2009); Ternes
and Joss (2006); Thomas et al. (2007); Santos et al. (2007); Gulkowska et al. (2008);
Huerta-Fontela et al. (2008); Spongberg and Witter (2008); Choi et al. (2008); Terzic
et al. (2008); Gros et al. (2009); Ghosh et al. (2009); Kasprzyk-Hordern et al. (2009))
and 3.12 (data from: Kummerer et al. (1997); Kummerer et al. (1998); Kummerer
et al. (1999); Kummerer (2001); Rule et al. (2006); Foster (2007); Oliveira et al.
(2007); Mahnik et al. (2007); Thomas et al. (2007); Verlicchi et al. (2008); Weiss-
brodt et al. (2008); Suarez et al. (2009)) show those found in UWWs entering a
municipal WWTP. Compounds are grouped into the different therapeutic classes
(analgesics, antibiotics, anticonvulsants, cytostatics, hormones, β-blockers, ICMs,
antihypertensives, antihistamines and lipid regulators) or according to the persis-
tent substances or elements they contain (AOX and heavy metals) or according to
their function (detergents/antiseptics). In addition, the stimulant caffeine and two
common fragrances (tonalide and galaxolide) are reported and compared in the two
kinds of WWs.
The literature data reported in these graphs generally refer to 24 h composite
water samples, thus giving the corresponding average values of the micropollutant
concentrations over the course of the day, equalizing the highest and lowest values
of their instantaneous concentrations during the 24 hours. It is worth noting that (i)
there is more literature data for UWWs than for HWWs. This is also due to the fact
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Figure 3.9.: Analgesics and antibiotics in HWWs
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Figure 3.10.: Other emerging contaminants in HWWs
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Figure 3.11.: Analgesics and antibiotics in UWWs
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Figure 3.12.: Concentrations of other classes of emerging contaminants in UWWs
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that quite often it is difficult to obtain permission to make analytical investigations
on hospital eﬄuents; (ii) for many compounds, the variability ranges are wider for
HWWs than for UWWs, as are the corresponding highest values. Using all the
collected data, (the expected) average concentrations for the different classes of
compounds were found. These are reported in table 3.8. Average concentrations in
HWWs are about 2-150 times the corresponding average concentrations in UWWs.
Table 3.8.: Ranges and average concentrations for the main classes of micropollu-
tants in HWWs and UWWs (µg L−1)
Therapeutic class HWWs UWWs HWWs
UWWs
Analgesics 100 11.9 8-15
Antibiotics 11 1.17 5-10
Cytostatics 24 2.97 4-10
β-blockers 5.9 3.21 1-4
Hormones 0.16 0.1 1-3
ICM 1008 6.99 70-150
AOX 1371 150 7-15
Gadolinium 32 0.7 35-55
Platinum 13 0.155 60-90
Mercury 1.65 0.54 3-5
3.5.3. PhCs concentrations over the course of the day
Figures 3.13 and 3.14 show the concentrations of some pharmaceutical compounds
in instantaneous HWWs samples. For most compounds, measured concentrations
keep quite low during the night and exhibit several peaks in the morning. as well as
in the afternoon, following different consumption and excretion patterns (Kummerer
et al. (1998); Kummerer et al. (1999); Kummerer and Helmers (2000); Joss et al.
(2005); Duong et al. (2008)). These significant discrepancies, with respect to the
corresponding daily average value, confirm that analytical investigations on phar-
maceutical compounds, must be performed on 24 hour composite water samples in
order to measure average concentrations for the different compounds, which would
better represent the potential impact of the HWWs.
Figure 3.15 shows that the diurnal variation pattern of several compounds is
paralleled by the nitrogen load, suggesting that human excretion is a major source
of PhCs in WWs. The fragrances studied (AHTN and HHCB) also show quite a
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Figure 3.13.: Concentrations of some pharmaceuticals in a hospital eﬄuent during
the daytime
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Figure 3.14.: Concentrations of some pharmaceuticals in a hospital eﬄuent during
the daytime
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similar daily variation pattern (Joss et al. (2005)).
Figure 3.15.: Diurnal variation of the influent load from Joss et al. (2005). The 8-h
composite samples show a similar relative variation as the flow rate
or the loads of nitrogen (Ntot), phosphorus (Ptot) or chemical oxygen
demand (CODtot). The mass flow is expressed as a relative difference
to the 24 h average
3.5.4. Hospital contribution on PhCs load
Table 3.9 taken from Beier et al. (2011) shows a mass balance reporting the propor-
tion of PhCs originating from hospitals in the UWWs.
Table 3.9.: Proportion of PhCs originating from hospitals in the UWWs
Substance Therapeutic use From the hospital (%)
Bezafibrate Lipid reducing drug 27
Bisoprolol Beta blocker 8-9
Carbamazepine Anticonvulsant drug 3-8
Clarithromycin Macrolide antibiotic 61-94
Ciprofloxacin Antibiotic 19-36
Diclofenac Anti-inflammatory drug 7-9
Ibuprofen Anti-inflammatory drug 3-7
Metronidazole Antibiotic 84
Moxifloxacin Antibiotic 34-42
Tramadol Analgesic 6-8
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Table 3.10.: Comparison between the proportion of PhCs (in percentage) originating
from hospitals in the UWWs showed in Beier et al. (2011), Ort et al.
(2010) and this study in Ferrara
Substance Beier et al. (2011) Ort et al. (2010) This study342 beds 190 beds 900 beds
Carbamazepine 3-8 0-1.3 3
Diclofenac 7-9 1 2
Ibuprofen 3-7 2.7-8.5 4
Tramadolol 6-8 1.2-6 –
As shown in table 3.10 the hospital dimension plays a significant role in the
percentage of the total PhCs originated from hospital structures.
3.6. Results of experimental investigations on
HWWs
The WWs collected from two different hospitals were analysed in order to charac-
terize and understand the effective proprieties of HWWs. In particular Lagosanto
Hospital and Ferrara Hospital were the two structures under studying.
Lagosanto Hospital is a 300 beds structure placed 30 km far from the town of
Ferrara and it presents different wards. Actually the WWs derived from this hospital
are collected and discharged into a public sewage. These eﬄuents are mixed with
the UWWs derived from the near town (about 5000 i.e.), co-treated in a common
conventional activated sludge (CAS) system and discharged in a small channel used
in agriculture.
Ferrara Hospital, located near the town center, instead, is a large hospital with
900 beds. The difference with Lagosanto Hospital beyond the different size of the
hospitals (300 beds versus 900) is due to the different capacity (230 000 i.e.) of the
final WWTP where HWWs and UWWs are co-treated.
All the samples were taken in dry season in a litre plastic bottle and immediately
prepared for the analysis. When the analysis were done in more time, all the samples
were refrigerated at -20 oC. For the analytical methods in these WWs samples the
techniques are reported in appendix A.
Tables 3.11 and 3.12 report the data of the different samples taken at the exit
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of the two hospital before the chlorination step. The first step of this study was
made in august/september 2009 and the second part (only in Ferrara Hospital) on
march 2010 in order to compare the possible differences in the concentration of PhCs
analysed due to the seasons.
In the first part of this experimentation (august september 2009) six samples were
collected, four in Lagosanto Hospital and two in Ferrara Hospital. In the second part
(march 2010) only the three samples in Ferrara HWWs were analysed.
In any case all the samples were taken in the middle of the week (Tuesday,
Wednesdy and Thursday) in order to avoid peak (in positive or in negative) in
water consumption and in the consequent PhCs concentrations. In fact it is possi-
ble that on Monday (or on Friday) the water consumption vary due to the presence
of the week end, because in an hospital structure many patients, with no relevant
pathologies, could go home in these days.
All the water samples in these two study phases were 24 hours samples collected
with an autosample in order to obtain a representative sample of all the day and
they were taken in dry period to avoid rain dilution.
Table 3.11.: Sampling date and day for Lagosanto analytical campaign in august
and september 2009
1st sample 2nd sample 3th sample 4th sample
Date August, 25 August, 26 August, 27 September, 1
Day Tuesday Wednesday Thursday Tuestay
Table 3.12.: Sampling date and day for Ferrara analytical campaign in september
2009 and march 2010
1st sample 2nd sample 3th sample 4th sample 5th sample
Date September, 2 September, 3 March, 16 March, 17 March, 18
Day Wednesday Thursday Tuesday Wednesday Thursday
3.6.1. Lagosanto Hospital
The large number of analysed compounds (the 73 reported in table 2.1) and the
large number of detected PPCPs in this kind of WWs (table C.6) cause a really
difficult in the comment of these results.
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Table C.6 reports the concentration in the four samples for the 59 detected com-
pounds. Ofloxacin (antibiotic), Furosemide (diuretic), Ciprofloxacin (antibiotic) are
the three compounds detected with the highest concentration.
On average the concentration of the detected compounds in this hospital are quite
constant, both for the average concentration, ranging from 1631 to 1918 ng L−1, and
for the sum concentration, variable from 84420 to 97842 ng L−1.
Table 3.13 shows the average, the standard deviation and the frequency of occur-
rence in the four samples taken in Lagosanto Hospital. For the complete analytical
results see table C.6 at the appendix C.
Table 3.13.: Analytical results on Lagosanto WWs. Average (ng L−1), Standard
Deviation (SD) and frequency of occurrence with n=4
Compounds Average SD Frequency
Acetaminophen 4533 1204 100
Atenolol 5131 1180 100
Atorvastatin 83 19 100
Azithromycin 60 69 50
Betaxolol 15 4 75
Bezafibrate 946 1349 100
Butalbital 22 13 75
Carbamazepine 733 105 100
Chlortetracycline 38 22 100
Cimetidine 26 5 100
Ciprofloxacin 11768 2124 100
Clarithromycin 59 52 100
Clofibric acid 23 17 75
Codeine 361 75 100
Diclofenac 304 118 100
Doxycycline 173 73 100
Enalapril 201 50 100
Enoxacin 410 60 100
Erithromycin 165 111 100
Famotidine 162 96 100
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Fenofibrate 19 11 50
Fluoxetine 18 – 25
Furosemide 14378 3081 100
Gemfibrozil 19 1 100
Glibenclamide 75 21 100
Hydrochlorothiazide 1748 432 100
Ibuprofen 1674 624 100
Indomethacine 2460 1610 100
Ketoprofen 5027 3524 100
Lisinopril 253 242 100
Loratadine 14 – 25
Lorazepam 668 81 100
Mefenamic acid 335 133 100
Metoprolol 826 173 100
Metronidazole 722 617 100
Mevastatin 1008 680 100
Naproxen 2340 874 100
Nifuroxazide 1397 1215 100
Norfloxacin 66 26 100
Ofloxacin 18605 4122 100
Oxytetracycline 781 433 100
Pentobarbital 35 28 100
Phenobarbital 28 1 100
Phenylbutazone 37 19 100
Pindolol 121 100 100
Pravastatin 624 348 100
Propranolol 46 8 50
Propyphenazone 15 5 75
Ranitidine 1468 848 100
Salbutamol 62 28 100
Salicylic acid 1320 466 100
Sotalol 4751 886 100
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Spiramycin 40 – 25
Sulfadiazine 32 2 100
Sulfamethazine 13 1 50
Sulfamethoxazole 4240 1570 100
Tetracycline 19 8 75
Tilmicosin 62 10 100
Trimethoprim 1192 488 100
As shown in the result table (for the complete results see table C.6) the compounds
detected in major concentration are the two antibiotics Ciprofloxacin and Ofloxacin
and the diuretic Furosemide. These compounds were detected in each sample with
concentrations in any case major than 10 µg L−1. The maximum concentration
arrived till 22 µg L−1.
3.6.2. Ferrara Hospital
Analytical results for Ferrara Hospital are reported in table 3.14 where the ratio
Winter
Summer
, the average values, the standard deviation (SD) and the frequency of oc-
currence with n=5 are shown.
Table C.7, instead, reports all the complete results. These tables show all the
concentrations of the detected compounds, without considering the two different
analytical period (september 2009 and march 2010).
Other important data reported in table 3.14, regards the ratio between winter and
summer season concentrations. It is clear that in winter season the concentration of
most compounds are much higher than in summer. In this hospital it is possible to
examine a high variability between summer and winter.
Table 3.14.: Ferrara Hospital results (ng L−1). Ratio Winter
Summer
, the average values, the
standard deviation (SD) and the frequency of occurrence with n=5
Compounds Winter
Summer
Average SD Frequency
Acetaminophen 0.6 3143 1175 100
Atenolol 2.4 4409 1917 100
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Atorvastatin 2.1 212 88 100
Azithromycin 16.5 497 442 100
Bezafibrate – 199 270 60
Butalbital 11.3 226 196 100
Carbamazepine 1.0 956 195 100
Chlortetracycline – 77 22 40
Cimetidine – 112 133 60
Ciprofloxacin 13.1 13487 11571 100
Clarithromycin 190.8 6589 6169 100
Clenbuterol – 1054 172 60
Clofibric acid – 13 1 40
Codeine 3.6 1343 1234 100
Diazepam – 31 9 60
Diclofenac 2.3 395 162 100
Doxycycline – 76 29 40
Enalapril 2.4 239 119 100
Enoxacin 3.4 196 151 100
Erithromycin 1.9 127 63 100
Famotidine 2.5 78 40 100
Fluoxetine 1.9 45 20 100
Furosemide 0.8 6280 916 100
Gemfibrozil – 33 28 60
Glibenclamide 1.4 85 22 100
Hydrochlorothiazide 3.2 1582 860 100
Ibuprofen 4.4 1813 1180 100
Indomethacine 0.2 1181 1258 100
Ketoprofen 1.2 1289 357 100
Lisinopril – 213 176 40
Loratadine – 20 6 60
Lorazepam 3.3 433 245 100
Mefenamic acid 4.7 376 278 100
Metoprolol 1.4 928 267 100
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Metronidazole 2.9 704 355 100
Mevastatin 0.3 288 194 100
Naproxen 11.9 3107 4444 100
Nifuroxazide 2.3 229 102 100
Norfloxacin 10.3 222 202 100
Ofloxacin 8.5 20032 15550 100
Oxytetracycline – 89 22 40
Paroxetine – 67 10 60
Pentobarbital 6.7 84 61 100
Phenobarbital 12.7 157 149 100
Phenylbutazone 2.2 107 46 100
Pindolol – 45 4 40
Pravastatin 2.4 129 86 100
Propranolol 0.5 60 27 100
Propyphenazone – 98 – 20
Ranitidine 2.3 2338 1399 100
Roxithromycin – 79 56 60
Salbutamol 4.5 83 53 100
Salicylic acid 2.2 1745 689 100
Sotalol 10.5 3238 2793 100
Spiramycin – 68 37 60
Sulfadiazine 3.4 236 133 100
Sulfamethazine – 23 9 60
Sulfamethoxazole 1.1 1921 1083 100
Tilmicosin 18.0 164 161 100
Timolol – 33 10 60
Trimethoprim 0.3 371 317 100
Table 3.15 reports that the concentration of PhCs compounds in Ferrara Hospital
have a high variation between summer and winter season. In fact the ratio between
these two season ( Winter
Summer
) is equal to 2.8 for the average concentration and equal
to 3.3 for the sum concentration. This is an expected result (although not expected
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in this size) because in winter the use of antibiotics (mainly Ciprofloxacin, Clar-
ithromycin, Ofloxacin for example) or analgesics/anti-inflammatories (like Naprox-
ene and Salycilic acid) is really relevant, comparing with the summer use.
Table 3.15.: Ratio between winter and summer concentration in Ferrara Hospital
during the experimental investigation
Average concentration Sum concentration
Winter
Summer
2.8 3.3
3.7. Discussion
Some interesting consideration about this chapter are:
• HWWs are subject to seasonal variations (see table 3.15) and in fact the exper-
imental campaign results from summer and winter are considered separately
in table 3.16.
• In terms of detected compounds, Lagosanto shows a higher value, if compared
both with Ferrara summer analysis, than with Ferrara winter analysis. In
particular, in Lagosanto WWs were found 59 compounds. In Ferrara WWs
there were a high variability from summer (47 compounds) to winter (57 com-
pounds).
• The more detected compounds are the two antibiotics Ciprofloxacin and Ofloxacin
and the diuretic Furosemide. Moreover, in Ferrara Hospital were detected also
a high concentration of the antibiotic Clarithromycin. This compound was
detected in concentration lowest in Lagosanto Hospital.
• Table 3.16 shows the pro capita contribute of the PhCs. The small hospi-
tal of Lagosanto presents a really high pro capita load (expressed as ng L−1
patient−1) if compared with that of Ferrara. The 5.8 ng L−1 patient−1 are
really a large contribute compared with the Ferrara summer values of 0.8 ng
L−1 patient−1. In total, referring to the reported analytical results, the sum
of PhCs for patient are 305 ng L−1 patient−1 in Lagosanto Hospital and only
38 (or 127) in Ferrara Hospital in summer (or in winter season). This is also
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due to the lowest water consumption in Lagosanto Hospital (670 L bed−1 d−1)
respect Ferrara Hospital (800 L bed−1 d−1).
• This problem puts the attention on the characteristics of the WWs, derived
from a small hospital structure (Lagosanto for example) that, in terms of
pollutant load, may represent an environmental problem, it is not adequately
treated before the discharge in a surface water body.
Lagosanto’s WWs are collected in a public sewage and co-treated with UWWs
in a CAS system (5000 i.e.). The final discharge point is an irrigational channel
with a dominant flow derived from the WWTP for almost 8 month for year.
Ferrara WWs are also collected in a public sewage, but co-treated with the
UWWs derived from all the town (130 000 i.e.) and mixed, before the discharge
in the final water body, with the industrial treated WWs derived from the
nearest petrochemical site (100 000 i.e.). Then, in this case, the dilution with
other kind of waters, plays a really important role in the final concentration,
before the discharge. So the impact of the WWTP on the final discharge, is
really low in term of PhCs concentration.
Table 3.16.: Comparison between the two studied hospital results
Compounds Lagosanto Ferrara FerraraSummer Summer Winter
Detected, n 59 47 57
Average, ng L−1 1731 729 2055
Sum, ng L−1 91591 34281 114440
Patient 300 900 900
Average pro capite, ng L−1 patient−1 5.8 0.8 2.3
Sum pro capite, ng L−1 patient−1 305 38 127
An interesting result of this study, is reported in table 3.17, that shows the av-
erage concentrations for the main therapeutic classes analysed. In particular, is
evident that diuretic and antibiotics represent the more presents classes, derived
from hospital eﬄuents, into the public sewage.
The results shown in Sim et al. (2011) confirm that the use of antibiotics and
Carbamazepine is relevant in hospital structures. The same result is found on a
different study conducted during this thesis, but it is important to underline, that
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Table 3.17.: Average concentration (ng L−1) for the different classes in Ferrara Hos-
pital compared with Ferrara WWTP and load percentage of the HWWs
compared with UWWs
Class Ferrara Ferrara Load %Hospital WWTP
analgesics/anti-inflammatories 1406 464 6
antibiotics 2803 311 19
antidiabetic 85 87 2
antihypertensive 885 1401 1
barbiturates 155 124 3
Beta-agonists 626 86 15
beta-blockers 1649 536 6
diuretic 6280 423 31
Lipid regulators 182 121 3
psychiatric drugs 362 225 3
Average 1443 378 9
Carbamazepine is considered an anthropogenic marker non specific for the hospital
eﬄuents, but for all kind of eﬄuents.
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CHAPTER 4
Experimental investigation
This chapter will describe the different pilot plants tested in this three years of
analytical campaign. Where necessary, the structure of the thesis is maintained and
a literature review comes before the experimental description.
At the beginning (section 4.1) the aim is placed on the disinfection of raw sewage,
a practice not recommended in developed countries, where there are centralized
WWTP. This helpful disinfection could be done in order to avoid major problems
or decrease hygiene risks, where there are no WWTP in the proximity of a hospital
structure.
Moreover, in section 4.2, the chapter will take in consideration Lagosanto Hospital,
a new hospital with a capacity of 300 beds built 30 km far from Ferrara in 2001.
The WWs derived from this hospital were studied with two different biological pilot
plant. These two MBR pilot plants present two different kind of membrane (MF -
UF) and analysis about BOD5, COD, SS and other macropollutants were done. The
data regarding the PhCs in this eﬄuents were reported in chapter 3 in particular
in section 3.6.1, because the experimental investigations with the two tested pilot
plants described in this chapter were only about the macropollutants and they did
not regard PhCs compounds.
In another part of the study, the experimental investigation was about the WWs
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deriving from the WWTP of La Spezia (section 4.3), where an MBR pilot plant is
tested and compared with the La Spezia CAS system.
At paragraph 4.4 PhCs were studied in inlet and outlet of Ferrara WWTP, in
order to analyse the removal rate of a conventional system. This WWTP treat a
mix of urban and hospital (low percentage) WWs.
Paragraph 4.5 is about the polishing treatment obtained after the conventional
WWTP in Ferrara with a natural treatment, like a constructed wetland (CW) pilot
plant, working as tertiary system. The aim of this section was understand the
buffering capacity of the natural treatment.
In order to confirm the buffering step of a final natural polishing treatment, an-
other experimental investigation was developed in section 4.6. The final eﬄuent
of the Ferrara WWTP was drugged with three PhCs and the influent and eﬄuent
concentration in CW were analysed. Aim of this experimental investigation was un-
derstand the efficiency of the natural step with high pharmaceuticals concentration.
All these steps are tested because, with the literature data, it is possible to say
that a MBR system can remove a lot of PhCs but a polishing final treatment is
recommended mainly to treat particular eﬄuent like HWWs.
An approach to this problem that consider the different PhCs as recalcitrant com-
pounds and that take in consideration the difficult in removing from the liquid phase
these pollutants is recommended and a multibarrier system is the best technology
to adopt. For more details about the different technologies (see chapter 5).
4.1. Disinfection of raw HWWs
This section will talk about the raw WWs disinfection with peracetic acid (PAA)
or with hypochlorite and it does not speak direct about the removing of PhCs
from the water. In addition to the different MBR, CAS or CW systems tested,
also a disinfection process could presents a real importance in the management and
treatment of HWWs mainly for the reduction of health risk.
This treatment sequence can provide a rapid solution of treatment in those cases in
which hospital eﬄuents are commonly not treated at all and are directly discharged
into a surface water body. As this practice is absolutely to avoid, in order to pre-
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vent the spread of pathogens microorganisms in water cycle, the tested sequence of
treatment, represents a strategy for the hospital eﬄuent management, waiting for
planning actions, including the construction of more complete WWTPs where not
only hospital, but also urban, industrial WWs could be conveyed and adequately
treated before their immission in surface bodies.
Disinfection is a treatment aimed at significantly reducing the content of microor-
ganisms (bacteria, viruses, protozoa) in WWs to a level of safety suitable for the
final use of the treated eﬄuent (discharge into a surface water body or reuse). Mi-
croorganism abatement or inactivation, may be performed by various mechanisms:
chemical (reactions with added agents) physical (radiation absorption, membrane
retention) or natural (natural death), solar radiation, high temperature, competi-
tion and predation). Microorganisms may be definitively removed or separated into
another phase (liquid or solid).
Assuming that the microorganism concentration in the influent and eﬄuent of
the disinfection stage is respectively N0 and N, the microorganism inactivation rate
may be expressed as percentage removal rate η, given by Eq. 4.1:
η =
N0 −N
N0
× 100 (4.1)
or as log reduction that is log units (l.u.), given by Eq. 4.2:
l.u. = log
N0
N
(4.2)
The correlation between l.u. and η is given by Eq. 4.3:
l.u. = − log
(
1− η
100
)
(4.3)
Reduction of bacterial content in the WWTP depends on the effectiveness of each
single stage (ATV (1998), Metcalfe and Eddy (1991)). Viruses are reduced by a
factor of some 2 powers of ten, through adsorption onto sludge. Worm parasites
and/or their adult stages, are increased by 70% to 90 % in the sludge of the me-
chanical phase. However, partial reactivation of all these microorganisms may occur,
especially in case of ultraviolet (UV) disinfection.
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Conventional disinfection is a treatment aimed at reducing bacterial load, gener-
ally faecal coliform (FC), to a level of 500-1000 MPN/100 mL1 in the final eﬄuent,
prior to either its discharge into a surface water body (sea, lake or river) or its
reuse. In the case of direct reuse in the absence of particular restrictions, or for
GW recharge, on the other hand, advanced disinfection may be necessary to further
reduce the microbial load (faecal or total coliforms) to 2-100 MPN/100 mL.
Conventional disinfection involves a removal rate of 2-3 l.u., which is easily guar-
anteed by modest concentrations of disinfectants and contact times. For instance, if
secondary biological eﬄuents with an FC concentration of 105 MPN/100 mL are sub-
jected to conventional disinfection which reduces its bacterial content by 2 l.u., the
final concentration will be equal to 103 MPN/100 mL, an acceptable level for various
eﬄuent purposes. In contrast, advanced disinfection requires higher concentrations
and longer contact times, and therefore results in higher doses (= concentration x
contact time).
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Figure 4.1.: FC levels in raw WWs and in the eﬄuents of different treatment steps
in a municipal WWTP
Direct chlorination or primary treatment followed by chlorination is the most
widely used method for disinfecting HWWs in order to prevent the spread of pathogenic
1The concentration of bacteria is generally reported as MPN/100 mL or CFU/100 mL, respec-
tively the Most Probable Number and the number of Colony-forming Units per 100 mL, de-
pending on the method used for their estimation in a water sample.
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microorganisms, causal agents of nosocomial infectious diseases (Liu et al. (2010)).
The widespread medical use of chlorine disinfection is due to its very broad spec-
trum of biocide activity against bacteria, virus and fungi and simple operation.
However, this method is capable of producing undesirable disinfection by-products
(DBPs), its efficacy depends much upon the quality of the feed water and in partic-
ular low efficiency of virus removal.
4.1.1. The experimental campaign
The management and the treatment of HWWs are an interesting field of research and
discussion for scientists, hygienists, environmental engineers, economists and admin-
istrators. They depend on different factors: legal requirements, existing WWTPs,
environmental conditions and accuracy. The discharge without any kind of treat-
ments is absolutely to avoid, a treatment is always necessary, a basic or advanced
one has to be adopted in the different situations. Pollutants concentration must be
reduced.
The best sequence of treatment should be defined on the basis of the hospital
characteristics (mainly size and wards), the receiving water body (average flow rate,
autodepurative capacity, final use), the environment conditions (temperature, urban
context. . . ), the existing WWTPs near the hospital to which the eﬄuent can be
conveyed.
The basic treatment to adopt for HWWs is the main objective of this research.
A sequence of preliminary treatments (mechanical ones) and a chemical disinfection
is investigated in order to evaluate the bacteria removal from a hospital eﬄuent.
NaClO and CH3COOOH (peracetic acid, PAA) have been tested at different con-
centrations and contact times on the raw eﬄuent from a small hospital, in Italy.
The scheme of the pilot plant (10 m3 h−1) tested in this investigation is reported in
figure 4.2.
Screening Pounding Sieving Chemicaldisinfection
NaClO orPAA
HWWs
Figure 4.2.: Scheme of the pilot plant for disinfection experimentation
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Table 4.1.: Characteristics of HWWs, UWWs and Italian legal limits for discharge
Parameter HWWs UWWs Legal limits
SS, mg L−1 10-1400 30-300 80
BOD5 , mg L−1 100-1600 10-130 40
COD, mg L−1 280-9000 90-500 160
COD/BOD5 1.4-6.6 1.7-2.4
Total P, mg L−1 3-8 8 10
N-NH3, mg L−1 10-55 30-40 15
Chlorides, mg L−1 80-188 50 1200
Hg, µg L 0.04-0.28 < 0.5 5
Total surfactants, mg L−1 3-7.22 4-8 2
Total Coliform, MPN/100 mL 106-109 107-108
Fecal Coliform, MPN/100 mL 103-107 106-107
E. coli, MPN/100 mL 103- 07 106-107 5·103
For the experimental investigation the used WWs derived from the eﬄuent of a
small hospital (50 beds) located near Rimini, Northern Italy.
The observation period were of two month in October-November 2009 and the
analysed compounds during this period were Total Coliform (TC), E. coli and Sus-
pended solids (SS).
The adopted analytical methods were the standard reported in APHA (2001).
Table 4.2.: Applied concentration and contact time for the two disinfectant during
the experimental investigation
Disinfectant Applied concent. Contact time Number of samplesmg L−1 min analyzed
NaClO 5, 10, 15, 20 10, 20, 30 24
PAA 5, 10, 15, 20, 40 10, 20, 30 36
Table 4.3 reports the state of the art about the predisinfection of raw WWs. All
the literature data reported derived from: Carrasco and Turner (2006), Sanchez-
Ruiz et al. (1995), Kitis (2004), Koivunen and Heinonen-Tanski (2005), Falsanisi
et al. (2006), Wiley (1999).
4.1.2. Results
On the basis of this experimental campaign it is possible to conclude that:
• PAA is able to reach higher removal rate for TC than E. coli (0.5-1 log unit
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Table 4.3.: State of the art - Predisinfection of raw WWs
Disinfectant Authors 
PAA, 
mg/L 
tcont, 
min 
c x t 
mg min/L 
TC removal 
(log unit) 
E. coli removal 
(log unit) 
PAA 
Sanchez Ruiz et al., 1995 
(Initial TC 106-108 MPN/100 mL) 
2 
10 
15 
20 
30 
80 
15 
15 
15 
15 
15 
15 
30 
150 
225 
300 
450 
1200 
0.95 
0.84-2.5 
3.75 
3.45-6.45 
0.8-5.7 
2 
Kitis, 2004  
(Initial TC 104-108 MPN/100 mL) 
 
 
 
40 
150 
225 
300 
1 
0.7-3 
3.7 
3.6 
0.6-2.5 
3.7 
0.75 
Koivunen et al., 2005 
(Initial TC 106-108 MPN/100 mL) 
5 
10 
15 
5 
10 
15 
5 
10 
15 
4-10 
4-10 
4-10 
10-20 
10-20 
10-20 
20-30 
20-30 
20-30 
20-50 
40-100 
60-150 
50-100 
100-200 
150-300 
100-150 
200-300 
300-450 
0.4-0.6 
2.2-3.2 
3.4-3.7 
0.7-0.9 
3.4 
3.9 
1 
3.5-3.6 
3.8-3.9 
Carrasco and Turner, 2006 
(Initial TC 107 MPN/100 mL) 
(Initial E. coli 106-107 MPN/100 mL) 
2 
2 
10 
5 
15 
15 
15 
30 
15 
30 
15 
30 
20 
30 
40 
40 
30 
60 
150 
150 
300 
450 
600 
1200 
0.56 
0.48 
0.46 
0.43 
0.37 
0.75 
2.57 
2.91 
0.57 
0.48 
0.29 
0.30 
1.1 
0.84 
3 
2.7 
Falsanisi et al., 2006 
(Initial TC 106 MPN/100 mL) 
(Initial E. coli 105 MPN/100 mL) 
 
30-40 
5 
10 
20 
40 
!!175 
!! 350 
!! 700 
!!1400 
2.94 
3.15 
3.40 
3.97 
4.55 
4.74 
4.93 
5.11 
NaClO 
Geo. Clifford White, 1999 
(Initial TC 106-108 MPN/100 mL) 
12-40 15-30 180-1200 3-4 
Carrasco and Turner, 2006 
(Initial TC 107 MPN/100 mL) 
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of difference on average at the same applied dose c x t) (Figure 4.3).
• On the contrary, NaClO is a bit more effective with E. coli than TC (Figure
4.4).
• Experimental data are quite spread due to the different characteristics of the
raw WW, influent to the pilot plant, in particular suspended solids that varied
in a wide range (Table 4.4). About this table some considerations are that
according to literature data, a concentration of SS up to 100 mg L−1 does not
influence the biocidal action of PAA. Greater concentrations can reduce it.
Table 4.4.: SS, E. coli, TC in the influent to the pilot plant
SS Experimental data
Sample number 10
min, mg L−1 133
max, mg L−1 1426
Average, mg L−1 504
S.D., mg L−1 484
E. coli, MPN/100 mL 105-107
TC, MPN/100 mL 107
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Figure 4.3.: TC and E. coli removal with PAA (experimental data)
On the basis of few literature data: E. coli is better removed with PAA and TC
with NaClO (Figure 4.5 and Figure 4.6).
With a raw WW of these characteristics (with a high SS content), at least:
• 600 mg min L−1 of PAA or
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Figure 4.4.: TC and E. coli removal with NaClO (experimental data)
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Figure 4.5.: E. coli removal with PAA and NaClO
0 
1 
2 
3 
4 
5 
6 
7 
0 200 400 600 800 1000 1200 
lo
g
(
N
0
/
N
)
 
c x t [mg min/L] 
Experimental data PAA 
Experimental data NaClO 
Literature PAA 
Literature NaClO 
Figure 4.6.: TC removal with PAA and NaClO
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• 150 mg min L−1 of NaClO
are required to reach a reduction of 2 log units of E. coli and at least:
• 400 mg min L−1 of PAA or
• 200 mg min L−1 of NaClO
to reach a reduction of 2 log units of TC.
Further researches are necessary in order to investigate the disinfection action of
PAA and NaClO at a lesser content of SS in raw WWs. Hence it is really important
to guarantee an efficient pretreatment step including a degritting, a pounding, a
sieving and a sedimentation in order to separate solids of different size that may be
present in the (hospital) eﬄuent and could reduce the disinfection effect.
4.2. MBR pilot plants in Lagosanto
This section will describe the experimental investigations about two different MBR
pilot plants treating the hospital eﬄuent derived from Lagosanto Hospital. For basic
information about MBR literature data see paragraph 5.1.3.
4.2.1. Screening of HWWs
As already reported the Lagosanto Hospital (built 30 km far from the town of Fer-
rara) is a structure in operation since 2001 with a capacity of 300 beds.It presents
the different departments of surgery, orthopedics, traumatology, obstetrics and gy-
necology, pediatrics, gastroenterology, cardiology, urology and psychiatry.
All the producted WWs (toilets, kitchen, pharmacy and the internal laundry) are
collected from the internal sewage, that consists in a separate type (stormwaters are
collected separately), and conveyed in 47 Imhoff tank (with an average of about 20
i.e. each) and, after a mild disinfection with sodium hypochlorite, are released into
the public sewer and conveyed in the local WWTP that also receives the UWWs
derived from the near town of Lagosanto. The HWWs accounts for 16% of the total
flow treated at the WWTP in dry weather.
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The experimental investigation was in support of the design choices for the con-
struction of the new WWTP for the new Ferrara Hospital, a 900 beds hospital under
construction 5 km far from Ferrara.
For this reason the experimental studies were conducted with a real eﬄuent de-
riving from the Lagosanto Hospital with the aim of:
1. understand the qualitative and quantitative nature of the HWWS before plac-
ing it into the public sewer in order to identify the most representative pollu-
tants
2. testing different pilot plants in order to evaluate the removal efficiency of
biological treatments comparing the removal rate with flat panels (MF), hollow
fiber (UF) and conventional systems
This part of the study was conducted between May 2007 and March 2008, focused
on the qualitative and quantitative aspect of the macro and micro parameter. An
in-depth survey conducted in collaboration with the local sanitary company, has
identified the types of drugs most commonly used at the hospital on an annual basis.
Antibiotics, anti-inflammatories and cortisone are the products most administered.
To these products we must add the antiepileptic drug carbamazepine.
The average monthly consumption shows significant changes, as described in figure
4.16 at page 114 and 4.17 at page 115.
For the qualitative and quantitative characterization of the raw HWWs (before
chlorination), we decided to limit the investigation to the antibiotics and carba-
mazepine and the full list of analyzed compounds in this phase of the study is
reported in table 4.5.
The research of these micropollutants has been extended to the inlet and outlet
WWs from Lagosanto WWTP, in order to compare the contribution of the urban
and hospital WWs and to evaluate the removal rate with conventional treatment
systems (activated sludge).
The analysis of PhCs were made using LC-ESI-MS/MS with 24 hours composite
samples collected in 1 liter plastic bottles taken during three different day on July
9, 10, 11, 2007. Each sample was taken in no rain day, in order to avoid a possible
dilution.
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In this particular month, the average consumption of antibiotics and carbamazepine
in the hospital structure, is major than the average monthly consumption. All the
analysis done in this period showed that, for all the investigated parameter, only
Cefazoline and Carbamazepine was above the detection limits.
Moreover, the concentration of Cefazoline and Carbamazepine at the inlet of the
Lagosanto WWTP, was higher than in the HWWs, probably due to a major load of
these substance from UWWs.
Table 4.5.: Antibiotics and Carbamazepine in Lagosanto HWWs, influent and eﬄu-
ent of Lagosanto WWTP
Parameter, µg L−1 Hospital WWTP influent WWTP eﬄuent
Amoxicillin – – –
Ampicillin – – –
Cefamandole – – –
Cefoperazone – – –
Denofloxacin – – –
Dicloxacin – – –
Enrofloxacin – – –
Flumequine, – – –
Oleandomycin – – –
Penicillin – – –
Spyramicin – – –
Sulphadiazine – – –
Sulphadimidine – – –
Sulphaguadinine – – –
Sulphamerazine – – –
Sulphametoxypiridazine – – –
Sulphathiazole – – –
Tylosin tartrate – – –
Cefazoline 0.23 3.57 –
Carbamazepine 0.54 1.05 0.44
The low values reported in table 4.5, probably are due to an uncorrect conservation
of the samples, that cause a rapid degradation of the detected compounds.
The aim of the experimental investigation was evaluate the tractability of the
HWWs using biological systems. For this reason two different MBR pilot plants
were tested:
• in the first part of the experimental investigation (from July to October 2007)
the pilot was a MBR Kubota plane membrane (MF) with a pore diameter of
0.45 µm (see figure 4.7)
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• in the second part of the investigation (from October to March 2008) the pilot
was an MBR hallow fiber membrane (Puron UF) with a pore diameter of 0.01
µm (see figure 4.8)
(a) Kubota pilot plant (b) Plane membrane
Figure 4.7.: The first membrane pilot plant tested (Kubota membrane)
(a) Puron pilot plant (b) Hallow fiber membrane
Figure 4.8.: The second membrane pilot plant tested (Puron membrane)
The main characteristics of the two pilot plants are reported in table 4.6. In each
phase the HWWs, taken with a pump from the final well before the chlorination,
was added continuously in the biological reactor.
Aeration was made by air insuﬄation from the bottom of the nitrification com-
partment and in the second pilot, larger than the first one, the dissolution of the
mixture of water and oxygen was guaranteed by the movement of an agitator. The
permeate extract was drained into a second well to prevent interference with the
feed plant.
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Table 4.6.: Characteristics of the two MBR pilot plants studied in Lagosanto
Parameter MF UF
Period July-October 2007 October-March 2008
Membrane Plane Hallow fiber
Pore diameter, µm 0.45 0.01
Superf. flux, L m−2h−1 11 15-35
Flow rate, L h−1 4 90
Volume, m3 Denitr. 0.2 - Nitr. 0.5 Nitr. 1.5
TMP pressure, mbar 200-250 400
Tot. surf. membr., m2 0.37 5
HRT, d 6 0.6
Sludge age, d 40 40
Membrane cleaning 1. Air insuﬄation 1. Air insuﬄation
2. Chemical cleaning 2. Relaxation
3. Backwash with permeate
4. Chemical cleaning
In the second phase of the experimental investigation, another aim was to compare
the CAS process efficiency with the MBR system under studying. To do this we did
not built another plant, but we used the same installed pilot using it as MBR or SBR
(Sequencing Batch Reactor) in function of the requirement. When we tested SBR
sequence we used the aeration tank (without the air insuﬄation) like a sedimentation
basin with a retention time of 2-3 hours.
During the starting period, each pilot is filled with an inoculum of activated sludge
taken from the Lagosanto WWTP. After a period of start up of about 30 days, it was
possible to start the analytical planning and the experimental investigation. The
conventional macroparameter analysed in this part of the investigation were: BOD5,
COD, filtered COD (with a 0.45 µm membrane), SS, PTot, NH4, anionic, cationic,
non ionic and total surfactants, Hg, E. coli, Cefazoline and Carbamazepine.
The influent and eﬄuent samples from the pilot and from Lagosanto WWTP
were made instantly, on the same day during the week. In particular, during the
second investigation phase, permeate (eﬄuent of the MBR) and clarified (eﬄuent
of the SBR) were obtained respectively at about 8 am and at 11, this was made to
evaluate the characteristics of the WWs maintaining equal environmental conditions.
The samples were immediately transported to the laboratory thermostated and
analysis on conventional macroparameter were made. In this first phase of the exper-
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imental investigation, the analysis of micropollutants were done in to a specialized
and certified laboratory.
The sampling points (reported in figure 4.9) were as follows:
1. HWWs before chlorination,
2. Permeate (extracted through the membranes)
3. Clarified (after sedimentation of 2-3 hours to simulate an activated sludge
process),
4. Influent Lagosanto WWTP,
5. Eﬄuent Lagosanto WWTP
Delta hospital
wastewaters
Imhof tank
Chlorination
Lagosanto WWTP
From Urban
utilities Discharge in a channel
Clarified
Permeate
MBR
Pilot station
SBR
Q
0.16 Q
0.84 Q
5
1
3
2
4
Figure 4.9.: Sampling point and pilot scheme
An in-depth literature review completed this part of our investigation. Data were
collected for BOD5, COD and SS in eﬄuents of hospitals of different sizes, services
(60-900 beds) and countries (Italy, France, Turkey, India, Iran, Thailand, Canada
and Greece) (Nardi et al. (1995), Wangsaatmaja (1997), Emmanuel et al. (2001),
Brown et al. (2006), Tsakona et al. (2007)Kummerer et al. (1997), Laber et al. (1999),
Altin et al. (2003), Chiang et al. (2003), Emmanuel (2004), Wen et al. (2004), Mohee
(2005), Rezaee et al. (2005), Kajitvichyanukul and Suntronvipart (2006), Pauwels
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and Verstraete (2006), Gautam et al. (2007), Machado et al. (2007), Sarafraz et al.
(2007), Boillot et al. (2008), Suarez et al. (2009)). Minimum and maximum values
for each of the three parameters in HWWs were grouped and elaborated in order
to obtain their corresponding cumulative frequency curves for each of the three
parameters, giving both the minimum and maximum cumulative frequency curve.
These curves are reported in Figures 4.10, 4.11 and 4.12 where they define the grey
bands representing the expected variability range for each of the three monitored
parameter in HWWs. Each curve is based on 25-30 literature values.
Concentrations of BOD5, COD, SS in the Lagosanto WWs was also analyzed
weekly during the experimental investigations period. These experimental curves
were compared with those drawn on the basis of literature data related to the min-
imum, average and maximum BOD5, COD and SS concentrations of HWWs. So
these figures are the same showed in figures 3.6, 3.7, 3.8, but in this case the lit-
erature data are completed with experimental results obtained in the analytical
campaign. Generally, all the data referred to the whole hospital eﬄuents, in some
cases to specific departments, such as dialysis, pediatrics, infectious and tropical
diseases.
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Figure 4.10.: BOD5 cumulative frequency curves for the eﬄuent of Lagosanto Hos-
pital (HWWs) and the influent to Lagosanto WWTP (UWWs) and
variability range for HWWs according to literature data
As reported for each of the three parameters, the concentrations in HWWs deriv-
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Figure 4.11.: COD cumulative frequency curves for the eﬄuent of Lagosanto Hos-
pital (HWWs) and the influent to Lagosanto WWTP (UWWs) and
variability range for HWWs according to literature data
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Figure 4.12.: SS cumulative frequency curves for the eﬄuent of Lagosanto Hospital
(HWWs) and the influent to Lagosanto WWTP (UWWs) and variabil-
ity range for HWWs according to literature data
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ing from this experimental campaign are in line with literature data and always on
top of the urban line, confirming the major pollution load discharge for the three
macroparameter in HWWs as jet reported in table 3.4.
Figures 4.13 and 4.14 show the changes in concentration of COD and SS in the
HWWs during the day and the trend found by Emmanuel (2004) in the eﬄuent of a
department of infectious and tropical diseases. The maximum COD concentration
values was both in Emmanuel (2004) research than in our studies at 18:00.
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Figure 4.13.: COD variation in Lagosanto eﬄuent. Comparison with Emmanuel
(2004) and Boillot et al. (2008)
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Figure 4.14.: SS variation in Lagosanto eﬄuent during the day
Moreover figure 4.15 reports the results deriving from the analytical campaign
hours by hours for COD and for SS.
The ratio between COD and BOD5 in HWWs is usually considered in the range
of 2-2.4, in agreement with the values found in Altin et al. (2003) and confirming
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Figure 4.15.: COD and SS variation in Lagosanto eﬄuent hours by hours in a day
during the experimental investigation
the applicability of the correlation of their proposal, made on the data of 5 Turkish
hospitals of various sizes as reported in equation 4.4:
ln(COD) = 1.16 · ln(BOD5)− 0.069 (4.4)
Literature data show that for particular departments, the ratio may be signifi-
cantly different: Chiang et al. (2003) found a value of 6.6 for the eﬄuent from a
dialysis unit.
Comparing the analysis about micropollutants (only referring to the two de-
tected compound: Cefazoline and Carbamazepine) we found concentrations major
in UWWs than in HWWs. This can be explained because in hospital, water con-
sumption per patient, is 2-3 times higher than in urban utilities. In fact making
a virtual assessment consumption per inhabitant (table 4.7) the daily contribution
pro capita are comparable.
Table 4.7.: Carbamazepine (CBZ) virtual consumption pro capita during the exper-
imental investigation
Users i.e. Specific flow Flow CBZ CBZ CBZL i.e.−1 d−1 m3d−1 µg L−1 mg d−1 mg i.e.−1d−1
Hospital 300 600 180 0.54 97.2 0.324
Urban 4000 300 1200 1.05 1260 0.315
On the basis of the conducted experimental investigation on the Lagosatnto Hos-
pital eﬄuent and on the influent of the Lagosanto WWTP, we found significant
differences between the two kinds of eﬄuents. These results are reported in table
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4.8. UWWs results from a greater number of samples because they include historical
data sets where available.
Table 4.8.: Number of samples and range of variability for HWWs and UWWs
Parameter HWWs UWWsSamples Average Samples Average
BOD5, mg L−1 20 240 ± 82 130 70 ± 43
COD, mg L−1 20 480 ± 125 130 180 ± 74
CODfiltered, mg L−1 20 331 ± 54 20 118 ± 36
SS, mg L−1 20 227 ± 57 130 41 ± 15
NH4, mg L−1 20 42 ± 9 130 25 ± 7
Total P, mg L−1 20 6 ± 2 130 3 ± 1
E. coli, CFU/100 mL 20 2·105 - 2·106 130 8·105 - 4·106
Referring to hospital water consumption, our experimental investigation revealed
that the specific rate per patient is about 600-700 L patient−1 d−1.
As to faecal bacteria, we limited our investigation to E. coli and we found sim-
ilar concentrations in the monitored hospital and urban WWs. This result is in
agreement with other authors, among them: Nardi et al. (1995), Leprat (1998);
Emmanuel (2004), Wen et al. (2004), Boillot et al. (2008); Sun et al. (2008).
In order to complete the comparison between the two eﬄuents, it is important
to underline that the main differences could refer to the presence of multiple drug-
resistant (MDR) bacteria. Few studies are available on this topic. Chitnis et al.
(2000) found that MDR bacteria population in Indian hospitals ranges from 0.58 to
40%, while it is less than 0.00002 to 0.025% in UWWs. This means that adequate
treatments for hospital eﬄuents are required in order to avoid the spread of such
bacteria to the environment and in particular to the community, and it is important
to verify the disinfection efficiency of the adopted treatment sequence.
Halling-Sorensen et al. (1998), Davidson (1999), Schwartz et al. (2002), Emmanuel
et al. (2005b) found and investigated the main factors that contribute to the devel-
opment and spread of resistance:
• mutation in common genes that extend their spectrum of resistance
• transfer of resistance genes among diverse microorganisms
• increase in selective pressures that enhance the development of resistant or-
ganisms
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Markers of viral pollution in water, such as enterovirus, adenovirus, rotavirus,
parvovirus, reovirus, Norwalk virus, calcivirus and coronavirus, have been identified
in the hospital eﬄuents (Leprat (1998)).
Regarding the consumption of PhCs, we made an investigation in collaboration
with the in-house pharmacy service of the Lagosanto Hospital, and we found that
on an annual basis, the classes of substances most commonly administered are anal-
gesics and antibiotics, followed by cytostatics, anesthetics and contrast media.
On the basis of an in-depth literature review, we found the concentration ranges
for the main groups of PhCs in HWWs as well as in UWWs (table 4.9).
Table 4.9.: Concentration range of PhCs in HWWs and UWWs. Literature data
Class Examples HWWs (µg/L) UWWs (µg/L)
Analgesics Diclofenac,
ibuprofen,
ketoprofen,
paracetamol,
salycilic acid
0.07-1368a 0.01-483e
Antibiotics Ciprofloxacin,
erythromycin,
tetracycline
0.04-125b 0.01-31.70f
Cytostatics 5-fluorouracil,
ifosfamide
0.001-124c 0.01-7g
Contrast media Iopromide,
iopamidol
0.2-2500d 0.2-22h
Hormones 17β-estradiol,
estriol, estrone
0.017-0.2a 0.001-0.2i
β-blockers Atenolol, metro-
prolol, propra-
nolol
0.4-25a 0.01-15e
aThomas et al. (2007); bDuong et al. (2008); cMahnik et al. (2007); dWeissbrodt
et al. (2008); eKasprzyk-Hordern et al. (2008); fRadjenovic et al. (2009);
gKummerer et al. (1997); hTernes and Joss (2006); iTeske and Arnold (2008).
Concentrations in HWWs are generally 2-100 times higher than those in UWWs,
but some PhCs, like hormones and β-blockers, are present at the same levels both
in urban and hospital eﬄuents, due to their prolonged and diffuse individual con-
sumption.
PhCs are generally persistent compounds, able to resist normal WWs treatments.
Their treatability characteristics, mainly biodegradability, adsorption or absorption
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tendency, and half-life time, may be significant different even among substances of
the same therapeutic class (Jones et al. (2005a); Oppenheimer et al. (2007); Suarez
et al. (2008); Radjenovic et al. (2009)).
4.2.2. Water consumption in Lagosanto Hospital
The study shows that water consumption in Lagosanto Hospital was about 600-700
L bed−1d−1 and in other hospitals in Ferrara area vary between 700 and 800 L
bed−1d−1.
The literature data referring to hospitals in different countries (table 4.10) in-
dicate a variability range between 340 and 1182 L bed−1d−1. Comparing hospital
consumption (L bed−1d−1) with their potential (beds) were not found any significant
correlation.
Finally, literature data show that the change in consumption during the day varies
between +20% and -30% as for example reported in Joss et al. (2005). During the
year, the largest consumption are meet in the summer months.
Table 4.10.: Water consumption in hospital structures
Source Consumption CountryL bed−1d−1
Lagosanto 670 Italy
Ferrara’s zone 700-800 Italy
Emmanuel (2004) 750 France
Emmanuel (2004) 970 USA
UBC, Technical Guidelines 2008 680 USA
Sarafraz et al. (2007) 362 Iran
Metcalfe and Eddy (1991) 738 USA
Wangsaatmaja (1997) 1182 Thailand
Chawathe and Fellow (2002) 340 if < 100 beds India
450 if > 100 beds
EPA (2002) 470-910 tipic 630 USA
Altin et al. (2003) 550-950 recommended 600 Turkey
4.2.3. Results
Table 4.11 shows the average percentage removal rate obtained by the tested systems:
MBR with MF (0.45 µm), MBR with UF (0.01 µm) and SBR.
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Table 4.11.: Removal rate for the main pollutants in Lagosanto tested pilots
Pollutant Removal rate, %MF UF SBR
SS 91.8 96.9 70.4
COD 91.5 91.1 72.7
Filtered COD 87.4 73.9
BOD5 96.9 97.1 91.9
NH4 97.8 28.2 25.6
Ptot 2.9 36 14
Total Surfactants 87.3 76.6
E. coli 99.8 99.993 60
Analysing the data is clear that MBR systems works better than the conventional
biological system (SBR), the best results have always obtained with the UF mem-
branes. The pores of these membranes, an average of 0.01 µm in fact can stop the
suspended solids more effectively than the pores of a MF membrane and with the
suspended solids a lot of pollutants.
It is important to put the attention on the permeate flux. In this flus, in fact, the
organic matter derived only from the dissolved pollutants.
From a microbiological point of view, the MF membranes stopped an average of
2-2.5 log units of E. coli, while the UF membranes can always removed at least 4
log units ensuring an eﬄuent with less than 10 E. coli 100 mL−1.
The viruses were not analysed in this study. An analysis of those presents in
WWs showed that they are usually 20-150 nm in size, so we can expect that the UF
membranes tested, having a pore size lower than this value, are able to retain them.
Table 4.12.: Viruses present in HWWS and relative dimensions
Virus Dimensions, nm Virus Dimensions, nm
Enterovirus 20-30 Norwalk 27-40
Adenovirus 70-80 Astrovirus 27-32
Rotavirus 60-80 Calicivirus 30-40
Parvovirus 20 Coronavirus 80-160
Reovirus 60-80
The study on the somministration of carbamazepine and antibiotics shows that
the presence in the HWWs is related to effective consumption: Obviously the con-
sumption of these substances is variable over the year, as shown in figure 4.16 and
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4.17.
For example, in samples taken in December, Carbamazepine and Cefazoline were
always below their detection limit: unexpectedly, in winter months the average
monthly consumption at the hospital are less than the monthly average on an annual
basis.
Withdrawals in September and January, Carbamazepine and Cefazoline were
higher in the permeate and clarified in relation to HWWs. This can be justified
by the fact that in this period samples were instantaneous and not on the average
of 24 hours. Moreover they not considered the effective hydraulic retention time of
the pilot plant and this can cause some comparative errors.
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Figure 4.16.: Monthly variation on the Carbamazepine consumption in Urbans and
Hospitals users in Lagosanto. Average values for Urbans users equal
to 18.7 kg month−1 and for Hospitals users equal to 1.45 kg month−1
4.3. CAS and MBR treatment in La Spezia
This section describes the experimental investigation carried out in La Spezia, north-
ern Italy, studying the municipal WWTP. This plant is a CAS system that treats
all the WWs derived from the town of La Spezia, including a the town hospital. In
order to compare the different efficiency in removing PhCs a MBR pilot was studied
in parallel with the CAS.
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Figure 4.17.: Monthly variation on the antibiotics consumption in Urbans and Hos-
pitals users in Lagosanto. Average values for Urban users equal to 0.31
kg month−1 and for Hospital users equal to 1.20 kg month−1
La Spezia municipal WWTP (figure 4.18) is a CAS system built for 120 000 i.e.
and consists in a conventional biological treatment that includes preliminary treat-
ments (screening and gritting) and biological section. The final eﬄuent is directly
discharged into the sea without any kind of disinfection.
The average influent and eﬄuent concentration for the main parameters in La
Spezia WWTP are reported in table 4.13.
Table 4.13.: La Spezia WWTP average influent and eﬄuent concentration for the
main macro parameter
Parameter Influent Eﬄuent
BOD5, mg L−1 356 3.3
COD, mg L−1 576 23
CODSoluble, mg L−1 107 22
SS, mg L−1 343 0.8
NH4, mg L−1 57 0.6
This experimental investigation was carried out in two month (May-June 2008)
with a total of 12 samples analysed. In particular 4 samples for the influent WWs
and 8 samples for the eﬄuent of the two plant, two for CAS eﬄuent, five for MBR
eﬄuent and finally one with the adding of ozone. For each sampling point a 24
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Figure 4.18.: La Spezia WWTP
hours composite sample was taken.
The sampling point during this experimental investigation were the following:
• Influent CAS and MBR (the WWs for the influent were the same)
• Eﬄuent CAS
• Eﬄuent MBR
• Eﬄuent MBR + O3 (an experimental investigation were made also with a
production of 8 g h−1 of O3 with a contact time of 5 mins)
The analysed compounds in this experimental section were the 38 reported in
table 4.14, moreover in table C.8 it is possible to compare all the different analytical
results during the experimental investigation. Figure 4.16 presents all the percent-
age removal rate from the average values comparing CAS, MBR and MBR + O3
treatments.
The main characteristics of the MBR pilot plant in La Spezia (figure 4.19) are
reported in table 4.15.
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Table 4.14.: Analysed compound in La Spezia
Amoxicillin Ibuprofen
Atenolol Idroclorotiazide
Atorvastatin Ketoprofen
Bezafibrate Lincomicin
Carbamazepine Metotressate
Ciclofosfamide Naproxen
Ciprofloxacin Oleandomicin
Claritromicin Ofloxacin
Clofibric acid Omeprazole
Demetildiazepam Ossitetraciclin
Diazepam Ranitidine
Enalapril Salbutamol
Deidro-Eritromicin + Eritromicin Sildenafil
Diclofenac Spiramicin
Estradiol Sulfamethoxazole
Estrone Tamoxifen
Etinilestradiol Tilmicosin
Furosemide Tilosine
Gemfibrozil Vancomicin
(a) La Spezia MBR pilot plant (b) Puron membrane in La Spezia
Figure 4.19.: The MBR tested in La Spezia (Puron membrane)
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The plant consists of three main tasks: denitrification tank, nitrification tank,
and a final tank, dedicated to the membrane module filtration as reported in figure
4.20.
QIN = 0.53 m3 h-1
DenitrificationV = 1.98 m3 NitrificationV = 2.57 m3
Sludge discharge
Tank for PuronMembraneV = 0.64 m3
QOUT
Sludge recycle
Concentrate recycle
Figure 4.20.: MBR scheme in La Spezia
Table 4.15.: Characteristics of the MBR pilot plant studied in La Spezia
Parameter UF
Period May-June 2008
Membrane Puron
Pore diameter, µm 0.05
Flow rate, m3 h−1 0.53
Superf. flux, L m−2h−1 22
Volume, m3 Denitr. 1.98 - Nitr. 2.57
TMP pressure, bar 0.1
Tot. surf. membr., m2 30
HRT, h 9
Sludge age, d 30
Membrane cleaning 1. Air insuﬄation
2. Chemical cleaning
As clearly reported in tables C.8 and 4.16 the effective removal efficiency is not
really constant for all the PhCs detected. CAS system may be sufficient to remove
some micropollutants, but a MBR plant certainly improve the final efficiency. More-
over an additional treatment like O3 transforms or degrades a lot of micropollutants
and, for this way, reduces the final impact of the WWTP discharge.
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Table 4.16.: La Spezia percentage removal rate from the average values. Comparison
between CAS, MBR and MBR + O3
Compound MBR CAS MBR + O3
Atenolol 91 80 97
Atorvastatin 98 81 100
Bezafibrate 82 88 99
Carbamazepine 2 4 0
Ciprofloxacin 88 20 39
Claritromicin 72 74 88
Demetildiazepam 42 21 20
Diazepam 43 0 8
Enalapril 100 100 100
Erytromicin 0 49 49
Diclofenac 53 12 26
Estrone 87 0 99
Furosemide 75 72 86
Gemfibrozil 97 69 97
Ibuprofen 100 98 100
Idroclorotiazide 61 0 0
Ketoprofene 92 73 97
Lincomicine 58 0 14
Naproxen 91 95 99
Oleandomicin 0 37 23
Ofloxacin 76 50 74
Ranitidin 88 97 94
Salbutamol 0 46 61
Sulfamethoxazole 79 93 68
Average 72 52 64
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Summing all the detected concentration and doing a mass balance, it is possible
to obtain the results in figure 4.21 where are shown the different load in g L−1
discharged before the relative treatment. In particular it is clear that a CAS system
is able to remove the analysed compound but, one times more, a MBR seems to
be able to improve the final efficiency. Another important aspect is related to the
ozonation final step that, as all the AOP treatment is able to degrade or transform
this micro contaminants and to improve the final efficiency.
Influent Effluent CAS Effluent MBR Effluent MBR + O3
0
50
100
150
200
250
300
350
Treatment
g/
d
Figure 4.21.: Mass balance for the results obtained in the experimental investigation
in La Spezia
Another important consideration is about the presence of the psychiatric drug
Carbamazepine. This compound used primarily in the treatment of epilepsy and
bipolar disorder, as well as trigeminal neuralgia is a recalcitrant compound present
in high concentration in WWs and the more important fact is that, mainly for his
stable chemical configuration (see figure 4.22) is stable on water and it resists to
main WWs treatment and also at the ozone treatment.
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N
O NH2
Figure 4.22.: Carbamazepine chemical structure
4.4. CAS treatment in Ferrara
This part of the study took place at the Ferrara municipal WWTP on march 2010.
This WWTP consists of two separate but very similar lines: one for UWWs (on
average 35 000 m3d−1 in dry weather), the other for industrial ones (on average
15 000 m3 d−1 in dry weather). Urban line is shown in figure 4.24 and it includes
preliminary treatments (screening and gritting), a biological treatment and a final
disinfection performed by adding NaClO, at an average concentration of 10 mg L−1
with a contact time on average of 30 min. Then the final eﬄuent is discharged into
a surface water body belonging to the local channel network used in the hot season
for agriculture irrigation.
The biological treatment consists of a CAS system, including the steps of denitrifi-
cation (V = 4000 m3), nitrification (V = 6100 m3) and then secondary sedimentation
(V = 6000 m3). It operates with an average hydraulic retention time (HRT) of 6 h,
a sludge age of 8 d and a concentration of the mixed liquor of about 3.5 kg m−3. An
image of the Ferrara WWTP is reported in figure 4.23.
Table 4.17 reports the main parameter of WWs influent and eﬄuent to the plant
and figure 4.24 shows a scheme of the WWPT including the final polishing treatment
consisting in a natural pilot plant CW.
Table 4.17.: WWs characterization macro-pollutants for influent and eﬄuent from
Ferrara WWTP
Parameter Influent Eﬄuent
pH 7.6 7.2
COD, mg L−1 109 45
BOD5, mg L−1 72 15
SS, mg L−1 85 22
TKN, mg NH4 L−1 26 5
Ptot, mg L−1 3 0.9
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Figure 4.23.: Ferrara WWTP with the two lines for urban and industrial WWs
SOLID WASTE
GRITTING
SAND
REMOVAL
THICKENING
ANAEROBIC
DIGESTION
NITR.
TANK CLARIFIER DISCHARGE
INTO RIVER
DEWATERING
SOIL DISPOSAL
DISINFECTION
BASIN
STORAGE
TANK H-SSF
1 2
3DENITR.
TANK
Legenda: 1: raw influent; 2: H-SSF bed influent (= WWTP secondary eﬄuent);
3): H-SSF bed eﬄuent.
Figure 4.24.: Flow scheme and sampling location (not in scale) of the Ferrara
WWTP and the pilot station where the experimental campaign was
carried out
4.4.1. PhCs removal rates in CAS
Literature data about the CAS systems and their capacity in removing PhCs are
really diffuse and among them Ternes (1998), Stumpf et al. (1999), Golet et al.
(2002); Rodriguez et al. (2003), Carballa et al. (2004), Kreuzinger et al. (2004),
Paxeus (2004), Bendz et al. (2005), Carballa et al. (2005), Clara et al. (2005a),
Clara et al. (2005b), Lindqvist et al. (2005), Tauxe-Wuersch et al. (2005), Vieno et al.
(2005), Batt et al. (2006), Brown et al. (2006), Castiglioni et al. (2006), Lindberg
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et al. (2006), Lishman et al. (2006), Nakada et al. (2006), Peng et al. (2006), Yu
et al. (2006), Gobel et al. (2007), Gomez et al. (2007), Jones et al. (2007), Kimura
et al. (2007), Ternes et al. (2007), Vieno et al. (2007a), Watkinson et al. (2007),
Xu et al. (2007), Gulkowska et al. (2008), Ghosh et al. (2009), Kasprzyk-Hordern
et al. (2009), Radjenovic et al. (2009), Santos et al. (2009), Zhou et al. (2009), Le-
Minh et al. (2007), Sipma et al. (2010)) are the fruit of experimental investigations,
generally carried out on full scale CAS systems treating real UWWs.
In general CAS system operated with a SRT of 10 d and at HRT of 7 h, with
different plant configurations (aiming for carbon removal only, or including nitrifi-
cation - denitrification steps as well as phosphate removal). For main details about
the literature data and the mechanisms in removing PhCs from WWs see paragraph
5.1.2
The degree of environmental risk posed by the presence of these micropollutants is
still under discussion. Safety threshold values have been defined for very few PhCs
and only in single compound-single organism toxicity studies. Many compounds
have not yet been extensively studied, and their toxicity data refer only to acute
effects.
In particular, Cleuvers (2003) analysed the toxicity of diclofenac, carbamazepine
and propranolol to Daphnia magna and found EC50 values equal to 68, 72 and 7.5 mg
L−1; these concentrations are significantly higher than the observed concentrations
in the secondary eﬄuent (ng L−1).
Nevertheless, the environmental impact of a mixture of different PhCs could be
more toxic than single compound alone. In fact, Daughton and Ternes (1999) and
Flaherty and Dodson (2005) found that a mixture of PhCs exhibits unpredictable
behaviour and can cause serious side effects such as deformities and increased mor-
tality in Daphnia magna. This implies that, in the future, it would be prudent
to begin monitoring of the most frequently administered and persistent compounds
(the so-called target compounds).
4.4.2. Observed secondary eﬄuent concentrations
Table 4.18 shows the observed concentrations of the PhCs of interest in the influent
and eﬄuent of the Ferrara WWTP. For each of the investigated pharmaceuticals, our
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experimental data are invariably within the variability ranges found in the literature,
thereby confirming that even though comparatively lower removal rates were found
in the Ferrara CAS, the resulting secondary eﬄuent had a similar quality to those
reported in literature.
Moreover this table shows the corresponding percentage frequency of occurrence
standard deviation. To see the complete analytical results see table C.9 at appendix
C. The sampling data for all the results shown in table C.9 were march, 15, 16, 19
and 24, 2010 and all the samples were 4 hours composite samples.
Interestingly, in the secondary eﬄuent, observed average concentrations for anal-
gesics or anti-inflammatories and antibiotics ranged between 15 and 664 ng L−1 and
between 10 and 1165 ng L−1 for all the other therapeutic classes. For many phar-
maceuticals, the concentrations in secondary eﬄuents are quite often greater than
50 ng L−1.
Table 4.18.: Average values (ng L−1, n=4) for the detected compounds in Ferrara
WWTP raw influent, Ferrara WWTP eﬄuent, corresponding percent-
age frequency of occurrence (f) and in brackets, standard deviation (SD)
Clas Compound
WWTP influent WWTP eﬄuent
f, % Aver. (SD) f, % Aver. (SD)
Analgesics Acetaminophen 100 813 (270) 100 30 (20)
or Codeine 100 107 (29) 100 66 (13)
anti-infl. Diclofenac 100 439 (55) 100 284 (49)
Ibuprofen 100 1026 (113) 100 81 (49)
Indomethacine 100 160 (60) 100 98 (31)
Ketoprofen 100 168 (27) 100 85 (21)
Mefenamic acid 100 903 (252) 100 664 (209)
Naproxen 100 832 (53) 100 178 (52)
Phenylbutazone 100 106 (30) 100 52 (11)
Propyphenazone 100 53 (18) 100 42 (20)
Salicylic acid 100 498 (378) 100 118 (8)
Antibiotics Azithromycin 100 112 (150) 100 131 (46)
Chloramphenicol 100 19 (5) – –
Ciprofloxacin 100 2212 (1085) 100 638 (349)
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Clarithromycin 100 308 (318) 100 284 (24)
Enoxacin 100 102 (22) 100 61 (28)
Erithromycin 75 58 (16) 50 23 (14)
Metronidazole 100 42 (13) 100 28 (12)
Nifuroxazide 100 52 (24) 50 18 (8)
Norfloxacin 100 203 (72) 100 152 (13)
Ofloxacin 100 1004 (822) 100 394 (138)
Roxithromycin 75 84 (49) 100 29 (18)
Spiramycin 75 81 (61) 100 31 (14)
Sulfadiazine 100 22 (6) 100 17 (5)
Sulfamethazine 100 18 (11) 75 12 (2)
Sulfamethoxazole 100 443 (200) 100 214 (35)
Tilmicosin 100 251 (183) 75 48 (29)
Trimethoprim 100 58 (14) 100 40 (7)
Antidiabetic Glibenclamide 100 87 (6) 100 55 (29)
Antihyp. Enalapril 100 82 (12) – –
Hydrochlorothiazide 100 2721 (1900) 100 1165 (199)
Barbiturates Butalbital 100 133 (80) 100 101 (16)
Pentobarbital 100 31 (11) 75 21 (6)
Phenobarbital 100 207 (79) 100 138 (27)
Beta- Clenbuterol 100 255 (29) 100 182 (37)
agonists Salbutamol 100 13 (4) 75 14 (3)
Beta- Atenolol 100 2081 (241) 100 734 (178)
blockers Cerazolol 25 11 – –
Metoprolol 100 255 (29) 100 182 (37)
Pindolol 25 11 – –
Propranolol 100 26 (14) 100 18 (6)
Sotalol 100 534 (122) 100 323 (115)
Timolol 100 14 (3) 25 12
Diuretic Furosemide 100 423 (42) 100 274 (128)
Lipid Atorvastatin 75 16 (4) 25 14
regulators Bezafibrate 100 90 (27) 100 36 (17)
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Fenofibrate 25 18 25 13
Gemfibrozil 100 200 (56) 100 108 (54)
Mevastatin 100 173 (70) 100 83 (57)
Pravastatin 100 114 (24) 100 54 (14)
Psychiatric Carbamazepine 100 581 (389) 100 372 (69)
drugs Diazepam 25 16 – –
Fluoxetine 100 106 (59) 75 57 (9)
Lorazepam 100 219 (34) 100 120 (27)
Paroxetine 100 41 (28) 100 13 (4)
Receptor Cimetidine 100 47 (15) 100 31 (15)
antagonists Famotidine 75 17 (6) – –
Loratadine 75 16 (5) – –
Ranitidine 100 111 (15) 100 78 (26)
Codeine is a compound scarcely referenced in previous studies, despite being the
most widely used naturally occurring narcotic in worldwide medical treatment. It is
an effective sedative, analgesic and antitussive agent. In this study, it was detected
in raw WW at a mean concentration of 0.107 µg L−1 (greatly below the observed
variability range of tables A.1. . . A.10 of 1.73-35 µg L−1), and only 33% of this
compound was removed after treatment (against 42-46% reported in literature).
Indomethacin was found at an average concentration of 0.160 µg L−1 in raw WW,
in agreement with the observed variability range in raw UWWs reported in tables
A.1. . . A.10.
Mefenamic acid is an hydrophobic compound which tends to sorb to sludge, and
may undergo degradation. However, high variability in its removal rates has been
observed by many Authors (Tauxe-Wuersch et al. (2005), Jones et al. (2007), Kimura
et al. (2007)).
Concerning propyphenazone, its frequently low, and sometimes negative, removal
rates can be ascribed to its hydrophilic nature (logKow =1.96) and chemical stability.
Low removal rates for some beta-blockers (in this study: metoprolol, propranolol and
sotalol), and even the occasionally measured negative removal (mainly atenolol and
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metoprolol), have been found by other Authors (among them Bendz et al. (2005),
Wick et al. (2009)).
Negative removals for macrolides including clarithromycin and erythromycin, are
likely due to the release of these compounds from excreta during biological treat-
ment, rather than presence of deconjugable metabolites: the load entering biological
treatment is therefore underestimated when taking only the dissolved fraction and
sorption to the suspended solids into account (Bryskier et al. (1993)).
Negative removal rates for carbamazepine are most likely due to enzymatic cleav-
age of the glucuronic conjugate of carbamazepine and the release of the parent
compound in the treatment plant (Vieno et al. (2007a)).
Receptor antagonists including cimetidine, loratidine, famotidine and ranitidine
have scarcely been studied and limited data (Gros et al. (2007), Radjenovic et al.
(2009), Kasprzyk-Hordern et al. (2009)) are available for comparison with those
found in this study. Furthermore, Radjenovic et al. (2009) found that their removal
in CAS is unstable and varies over a wide range.
Although, clofibric acid is a common lipid regulator previously found to be quite
persistent, it was not detected in this study. Similarly, Hijosa-Valsero et al. (2010b)
failed to detect it in raw WWs.
Low elimination rates could be due to the fact that contaminants are present at
very low concentrations in the influent, and their removal mechanisms barely have
a chance to occur. For this reason, PhC concentrations in CAS secondary eﬄuents
merit comparison.
4.5. CW pilot plant in Ferrara - Standard usage
The CW pilot station in Ferrara has been operating since 2003 and it is directly
fed by the eﬄuent of the near WWTP. The investigated H-SSF CW is a long and
narrow bed (28 x 1), filled with gravel (8-10 mm), with a depth ranging between
0.7 at the beginning and 1.75 m at the end of the bed and spontaneous plants and
grass on turf (see figure 4.26).
In this experimental campaign, carried out on march and april 2010, the pilot
plant feed was the eﬄuent of the secondary clarifier, as shown in figure 4.24. It was
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Figure 4.25.: Ferrara H-SSF pilot plant for the first investigation
pumped into a 10 m3 tank placed at 3 m above the ground and fed by gravity to
the pilot plants. The influent flow rate was set by a valve, regularly monitored by
a flowmeter and kept at a constant flow rate of 8 m3 d−1. The HRT was about
1 d. The main parameters of the WWs before and after the CW treatment are
shown in table 4.19, with the corresponding standard deviation (SD) in brackets.
The reported values are the average ones on the basis of the data set referring to
2009 (n = 20-80, depending on the parameter).
Waste water Cleaned water
Porosity = 0.33
Figure 4.26.: Scheme of the tested natural system pilot plant
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Table 4.19.: Characteristics of the investigated pilot plant and treatment perfor-
mance during the first investigation
Parameter Pilot plant under study
Length L, m 28
Width W, m 1
Aspect ratio, L:W 28:1
Average filling depth (max), m 1.2 (1.75)
Filling material, mm Gravel, 8-10
Porosity, % 33
Plants Spontaneous plants and grass on turf
Flow rate, m3 d−1 8
Design i.e. 53
Treatment performance (in/out)
COD, mg L−1 45(15)/11(6)
BOD5, mg L−1 18(10.8)/3 (1)
SS, mg L−1 22(8)/4 (1)
TKN, mg NH4 L−1 5 (2)/3 (2)
Redox, mV 194 (40)/104 (25)
Sulphates, mg L−1 60.5 (15)/63.5 (10)
4.5.1. PhCs removal rates in H-SSF
The present study investigates the ability and reliability of an H-SSF bed in removing
the 73 PhCs of interest, from a secondary eﬄuent feed to the pilot plant, as reported
in figure 4.24. H-SSF systems seem to be effective at removing PhCs, despite the
fact that the main removal mechanisms remain to be fully elucidated.
In general literature data refer to H-SSF beds of different sizes, aspect ratios
(width:length), water depths, vegetation presence, hydraulic loading rate, hydraulic
retention time, environmental conditions (mainly T and insolation) and soil matrix.
Most of them are laboratory or pilot plants, acting as secondary or tertiary treat-
ments, fed by real WWs. Analyses were usually performed on 24 h composite water
samples taken in dry periods. Not a lot of literature data are available on the re-
moval of PhCs by natural treatments and among them ther are: Drewes et al. (2002),
Matamoros and Bayona (2006), Ternes et al. (2007), Matamoros et al. (2009), One-
sios et al. (2009), Hijosa-Valsero et al. (2010a), Hijosa-Valsero et al. (2010b).
For more details about the removing of PhCs with natural treatment see para-
graph 5.1.8
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4.5.2. Observed H-SSF eﬄuent concentrations during the
first investigation
Table 4.20 shows the average values an the relative standard deviation for the de-
tected compounds in the H-SSF bed eﬄuent. Moreover this table shows the cor-
responding percentage frequency of occurrence (f). To see the complete analytical
results see table C.10 for the CW influent and table C.11 for the CW eﬄuent. The
sampling data for all the results shown in appendix C were: march, 30, april 1, 2
and 6, 2010 and all the samples were 4 hours composite samples. All the samples
take into consideration the correct HRT of the natural systems.
Table 4.20.: Average values (ng L−1, n=4) with standard deviation in H-SSF bed
eﬄuent, corresponding percentage frequency of occurrence (f)
Class Compound
H-SSF bed eﬄuent
f, % Aver. (SD)
Analgesics Acetaminophen 75 16 (6)
or Codeine 100 28 (8)
anti-infl. Diclofenac 100 271 (59)
Ibuprofen 75 58 (14)
Indomethacine 100 54 (17)
Ketoprofen 100 69 (13)
Mefenamic acid 100 533 (116)
Naproxen 100 114 (64)
Phenylbutazone 100 23 (8)
Propyphenazone 75 50 (18)
Salicylic acid 100 110 (5)
Antibiotics Azithromycin 25 19
Ciprofloxacin 100 208 (105)
Clarithromycin 100 265 (57)
Enoxacin 100 38 (26)
Erithromycin 25 28
Norfloxacin 100 74 (18)
Ofloxacin 100 64 (17)
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Roxithromycin 100 42 (34)
Spiramycin 50 12 (2)
Sulfadiazine 100 20 (6)
Sulfamethoxazole 100 180 (47)
Tilmicosin 25 18
Trimethoprim 100 25 (88)
Antidiabetic Glibenclamide 100 42 (14)
Antihypertensive Hydrochlorothiazide 100 432 (174)
Barbiturates Butalbital 100 59 (25)
Pentobarbital 50 12 (1)
Phenobarbital 100 114 (33)
Beta-agonists Clenbuterol 100 162 (24)
Beta-blockers Atenolol 100 383 (151)
Metoprolol 100 162 (24)
Propranolol 25 11
Sotalol 100 306 (114)
Timolol 25 11
Diuretic Furosemide 100 179 (85)
Lipid regulators Bezafibrate 75 26 (3)
Gemfibrozil 100 84 (46)
Mevastatin 100 39 (16)
Pravastatin 100 26 (12)
Psychiatric drugs Carbamazepine 100 387 (55)
Fluoxetine 100 44 (32)
Lorazepam 100 105 825)
Receptor antagonists Cimetidine 100 23 (11)
Ranitidine 100 46 (22)
131
4. Experimental investigation
4.6. CW pilot plant in Ferrara - Increasing of the
PhCs influent concentration
In order to confirm the buffering step of a final natural polishing treatment this
experimental investigation was carried out with the aim to observe the behaviour
of some common antibiotics: Ciprofloxacin, Sulphametoxazole and Trimethoprin
during the passage through a H-SSF pilot plant.
Every 5 days, 1 m3 of tap water was spiked with 2.5 g of Ciprofloxacin, 2 g of
Sulphametoxazole and 0.4 g of Trimethoprin. This mixture was homogenized and
then added to the secondary eﬄuent, using a peristaltic pump, and fed to the pilot
plant.
The characteristics of the studied pilot plant (figure 4.27) are reported in table
4.21.
Figure 4.27.: Ferrara H-SSF pilot plant for the second investigation
The pilot plant consists of a vegetated (Phragmites australis) H-SSF bed (12 m
x 2.5 m x 0.8 m), filled by gravel (8-10 mm), located at the municipal WWTP of
Ferrara. It is fed by the secondary biological eﬄuent, at a constant flow rate of 8
m3 d−1.
Twelve composite water samples have been withdrawn at the inlet and the outlet
of the bed and performed for the three antibiotics, during the observation period
March-June 2010.
All the twelve samples were taken in dry season in order to avoid a possible dilution
with the rain water. The samples were 4 hours composite and each one takes in
consideration the correct HRT of the system. They were taken in glass cleaned
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bottle and analysed at the Department of Analytical Chemistry of the University of
Ferrara.
Table 4.21.: Characteristics of the investigated pilot plant during the second
investigation
Parameter Pilot plant under study
Length L, m 12
Width W, m 2.5
Aspect ratio, L:W 12:2.5
Average filling depth, m 0.8
Filling material, mm Gravel, 8-10
Porosity, % 33
Plants Phragmites australis
Flow rate, m3 d−1 8
Design i.e. 56
4.6.1. Observed H-SSF eﬄuent concentrations during the
second investigation
Figures 4.28, 4.29 and 4.30 show concentration of the three PhCs in the influent and
in the eﬄuent of the H-SSF bed.
The variability range of the influent concentration has been really wide for Sul-
phamethoxazole (14-350 µg L−1), modest for Trimethoprim (4-16 µg L−1)and quite
small for Ciprofloxacin (0.26-4µg L−1). For each investigated compound, the vari-
ability range of the eﬄuent concentration, has been always smaller than the corre-
sponding range in the influent.
The three antibiotics have had a different behavior, passing through the H-SSF
bed: Sulphamethoxazole was scarcely removed (20% on average), while Trimetho-
prim and Ciprofloxacin had high average removal rates: respectively of 56%(SD=17)
and 84% (SD=7).
Watching the figure and the complete results reported in appendix C, in table
C.12, it is clear that also at hight concentration of these compounds CW can have
an important buffering function, and it is able to reduce the concentration of the
influent pollutant. Only for the Sulphamethoxazole the efffluent concentration is
highest than the influent because an uncorrect calculation of the HRT or an effective
release of this antibiotic.
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Figure 4.28.: Sulphamethoxazole removing in CW during the second investigation
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Figure 4.29.: Ciprofloxacin removing in CW during the second investigation
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Figure 4.30.: Trimethoprim removing in CW during the second investigation
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4.7. Discussion
This chapter presents all the experimental investigations carried out during this
Ph.D. research and a summary of all the works is reported in appendix B.
The treated technologies here reported are different and the starting point were
a simple disinfection of the raw HWWs with PAA or NaClO for those situation
where is not present a WWTP able to treat this specific WWs. The successive
experimentation regarded the comparison between CAS, MBR and CW system,
with a small experimentation with ozone before MBR treatment in order to see the
effective improvement of the water quality with this strong oxidant.
In general, the final results of each experimental investigation, shown that a multi-
barrier system can improve the water quality guaranteeing an hight removal effi-
ciency mainly in those pollutant (like micropollutant and PhCs) that are present in
very small quantity in WWs. This because the typical WWTP are able to remove
the carbonaceous fraction (like COD, BOD5) and the nutrients (N and P) present
in WWs but not all the pollutants that present concentration with magnitudo order
of µg L−1 or ng L−1. This because the typical biological treatment needs time and
quantity to develop bacterial and biomasses able to degrade and transforms also the
micro-compounds.
Section 4.2 reported only the results from an experimental investigation about
MBR in HWWs from a typical point of view, in substance mainly studying the
macroparameter and the problem connected with the hospital eﬄuent.
The successive section (from section 4.3 to section 4.6) instead shown the study
about PhCs in different pilot plants CAS, MBR and CW in order to focus the
attention in these important technologies.
The last investigation carried out (section 4.6) had the aim to assess CW ability
in removing three antibiotics (Sulphametoxazole, Trimethoprin and Ciprofloxacin),
commonly used. It was found that there average removal rates decrease in the order
Ciprofloxacin > Trimethoprin > Sulphametoxazole.
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4.7.1. Removal rate by CAS and H-SSF
This section describes and discusses the connection between CAS and natural tech-
nologies and in particular the use of the natural step at the end of the biological
treatment, in order to guarantee a buffering, able to stop pollutant and reduce the
final discharge impact in waters bodies.
Figure 4.31 reports the percentage removal rates for the 11 investigated thera-
peutic classes, to the CAS system and to the polishing stage. In this figure the two
parts of each rectangle represent the contribution of the CAS system and the H-SSF
bed in the removing of all the compounds of a class.
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Figure 4.31.: Overall average removal rates for the 11 investigated therapeutic
classes
This figure reports the overall average removal rates ηh for the therapeutic classes
of interest as well as the contributes of the two steps j in the removal performances.
These removal rates have been obtained applying eq. 4.5.
ηh|j =
∑
i(h) ciaverage,inf −
∑
i(h) ciaverage,eff∑
i(h) ciaverage,raw
|j × 100 (4.5)
where i(h) represents each of the PhCs belonging to the therapeutic classes h, caverage
is the average concentration of the generic compound i in the influent (pedix inf)
or in the eﬄuent (pedix eff) of the treatment step j or in the raw influent to CAS
system (pedix raw).
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The H-SSF bed manages to fatherly reduce the overall concentration of each class,
improving the quality of the final polished eﬄuent. Its contribute varies between 1
to 26 %, on average 16 % with a standard deviation equal to 7.
An analysis and a comparison of the mass loadings for each of the therapeutic
classes of interest in raw UWWs, in the secondary eﬄuent and in the polished
one may better show this capacity. Table 4.22 reports the mass loadings, referring
to a small communities of 1000 inhabitants, on the basis of the observed average
concentration discussed above. The main contributes are due to analgesics and anti
- inflammatories, followed by antibiotics. In raw UWWs the mass loading amounts
to 5.39 g 1000−1 i.e.−1 d−1, after a CAS including nitrification - denitrification steps
the mass loadings lowers to 2.38 g 1000−1 i.e.−1 d−1 and after a further subsurface
flow system treatment reduces to 1.55 g 1000−1 i.e.−1 d−1.
Table 4.22.: Specific mass loadings of an urban settlement of 1000 i.e., in case of a
discharge of raw UWWs, secondary eﬄuent and polished one by means
of H-SSF bed. Data reported in g 1000−1 i.e.−1 d−1
Class Raw UWWs Secondary eﬄ. Polishing eﬄ.
Analgesics/anti-infl. 1.47 0.49 0.37
Antibiotics 1.44 0.70 0.42
Antidiabetics 0.03 0.02 0.01
Antihypertensives 0.81 0.34 0.12
Barbitures 0.11 0.07 0.05
Beta-agonists 0.08 0.06 0.05
Beta-blockers 0.84 0.36 0.25
Diuretics 0.12 0.08 0.05
Lipid regulators 0.17 0.08 0.05
Psychiatric drugs 0.27 0.16 0.15
Beta-antagonists 0.05 0.03 0.02
Total PhCs 5.39 2.38 1.55
The reported results show that a final natural polishing treatment is able to favour
different removal pathways which become necessary due to the great variability of
the contaminants of interest.
If the receiving river is an eﬄuent dominant water surface body, becomes nec-
essary to improve the quality of the discharge in order to reduce the long term
environmental impact.
CW require high surface i.e.−1 ratio, these natural polishing treatments represent
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adequate solution for small communities or the last treatment step for the dedicated
treatment of specific users, such as heath care structures or HWWs where the con-
centrations of such micropollutants should be more carefully removed. Matamoros
et al. (2008) found that when these natural tertiary treatments are compared with
advanced oxidation treatments like ozonation (Zwiener and Frimmel (2000) or MBR
(Kimura et al. (2005)) the PhCs removal efficiencies are similar.
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Technologies and management
This Chapter describes the different technologies used to remove the PhCs from
WWs. All these considerations derived from literature research and from the expe-
rience done during this Ph.D., in fact this research work, made from the management
of numerous pilot plant, working with different scenarios.
A really interesting explanation of the historical evolution of the different step of
WWTP, is reported in Ternes et al. (2004b) where the figure 5.1 is an important
starting point:
In the 1950s, WWTPs were designed only for biological oxygen demand (BOD)
removal. In the 1960s, chemical phosphate precipitation was introduced to reduce
the phosphorus load being discharged. In the 1970s, processes were implemented to
convert ammonia (primarily derived from urine, and toxic to fish) to nitrate (a less
toxic form of nitrogen). In the 1980s, engineers put in place methods to partially
convert nitrate to molecular nitrogen. Enhanced biological phosphate elimination
was introduced in the 1990s when an anaerobic zone was implemented.
5.1. Overview of the removal processes
The removal of PhCs during WWs treatment can occur by means of the following
mechanisms:
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Figure 5.1.: Historical development of activated sludge treatment in Europe. Imag-
ine adapted from Ternes et al. (2004b)
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• Biological degradation: sludge age has shown to be a major factor influ-
encing the palette of chemical structures being microbiologically transformed.
The observed degradation rates of various compounds differ significantly with-
out showing any evident correlation to specific molecular structure: currently
no quantitative structure activity relationship (QSAR) can be identified. The
observed removal rates vary form very fast (e.g. estradiol, paracetamol) to
zero (e.g. carbamazepine, diatrizoate). Therefore the degradation of each
compound has to be determined experimentally (i.e. the rate constant related
to sludge concentration and sludge age).
• Sorption onto sludge issues in a removal of the sorbed share out of the
water phase and into the sludge processing path. Sorption behaviour can be
estimated with the help of the sorption coefficient (Kd), a value depending
mainly from characteristics of the compound, as well as of the sludge. Cur-
rently no correlation of the observed Kd with literature value (e.g. octanol
water partitioning KOW or partitioning to soil organic carbon KOC) could
be found: besides hydrophobic also electrostatic interactions are relevant for
sorption onto activated sludge. Nevertheless for the musk fragrances the high
KOW correlated with a high Kd. Therefore, the sorption coefficient has to
be measured for each compound and for each sludge type (e.g. primary, sec-
ondary, digested). Concerning the elimination from the water phase of UWWs,
sorption can be neglected for compounds with a Kd < 500 L kgSS−1.
• Stripping is not a relevant process for PhCs, since these exhibit a fairly
good solubility and therefore a low gas-water-partitioning coefficient. WWTPs
equipped with mechanical surface or coarse bubble aeration (e.g. MBR) rep-
resent an exception, due to the higher amount of air getting in contact with
the WWs compared to fine bubble aeration: in this case volatile compounds
(e.g. musk fragrances) can be stripped in significant amounts.
• Chemical oxidation: ozonation of the eﬄuent, has confirmed, being a fea-
sible polishing step for biologically treated wastewater with the potential of
eliminating a wide variety of PPCPs.
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In conclusion of this rapid focus on removal mechanisms, it is possible to see, that
biological degradation and sorption are the main mechanisms for PPCPs removal
during municipal WWs treatment. Ozonation is an interesting option for advanced
treatment.
On the basis of the literature data, the capacity in removing pharmaceuticals
compounds from WWs, depends on the chemical and physical properties of the
specific compound.
While it can be said that the effect of primary treatment of sedimentation is very
poor, the effectiveness of biological treatments varies with the type of contaminant.
As reported, there is no specific treatment able to remove, at high percentage, all
kinds of micropollutants typically found in HWWs, due to their differing behaviour
during treatments. In addition, removal efficiencies may vary from hot seasons to
cold ones as reported in Jones et al. (2005b), Castiglioni et al. (2006), Lindberg
et al. (2006), Lishman et al. (2006), Pauwels and Verstraete (2006), Matamoros
et al. (2008) and Miege et al. (2008).
HWWs are generally co-treated with UWWs in conventional WWTPs and are then
released into the environment. However, many PhCs are resistant to conventional
treatments. Elimination efficiencies of these compounds in municipal WWTPs have
been investigated recently by many authors like among them Carballa et al. (2004),
Nakada et al. (2006), Batt et al. (2007), Oppenheimer et al. (2007), Santos et al.
(2007), Vieno et al. (2007a), Terzic et al. (2008), Teske and Arnold (2008). Consid-
ering all the PhCs investigated, the overall average removal rates range between 10
and 90%. Different operational configurations should be developed and calibrated,
thus generating the potential for practitioners to be informed about the financial
aspects and overall risks associated with putative treatments of HWWs (Pauwels
and Verstraete (2006)).
Source controls could be an effective precautionary measure and an alternative
to end-of-pipe upgrading of treatment plants. As reported below, administrated
PhCs are excreted from the human body via faeces and urine at a percentage which
changes with the compounds. Separate collection of urine, can contribute to keep-
ing these substances away from WWs, but it will not be the perfect solution. Urine
source separation (Nomix technology) can be more conveniently adopted for other
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reasons, for instance water pollution control with respect to nutrients. In this case,
facilitated removal of pharmaceuticals could have very welcome side effects (Lienert
et al. (2007a)). A correct management of hospital eﬄuents, requires that discharges
from toilets used by patients undergoing nuclear medicine therapy must be collected
into separated tanks and treated in the required way, thus avoiding immission of ra-
dioactive compounds into the hospital sewage and from there into the public sewage
(Emilia-Romagna (2009)).
A dedicate treatment for HWWs is always a good solution, especially in the case
of a large hospital in a rural area, where its treated eﬄuent will be indirectly reused
for irrigation after its discharge into a surface water body.
A co-treatment with UWWs at a municipal WWTP is a common practice, but it
has several drawbacks. In the first place, dilution of HWWs with UWWs is not a
correct practice, as some substances in the hospital eﬄuents may result in inhibition
of the biomass and reduce the removal efficiency. Different WWs treatments may
be appropriate only for some groups of compounds, depending on their chemical-
physical characteristics. Next section gives an overview of the removal capacity of
different treatment steps.
Larsen et al. (2004) explain that parameters influencing the degradation efficiency
are not yet fully understood; in the focus of current research are sludge age (solids
retention time, figure 5.2), substrate availability (substrate inhibition), redox condi-
tions (aerobic, anoxic or anaerobic), sorption (as competitive reaction), and reactor
configuration (number of cascaded compartments, biofilm growth surface, sand fil-
tration).
5.1.1. Physico-chemical treatments
Ternes and Joss (2006) explane that a coagulation - flocculation process was gener-
ally found to be unable to remove PPCPs.
On the contrary, adsorption by activated carbons (both powdered and granular
forms: respectively PAC and GAC) has a great potential for the removal of trace
emerging contaminants, in particular non-polar compounds with a logKow > 2.
PAC dose or GAC regeneration or replacement are critical for excellent removal
rates (Snyder et al. (2006), Bolong et al. (2009)).
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Figure 5.2.: Biological degradation resp. transformation of a micropollutant depends
on the aerobic solids retention time, SRT (adapted from Larsen et al.
(2004))
Schafer et al. (2003) found that the potential of endocrine disrupter compounds
removal by powdered activated carbon, may be up to 90% (at 5 mg L−1 of PAC and 4
hour contact time); Snyder et al. (2006) examined 66 PPCPs and only 9 of them had
a removal efficiency less than 50% at a dose of 5 mg L−1 PAC with 5 h of contact time.
It is important to consider the unavoidable carbon regeneration/disposal issue. PAC
must be disposed of through land, filling, or other solids handling, while spent GAC
must either be disposed of or regenerated. Thermal regeneration of GAC requires
a significant quantity of energy, which may lead indirectly to greater environmental
risks than the presence of trace micropollutants. A cost benefit analysis should take
these factors into account.
Suarez et al. (2009) explain that coagulation-flocculation can be a suitable pre-
treatment option for HWWs in order to partially assimilate their physico- chemical
characteristics to that of UWWs. Concentrations of suspended solids, which showed
to be up to three fold higher in the hospital eﬄuent considered compared to mu-
nicipal sewage, could be very efficiently removed during coagulation- flocculation.
Similarly, hospital eﬄuents were in some occasion significantly stronger polluted
with total COD compared to municipal sewage, which was also partially removed
during pre-treatment.
The lipophilic character of a substance play an important role in the removal rate
with this technologies and those substances that presents strong lipophilic character
shows highest efficiencies.
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5.1.2. Biological treatments
There are five major groups of processes used for WWs treatments (Metcalfe and
Eddy (1991)) and they are: aerobic processes, anoxic processes, anaerobic processes,
combined aerobic, anoxic, and anaerobic processes, and pond processes.
The individual processes are further subdivided, depending on whether treatment
is accomplished in suspended-growth systems, attached-growth systems, or combi-
nations thereof.
It should be noted that all of the biological processes used for the treatment of
WWs, are derived from processes occurring in nature.
As reported in Metcalfe and Eddy (1991), the principal applications of these
processes are for:
1. the removal of the carbonaceous organic matter in WWs, usually measured as
BOD5, total organic carbon (TOC), or chemical oxygen demand (COD);
2. nitrification;
3. denitrification;
4. phosphorus removal;
5. waste stabilization
Several studies have examined the effectiveness of conventional activated sludge
processes (CAS) and UF MBR in removing emerging contaminants (among them
Clara et al. (2005a), Kimura et al. (2007) and Radjenovic et al. (2009)). The main
aspects they investigated have been: role of SRT in removal efficiency and role of
nitrifying bacteria in biodegradation. It was found that:
• Removal efficiencies were enhanced for several investigated contaminants at
longer SRT (> 15 d), with threshold SRT for some compounds, beyond which
removal rates did not improve. Longer SRT allows for the establishment of
slower growing bacteria (i.e. nitrifying bacteria) which in turn provide a more
diverse community of microorganisms with broader physiological capabilities,
enhance metabolic and co-metabolic processes which also affect recalcitrant
compounds and promote a more complete mineralization (Kreuzinger et al.
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(2004), Clara et al. (2005a); Clara et al. (2005b); Daigger et al. (2005); Op-
penheimer et al. (2007)).
• For some compounds (ibuprofen, methyl paraben, galaxolide, triclosan, caf-
feine) there is no significant difference in removal efficiencies by CAS and
MBR (Oppenheimer et al. (2007)), while for many other pollutants experi-
mental investigations have demonstrated that MBR technology generally out-
performs the CAS treatment in their removal from WWs, the removal effi-
ciency by MBR was 30-50% greater than in CAS. Moreover the elimination
of some compounds that showed recalcitrant for the CAS treatment, such as
mefenamic acid, indomethacin, diclofenac, and gemfibrozil, was significantly
improved in the MBRs at up to around 40, 40, 65, 32-42% (Ternes and Joss
(2006); Bouju et al. (2008); Reif et al. (2008); Radjenovic et al. (2009)). Some
persistent substances as carbamazepine were not removed by either MBR or
CAS treatment.
• No relationship was found between the structures of the investigated com-
pounds and their removal during WWs treatment. The range of variation of
the efficiency of removal by MBR was small for most of the compounds, while
in conventional treatments, greater fluctuations were observed, and removal
efficiency was found to be much more sensitive under operating conditions
(pH, redox potential, temperature, flow rate, etc) (Ternes and Joss (2006);
Radjenovic et al. (2007)).
• The constant of biological degradation kbiol provides information about the
tendency of the compounds to be removed by biological processes. If kbiol <
0.1 L gSS−1 d−1 degradation is in general < 20%, if kbiol > 10 L gSS−1 d−1 the
biodegradation is greater than 90% (Ternes and Joss, 2006). The table in the
appendix reports the values, or the range of values, for many pharmaceuticals
and other emerging contaminants, found for MBR and CAS systems.
• Dividing the available reactor volume into reactor cascades can significantly
improve performance (Joss et al. (2006), Ternes and Joss (2006)).
• Batt et al. (2006) and Marttinen et al. (2003) found that nitrifying bacteria
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have a key role in the biodegradation of pharmaceuticals in WWTP that are
operated at higher SRTs. Miege et al. (2008) found that in biological sys-
tems with nitrogen treatment the removal efficiency of PPCPs is in general
higher than for other treatments such as submerged biofilters or fixed biomass
reactors.
• All the investigations agree in considering secondary biological treatments to
be an effective barrier for most emerging compounds.
Resuming the main PhC removal mechanisms in CAS processes are a combina-
tion of biodegradation due to suspended biomass and sorption onto particles, flocks
and then sludge. Many factors, other than the characteristics of the compounds
themselves, affect the elimination rate of PhCs. The most important are design and
operational factors such as SRT, HRT, water temperature, pH, load factor to the
biological reactor, configuration and type of plant. In general, biological degrada-
tion is favoured by higher SRTs, although not all PhCs exhibited a critical SRT.
Indeed, although Clara et al. (2005a) found that a SRT > 10 d is needed for some
biodegradable PhCs to achieve low eﬄuent concentrations, other studies (Joss et al.
(2005), Vieno et al. (2007a)) noticed no clear correlation between elimination rate
and SRT.
A minimum HRT is also important, as it allows the degradation of PhCs. Rain
events in areas with combined sewer systems compromised the removal efficiencies
of CAS, presumably due to shorter HRTs and washout of certain microorganisms
(Vieno et al. (2007a)). Biological reactions are greatly affected by temperature,
and lower efficiencies have been observed during winter seasons in colder climates
(Vieno et al. (2005)). However, it is still unclear whether temperature dependencies
commonly observed for biological treatment also apply to the transformation of an-
tibiotics or micropollutants in general (Ternes (1998), Tauxe-Wuersch et al. (2005),
Gobel et al. (2007)). High removal rates of PhCs have been suggested to occur
in WWTPs with high levels of nitrogen removal (Clara et al. (2005a), Batt et al.
(2006)), although Vieno et al. (2007a) found that nitrifying reactors do not enhance
the elimination of fluoroquinolone antibiotics, beta - blockers or carbamazepine.
Sorption to activated sludge was also found to be of minor importance for those
compounds, with an estimated sorption constant Kd of between 114 and 460 L kg−1.
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In general, less than 10% of for compounds with Kd < 500 L kg−1 elimination by
sorption onto activated sludge at an average sludge production of 200 g m3 is less
than 10% (Ternes et al. (2004a)).
Analysis of the influence of the redox conditions on PhC removal in the con-
ventional treatments, has not yet been extensively considered. In a CAS system,
this parameter varies greatly between the different compartments of nitrification (>
100mV) and denitrification (from about -200 to +100 mV).
This behaviour of PhCs in CAS system can be correlated to:
• the configuration of the biological reactor: beta-blockers, for example, seem
to be eliminated to a lower degree in denitrification processes, as compared to
activated sludge treatment, designed for the removal of biologically degradable
organic matter, or to ditch oxidation processes (Vieno et al. (2007a));
• the presence of deconjugates which interfere to a viable extent with biological
transformation of the deconjugated compounds.
An interesting representation of the fate of the organic contaminant during sewage
eﬄuent treatment is done from Rogers (1996). This article explains that organic con-
taminants in eﬄuent streams can be removed by a wide range of different processes,
as reported in figure 5.3. However, most of these techniques are only appropriate to
specific eﬄuents of industrial origin and are expensive. In order to predict whether
or not a particular organic contaminant is likely to be accumulated by the sewage
sludge matrix, the following factors need to be taken into account.
• sorption (onto solid surface or association with fats and oils)
• chemical degradation (abiotic processes e.g. hydrolysis)
• biodegradation
• volatilisation
Sorption and volatilisation are physical processes and their importance for specific
contaminants can be predicted using physicochemical data. During primary sedi-
mentation, hydrophobic contaminants may partition onto settled primary sludge
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Figure 5.3.: Organic contaminant fate during sewage and industrial eﬄuent treat-
ment adapted from Rogers (1996)
solids and this tendency to accumulate in sewage sludge solids, can be assessed us-
ing the octanol - water partition coefficient (Kow). In general the following guide to
the significance to sorption can be used:
logKow < 2.5 low sorption potential
logKow > 2.5 and < 4 medium sorption potential
logKow > 4 high sorption potential
The significance of volatilisation losses of specific organic compounds during sewage
treatment, can be estimated using the following empirically defined categories, based
on Henry’s Law constant (Hc) and Kow:
Hc > 1× 10−4 and Hc/Kow > 1× 10−9: high volatilisation potential
Hc < 1× 10−4 and Hc/Kow < 1× 10−9: low volatilisation potential
Figure 5.4 (from Joss et al. (2006)) gives an overview of kinetic degradation rate
constants for 35 PhCs, hormones and personal care products in nutrient-eliminating
sludge. According to these data, the load of only four compounds (ibuprofen, parac-
etamol, 17β-estradiol and estrone) out of 35, are expected to be biological trans-
formed, by more than 90% (kbiol >10 L gss−1 d−1). Sixteen compounds are expected
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to be partially removed (0.1 > kbiol >10), whereas no remarkable biological transfor-
mation is predicted for 17 compounds (kbiol < 1; among others most of the macrolide
and sulfonamide antibiotics observed). The results of figure 5.4 are generally in good
agreement with data found in the literature (Beausse (2004), Buser et al. (1999),
Heberer (2002a), Heberer (2002b), Ternes (1998)).
Figure 5.4.: Kinetic degradation constants of 35 pharmaceuticals, hormones and per-
sonal care products observed in sludge from nutrient and removing in
WWTP
However, some studies differ significantly from our results (diclofenac and in-
domethacin in Ternes (1998), fenoprofen, ibuprofen, indomethacin, gemfibrozil and
estrogens in Urase and Kikuta (2005)): at least part of the difference may be ex-
plained by (i) substantially higher experimental pharmaceutical concentration, (ii)
sludge origin (sludge age, WW composition, flow scheme) or (iii) sludge handling
prior to batch experiments (e.g. artificial substrate dosing, sludge storage).
In figure 5.4 the error bars indicate the 95% confidence interval. The lines at kbiol
0.1 and 10 L gss−1 d−1 indicate the limits for less than 20% and more than 90%
removal expected for nutrient and removing in WWTP. The faded columns indicate
values for which the limited experimental resolution allows only identifying an upper
limit for kbiol (upper error bar).
Stasinakis et al. (2010) explained that investigation of EDCs sorption in batch
experiments showed that SRT did not affect the sorption potential of TCS and
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BPA, while higher sorption constants were observed for 4-n-nonylphenol at SRT of
20 days. The use of lab-scale continuous-flow systems, showed that for an HRT of 10
h and SRT ranging between 3 and 20 days, the major part of EDCs (>90%) can be
removed during activated sludge process, mainly via biodegradation. Calculation of
the mean pseudo- first-order biotransformation rates at different SRT showed that
EDCs values were ranged between 178 to 507 L g VSS−1 days−1, 30 to 288 L g
VSS−1 days−1 and 17 to 113 L g VSS−1 days−1 for 4-n-nonylphenol, triclosan and
bisphenol A, respectively.
Resuming the most important removal pathways of organic compounds during
WWs treatment are biotransformation - biodegradation, adsorption to the sludge
(excess sludge removal) and stripping by aeration (volatilization). Also, abiotic
removal from the aqueous phase by hydrolytic degradation and/or isomerisation -
epimerisation can occur.
In most of the studies, two processes of abiotic (adsorption) and biotic degrada-
tion (transformation by microorganisms) could not be distinguished, and the term
removal usually refers to a conversion of a certain micropollutant to other com-
pounds than the parent compound. Moreover, without stoichiometric accounting
for the human metabolites and products of photo and biodegradation one cannot
conclude whether the compound was structurally altered or destroyed, since it could
only exist in another state or form.
Sorption of micropollutants onto sludge will mainly depend on two mechanisms
(see figure 5.5):
• absorption: hydrophobic interactions of the aliphatic and aromatic groups of
a compound with the lipophilic cell membrane of the microorganisms or the
lipid fractions of the sludge,
• adsorption: electrostatic interactions of positively charged groups of chemicals
with the negatively charged surfaces of microorganisms.
Suspended-growth systems: Limiting factors
The behaviour of micropollutants in suspended biomass in biological systems, which
are very common. It is seen that, their biodegradation is tied to a particular pa-
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Negatively loaded surface
Lipophilic cell membrane
Adsorption of a positivecharged compoundor Van der Waals bonds
Absorption of a hydrophobic compoundin the cell membrane
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Bacterium
Figure 5.5.: Illustration of adsorption and absorption of pharmaceutical onto the
microorganism cell (Larsen et al. (2004))
rameter: the age of the sludge when high (> 20 d) helps the acclimation of many
bacterial.
In most WWTP the biological system concerns in a biological treatment, with
activated sludge, with sludge age in a range of 5 and 8 days. To increase the mi-
cropollutant (like PhCs) removal efficiency may be possible two different strategies:
to upgrade the existing plants or to add final treatments (end-of-pipe).
Some compounds may be absorbed or adsorbed into the activated sludge biomas.
This is relevant only for those lipophilic and hydrophilic compounds that can interact
specifically (such as surfactants) with the staple of activated sludge. In these cases,
those compounds captured from the flakes of activated sludge, partially degraded
inside sludge floc bacteria, some remain in the settled sludge and then passed to
subsequent stages of treatment sludge.
In the case of CAS systems, the eﬄuent of the secondary settler is subject to vari-
ations in the content of suspended solids, to the inevitable leakage of the activated
sludge tank. Consequently, even as it was adsorbed / antigen is not retained. MBR
system guarantees a constant high quality final eﬄuent for the most efficient removal
of suspended solids (often < 1 mg L−1). The difficulty at this point is to identify
classes of compounds that are not adsorbed by activated sludge and, because of their
chemical and physical - remain dissolved in water and are difficult to degrade, such
as certain medications such as carbamazepine, diclofenac, contrast media. Some of
the most recent published studies analysed, with regard to the removal of these mi-
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cronquinanti, the succession of different steps of advanced treatments downstream
of activated sludge biological systems (Okuda et al. (2008), Suarez et al. (2008)).
5.1.3. MBR
There is a lot to admire about membrane bioreactors (MBRs). This emerging WWs
treatment technology combines a suspended growth biomass, similar to those used
in the traditional activated sludge process, with a membrane system that replaces
gravity sedimentation and that retains biomass and clarifies eﬄuent (Stephenson
et al. (2000)). MBRs offer a host of technical advantages over activated sludge
systems, such as small size, and seem to be well suited for applications such as
water reuse. Figure 5.6 illustrates the components of an MBR and contrasts them,
with those of a traditional activated sludge process, as reported for example in
Daigger et al. (2005).
(a)
(a) Traditional and (b) membrane bioreactor system that use activated sludge have the same basic components, but the details differ when membranes replace thesettling tank to separate out solids. RAS = return activated sludge; WAS = waste activated sludge
RAS WAS
RAS
(b)
Membrane separator
WAS
Figure 5.6.: Comparison of traditional and bioreactor methods (from Daigger et al.
(2005))
One of the key issues in wastewater recycling is the emerging problem of microp-
ollutants such as pharmaceuticals, hormones, fragrances and personal care products
(PCPs).
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The MBR technology integrates biological degradation of organic matter present
in wastewater with membrane filtration, thus surpassing the limitations of the con-
ventional activated sludge (CAS) treatment (e.g., limited operational solids retention
time (SRT), sludge settling characteristics). At prolonged SRT applied in an MBR
the biomass growth is not restricted to fast-growing and floc-forming microorgan-
isms, whereas the dispersed bacteria can develop.
The fate of a certain pharmaceutical in a complex system of WWTP will depend
on various parameters (e.g., applied SRT, hydraulic retention time (HRT), tem-
perature, pH, biomass concentration, compound’s polarity, biodegradability, cation-
exchange properties). During sewage treatment pharmaceutical residues can be
removed from the aqueous phase either through abiotic processes (e.g., sorption iso-
merisation or epimerisation, hydrolytic degradation) or by biotic transformation or
degradation.
However, PhCs can absorb onto bacterial lipid structure and fat fraction of the
sewage sludge through hydrophobic interactions (e.g., aliphatic and aromatic groups),
adsorb onto often negatively charged polysaccharide structures on the outside of bac-
terial cells through electrostatic interactions (e.g., amino groups), and or they can
bind chemically to bacterial proteins and nucleic acids (Meakins et al. (1994)).
Some authors tried to estimate separately contributions of adsorption and biodegra-
dation to the removal of PhCs in CAS and MBR treatments based on literature
values for solid-water distribution coefficients (Kd) or by direct measurements of the
adsorbed and dissolved amounts of pharmaceuticals in batch experiments (Kimura
et al. (2007), Clara et al. (2005a), Joss et al. (2006), Urase and Kikuta (2005)).
In genearal MBR technology generally outperforms the CAS treatment in remov-
ing PhCs from WWs (Radjenovic et al. (2009)).
As reported for example in Radjenovic et al. (2009), the elimination of some com-
pounds that showed recalcitrant for the CAS treatment was significantly improved
in the MBRs up to around from 32 to 65% (figure 5.7).
From the aspect of the excess sludge produced, advanced MBR technology would
be attractive concept, not only in terms of the cost reduction of sludge treatment due
to its lowered production, but also because it diminishes the environmental impact
of WWs treatment, since the MBR sludge is less contaminated with PhCs than the
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Figure 5.7.: Comparison of the mean removals of encountered pharmaceuticals in
full-scale CAS and pilot-scale MBRs. From Radjenovic et al. (2009)
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sludge produced during the conventional treatment. The amount of PhCs, sorbed
onto sewage sludge may increase the environmental risk of these micropollutants,
since they can become bioavailable when conditions for desorption are created.
Moreover the literature in Bouju et al. (2008) shows that MBRs should be more
efficient on Persistent organic pollutants (POPs) removal than CAS, especially on
the substances which are poorly biodegradable, while it does not improve the removal
efficiency for the non-degradable ones. The comparison with the removal obtained
in a very large conventional WWTP operating at quite high SRT will be particularly
significant.
Also Hawkshead (2008) concludes that MBR system can represent an important
alternative to CA in the HWWs treatments and, for a correct treatment of HWWs,
Beier et al. (2011) reports the design requirements for MBRs. Based on the oper-
ational experience gained at this site and on technical and economic optimisation,
the following aspects should be considered in the design of MBR treating hospital
wastewaters in high density urban areas:
• separate rainwater collection to reduce dilution effects
• where applicable, separation of water streams with low pharmaceutical con-
centrations (e.g. kitchen and laundry wastewaters)
• sludge age in the MBR > 100 days to allow for biomass adaptation
• thermal treatment of the waste activated sludge and screenings for complete
destruction of the adsorbed pharmaceuticals
• consideration of the special requirements on emission levels (noise and aerosols)
for hospital patients with a weak immune system and/or needing a quiet en-
vironment as well as those of nearby residents.
Also Liu et al. (2010) think that membrane technology is more efficient at remov-
ing pathological microorganism, compared with other WW treatment systems.
Recently, more attention has been paid to the membrane bioreactor (MBR) tech-
nology for HWWs treatment, because of its higher efficiency in pollutant removal,
excellent eﬄuent quality, low/ zero sludge production, compact size and lower en-
ergy consumption (Stephenson et al. (2000),). Previous researches on MBRs have
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shown that an MBR is extremely efficient in the removal of bacteria (Krauth and
Staab (1993)) and viruses (Lv et al. (2006)).
5.1.4. Nanofiltration
The removal of PhCs by NF membranes occurs via a combination of three mecha-
nisms: adsorption, sieving and electrostatic repulsion. The removal efficiency can be
very different and varied from compound to compound and it is strictly correlated
to:
• micropollutants physical-chemical properties like molecular size, solubility, dif-
fusivity, polarity, hydrophobicity and charge,
• membrane properties like permeability, pore size, hydrophobicity and surface
charge
• membrane operating conditions like flux, transmembrane pressure, rejections
or recovery and water feed quality.
NF has been demonstrated to be a promising alternative for eliminating PhCs,
as it is able to achieve removal rates greater than 90%, as reported for example in
Yoon et al. (2006) and Bolong et al. (2009).
It is also important to consider RO and NF brine disposal. In general, brine is
much more toxic than the influent water, so it is not sustainable to dispose of it into
natural water as reported by Watkinson et al. (2007).
Beier et al. (2010) conclude his comparison between NF and RO, explaining that
in general MBR technology and downstream high pressure membrane filtration is
an adequate approach for the specific treatment of hot spot wastewater with hight
concentrations of trace pollutant or PhCs residues. In particular only RO ensured
an entire removal of relevant PhCs residues from HWWs. Nonetheless, RO has some
major disadvantages particularly due to the limited yield and the retentates which
need to be adequately disposed. However, the appropriateness of an application of
NF/RO should be checked for each individual case.
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5.1.5. Reverse osmosis
Several studies describes the effectiveness of RO in the removal of PPCPs and en-
docrine disrupter compounds from secondary wastewater eﬄuents (among them
Snyder et al. (2003), Oppenheimer et al. (2007)). Braghetta and Brownawell (2002)
estimated removals of many compounds to be greater than 90%. Lower removal
rates were found for diclofenac (55.2-60%) and ketoprofen (64.3%). According to
WERF (2005), RO achieved removal rates of 90% or better for naturally occurring
and synthetic steroids, organohalides and other compounds. Oppenheimer et al.
(2007) found that RO was able to remove all the investigated compounds below
their corresponding detection limits, including those that were not significantly re-
moved at SRTs of 30 days (for instance, galaxolide) using CAS treatment or media
filtration.
Beier et al. (2010) show that only RO ensured an entire removal of relevant phar-
maceutical residues from HWWs.
5.1.6. Chlorination
Ternes et al. (2003), and Huber et al. (2005) demonstrated that the ozone amounts
required for PPCPs oxidation lead to a partial disinfection. It is expected that, as
for sorbed compounds, microorganisms incorporated into particulate matter, would
be significantly shielded from ozone or OH. radicals. A concentration of 5-10 mg O3
L−1 and a contact time of 15-20 min are sufficient to obtain a reduction of 2-3 log
units (Chiang et al. (2003); Ternes and Joss (2006)). Referring to the disinfection
action of chlorine and its compounds, Nardi et al. (1995) found a good removal rate
of bacteria as well as viruses in the eﬄuent from an infectious diseases ward by
adding 10 mg L−1 of ClO2 and guaranteeing a contact time of 30 mins. Emmanuel
(2004) studied the toxicological effects of disinfection using NaClO. He found that
doses of 1-8 mg L−1 of disinfectants can greatly reduce bacteria pollution but give
rise to toxicity effects on aquatic organisms, thereby contributing to the formation
of AOX in HWWs.
For our studies about the disinfection with PAA and NaClO of raw HWWs see
section 4.1 where are reported all the results and some comments about this practice.
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5.1.7. Ozonation and AOPs
These techniques are promising for an efficient degradation of pharmaceuticals in wa-
ter and wastewaters (Chiang et al. (2003); Huber et al. (2003); Balcioglu and Otker
(2003); Ternes et al. (2003); Andreozzi et al. (2005); Machado et al. (2007); Zim-
mermann et al. (2008)). A common result is an increment in the ratio BOD5/COD
and the improvement in the biodegradability of persistent substances such as an-
tibiotics, cytostatic agents, hormones, X-ray contrast media, carbamazepine and
some acidic drugs like clofibric acid. Some pharmaceuticals are extremely reactive
towards molecular ozone: some antibiotics, the anticonvulsant carbamazepine, the
antinflammatory diclofenac, the estrogen 17β-estradiol. Others are relatively resis-
tant to ozonation: the anti-anxiety agent diazepam, the analgesic ibuprofen. ICM
are in general particularly refractory to ozonation.
Ozone-base AOPs (O3/H2O2, O3/UV), Fenton-type processes and photochemical
AOPs are generally more effective than ozonation alone due to enhanced generation
of hydroxyl radicals and photon-initiated cleavage of carbon-halogen bonds, thus
they are recommended for the treatment of these recalcitrant substances (Ikehata
et al. (2006)).
The degree of degradation of PhCs achieved by ozonation or AOPs depends on
a number of factors: oxidant dose, concentration of pharmaceuticals, wastewater
quality parameters, mode of operation.
The dose of ozone that is commonly applied ranges between 5-15 mg L−1 depend-
ing on the COD in the wastewaters, and a contact time of about 15-30 min (Ternes
et al. (2003); Ternes and Joss (2006)). The removal of PhCs is in general > 90%. The
presence of particulate matter at concentrations regularly present in the secondary
eﬄuent does not influence the removal efficiency of soluble compounds showing high
reaction rates with ozone. Huber et al. (2005) show that soluble compounds readily
reacting with ozone, will be oxidized a hundred times faster than organic matter ag-
glomerated particles due to limitation by diffusion. However, the removal efficiency
of compounds requiring higher ozone dosage is reduced with increasing content of
organic particulate matter due to the loss of oxidant equivalents.
AOPs can be more effective than ozonation for many compounds, but for others,
like ICMs or complex molecule compounds containing chlorines, they lead to a slight
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increase of oxidation efficiency (Joss et al. (2004); Wen et al. (2004); Pauwels and
Verstraete (2006); Bouju et al. (2008)), thus further studies are necessary.
Ternes et al. (2003) reports that Ozonation using 5-15 mg L−1 of ozone is appro-
priate to oxidize pharmaceuticals, musk fragrances, estrogens and to simultaneously
inactivate relevant microorganisms.
The results presented in Huber et al. (2005) have shown that important classes of
pharmaceuticals present in WWs eﬄuents such as macrolide and sulfonamide antibi-
otics as well as synthetic and natural estrogens, can be selectively oxidized by use
of relatively low O3 doses. Furthermore, the results demonstrated that suspended
solids have only a minor effect on the oxidation of pharmaceuticals. Ozonation of
wastewater eﬄuents will mainly be a viable solution when the treatment objectives
include micropollutant oxidation and disinfection. Though suspended solids have
limited effect on micropollutant oxidation, they have a clearly negative impact on
disinfection as shown in ref 36 and indicated by the inactivation data for E. coli in
the present study. In the regular CAS eﬄuent, an O3 dosage of 5 mg L−1 seems
sufficient to achieve the guideline values (100 fecal coliforms/100 mL) set by the EU
bathing water quality directive.
5.1.8. Natural polishing treatment
Works about natural treatments are not quite diffuse and in general the authors
are:: Golet et al. (2003), Clara et al. (2004), Clara et al. (2005a), Lindqvist et al.
(2005), Brown et al. (2006), Lindberg et al. (2006), Lishman et al. (2006), Nakada
et al. (2006), Yu et al. (2006), Gomez et al. (2007), Kim and Aga (2007), Kimura
et al. (2007), Santos et al. (2007), Vieno et al. (2007a), Watkinson et al. (2007), Choi
et al. (2008), Gulkowska et al. (2008), Kasprzyk-Hordern et al. (2009), Matamoros
et al. (2009), Santos et al. (2009), Zhou et al. (2009), Rosal et al. (2010).
CWs can promote removal of PhCs through a number of different mechanisms,
including photolysis, plant uptake, microbial degradation and sorption to the soil
(White et al. (2006), Matamoros et al. (2005), Matamoros et al. (2008)). The main
benefits of horizontal and vertical subsurface flow systems are the existence of aer-
obic, anaerobic and anoxic conditions in proximity to the plant rhizomes which
provide an opportunity to reduce concentrations of different drug compounds, as
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some pharmaceuticals are best reduced under aerobic conditions (ibuprofen), re-
moval of others is favored by anaerobic conditions (clofibric acid, diclofenac) (Lin
and Reinhard (2005)) and halogenated pollutants are eliminated at a higher rate
in anoxic conditions. Experimental studies conducted by Matamoros et al. (2008)
and Zwiener and Frimmel (2003) showed that aerobic conditions are in general more
efficient in removing most emerging contaminants than anerobic pathways. In ad-
dition, the photodegradation processes, which take place in surface flow systems,
are able to eliminate certain PPCPs (like ketroprofene and diclofenac) from aquatic
environments (Andreozzi et al. (2003), Bartels and von Tumpling (2008), Zhou et al.
(2009)). High hydraulic retention times promote biodegradation and photodegrada-
tion reactions involved in the removal of emerging contaminants.
Compact biofilters, biological sand filters and constructed wetlands are feasible
technologies to remove a broad spectrum of contaminants including PPCPs from
UWWs in sparsely populated areas. Further research on household WWs treat-
ment systems is, however, still required to fully confirm these results as reported in
Matamoros et al. (2009).
Matamoros et al. (2008) explain that the higher removal efficiencies for emerging
micro contaminants observed in his study than those reported for H-SSF CW and
conventional WWTPs seem to be related to the high HRT (i.e. 1 month in his
study). This high HRT promotes biodegradation and photodegradation reactions
that are involved in the removal of emerging contaminants. Furthermore, seasonal
and spatial trends showed a high dependence on temperature (biodegradation) and
sun irradiation (photodegradation) for the moderately removed compounds. Appar-
ent distribution constants Kd are strongly dependant on the compound ionization.
On the other hand, the neutral compounds are correlated to their hydrophobicity
(log Kow). In general, the studied wetland has a good capacity for removing a variety
of emerging contaminants, close to the ones obtained in highcost tertiary treatments
(ozonation or MBR). Therefore, the application of cost-effective technologies such
as CWs should be considered as an efficient alternative for reducing the amount of
emerging contaminants discharged into aquatic ecosystems.
Moreover Park et al. (2009) studied an engineered CW connected to both a
WWTP and a river with respect to removal potential and related mechanisms for 9
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different organic micropollutants, including PhCs, EDCs and personal care products.
Fairly good removal trends were shown for atenolol, naproxen and triclosan. Sul-
famethoxazole and dilantine, and carbamazepine, diazepam and triclosan exhibited
medium-range and fluctuating (or somewhat low) removal behaviors, respectively.
Attempts were made to determine the dominant removal mechanisms for tested
micropollutants extracted from wetlands soils and plants, using micropollutant ex-
traction methods and two parameters (i.e., logKow and pKa); however, no distinct
patterns were found. Hence, the results of Park et al. (2009) suggest the neces-
sity for further investigations into the removal mechanisms of micropollutants via
biodegradation under anoxic conditions.
Biodegradation, plant exudates and uptake, sedimentation and sorption onto fill-
ing media are the main elimination pathways. Many attempts have been made to
find some relationship between the physicochemical characteristics of PhCs (octanol
water partition coefficient Kow, Henry’s constant H, water solubility Sw, vapour pres-
sure Pv, organic carbon partition coefficient Koc, acid dissociation constant Ka) and
their fate in constructed wetland systems (Imfeld et al. (2009), Kummerer (2009),
Park et al. (2009)), but no clear correlation has yet been found due to the great
variability of compounds and their behaviour. Thus, graphs plotting the percentage
removal rate vs. molecular weight or vs. logKow yield clouds of data, showing a
wide variability in the behaviour of the substances considered.
For instance, some pharmaceuticals contain planar aromatic structures, which
favour intercalation, for example into the layers of some clay minerals. Therefore,
the sorption of such compounds depends not only on the logKow, which is the
lipophilicity of the sorbed molecule, but is also governed by pH, redox potential,
stereochemical structure and the chemical nature of both the sorbent and the sorbed
molecule (Kummerer (2009)).
The coexistence of several microenvironments in CWs allows both the thermo-
dynamic feasibility of chemical reactions and the development of a great variety of
microbiological communities able to guarantee the enzymatic capacity necessary to
achieve the target biogeochemical reactions. This favours various metabolic path-
ways and therefore leads to PhC degradation.
This microenvironmental coexistence is due to the variation of physicochemical
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parameters on different gradients inside the CWs (D’Angelo (2002), Dusek et al.
(2008), Imfeld et al. (2009)), some of which may be generated by the organisms
inhabiting the CW, or by the presence of ramified roots within the medium. These
tend to create aerobic zones near anoxic or anaerobic ones (Stottmeister et al. (2003),
Imfeld et al. (2009)), establishing dynamic oxic or anoxic interfaces in wetlands as
a result of water level fluctuations, oxygen diffusion or advection through the water
column and filling medium, and active oxygen transport through the rhizosphere
via plant tissues.
Summer conditions (mainly warmth and plant activity), high redox potential
(anoxic and oxic conditions) promote the removal of PhCs (Hijosa-Valsero et al.
(2010b)). It also seems that anoxic conditions favour the biodegradation of mi-
cropollutants as they promote biogeochemical reactions: for example, the biological
transformation of amide and urea functional groups (attached to atenolol, carba-
mazepine, dilantin) via mediated hydrolysis reactions has been documented (Chisaka
and Kearney (1970), Englehardt et al. (1973), Matamoros et al. (2008)).
However, aerobic transformations are generally faster than anaerobic ones for
low-chlorinated compounds, while for polyhalogenated compounds aerobic degrada-
tion rates are slower. Furthermore, highly chlorinated substances, like diclofenac,
are known to be biodegraded via a microbe-mediated reduction (Mohn and Tiedje
(1992), Schwarzenbach et al. (2003), Matamoros et al. (2007b), Matamoros et al.
(2008)). These compounds, characterized by their low water solubility, become more
soluble, and therefore more bioavailable, after some initial reductive dechlorination
steps. Under anaerobic conditions, however, microbial degradation takes time and
a subsequent aerobic degradation step is necessary for breaking down the remaining
carbon skeleton.
According to Jones et al. (2005a), long and highly branched side chains render
a compound more persistent, whereas unsaturated aliphatic compounds are more
biodegradable than saturated or aromatic ones featuring complex ring structures
and sulphate or halogen groups.
Occasionally, release of pharmaceuticals occurred in natural systems. It could be
attributable to the presence of substances, e.g. human metabolites, in the inflow to
the treatment step. These could subsequently be transformed into the investigated
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PhC during treatment, as in the case of sulfadiazine and sulfamethoxazole (Gobel
et al. (2005). It is also possible that the PhC was hidden among the suspended
particles in the influent and later released into the water column during its passage
through the filling medium. Indeed, carbamazepine, as already noted, is one of the
most recalcitrant PhCs due to its high hydrophobicity (logKow is 3.5) and refractory
behaviour. Its main elimination mechanism is by retention and adsorption onto the
organic surfaces available in the CW. It is possible that when sorption - desorption
equilibrium is reached, the contaminant will be reversibly retained and then released
into the water column.
The removal mechanisms include abiotic and biotic pathways: sorption onto sedi-
ments and gravel and biodegradation. They depend on many aspects: in particular
H-SSF bed conditions (redox conditions, pH and temperature) chemical charac-
teristics of the wastewater (COD and N compounds), chemical properties of the
pharmaceuticals (Log Kow, pka, logkd).
5.1.9. Photodegradation
Generally speaking, both abiotic and biotic processes determine the fate of organic
compounds in the aquatic environment. For any pollutant, including PhCs, abiotic
transformations in surface waters may occur via hydrolysis and photolysis. Phar-
maceuticals, usually designed for oral intake, are as a rule resistant to hydrolysis
suggesting the mechanism of direct and indirect photolysis as a primary pathway for
their abiotic transformation in surface waters. While direct photolysis of chemical
species is caused by direct absorption of solar light (Zepp and Cline (1977)), the
indirect photolysis involves natural photosensitizers like nitrate and humic acids.
Under solar irradiation, these naturally occurring constituents can generate strong
oxidant species such as hydroxyl radicals and singlet oxygen (Zepp et al. (1981)).
On the other hand, humic acids absorbing solar radiation (Gao and Zepp (1998))
may, by inner filtering, reduce the rate of photodegradation of other organic species
present in the aquatic environment. An additional factor that strongly influences the
rate of photodegradation for any particular pharmaceutical present in the surface
waters, is the variation in the intensity of solar irradiance with both latitude and
season. For a given latitude and the season, the spectral solar irradiance can be
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measured experimentally using pyranometer or can be found in specialized literature
(Frank and Klopffer (1988); EPA (1996)).
STP eﬄuents from four European countries (France, Italy, Greece and Sweden)
with no previous record of pollutants of this type, have been analyzed for the pres-
ence of pharmaceutical residues. The analyses were performed using GC-MS and
HPLC-MS/MS procedures developed in this study. More than 20 individual phar-
maceuticals belonging to different therapeutic classes have been found. Antibiotics,
gemfibrozil, ibuprofen, naproxen, carbamazepine and the majority of b-blockers have
been detected in all samples. The presence of ofloxacin, lomefloxacin, enoxacin and
flurbiprofen found in this study has not previously been reported in STP eﬄu-
ents. In contrast to data published for Germany, betaxolol was not detected in
any of the investigated STP eﬄuents, while trimetoprim and sulfamethoxazole were
present in much lower concentrations than reported for the eﬄuents from German
STPs. The persistence to abiotic photodegradation has been evaluated for six se-
lected pharmaceuticals among those found in the STP eﬄuents. Quantum yields
for photodegradation in salt- and organic-free water estimated for carbamazepine,
diclofenac, clofibric acid, sulphamethoxazole, oflaxocin and propranolol have been
used to predict half-life times at varying seasons and latitudes. The results demon-
strate that the photodegradation halflife times of carbamazepine and clofibric acid
are approaching 100 days in winter at the highest latitudes (50 N), whereas under
the same conditions sulfamethoxazole, diclofenac, ofloxacin and propranolol undergo
much faster degradations with t1/2 respectively of 2.4, 5.0, 10.6 and 16.8 days. The
presence of nitrate ions in aqueous solutions (5.0-15.0 mg L−1) results in a reduction
of t1/2 for the studied compounds, propranolol excepted. Humic acids (concentration
of 5.0 mg L−1) act as inner filters during the photodegradation of carbamazepine
and diclofenac and as photosensitizers for sulphamethoxazole, clofibric acid, oflax-
ocin and propranolol Andreozzi et al. (2003).
The data strongly suggest inputs of diclofenac into rivers and lakes from human
medical use viaWWTPs. The study of Buser et al. (1998), however, also showed that
diclofenac is not very persistent in a lake (Greifensee) and that it is rapidly degraded,
most likely via direct photolysis. The results are important because they document
the rapid elimination of this compound in surface water under field conditions. The
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findings have transfer character because the same process can be expected in other
water bodies (lakes, streams) with a sufficient time constant, as suggested by the
consistently low concentrations observed in the outflows of other lakes. This rapid
elimination of diclofenac in the lake is different from the behavior of many other
environmental contaminants. So far, the evidence for photodegradation is from
laboratory experiments and kinetic considerations. Direct evidence, such as from
photodegradation products in the lake, is still lacking and additional research is
required for verification.
5.2. Role of pH and Redox potential
Many pharmaceuticals have weak acid or weak base functional group as part of
their structure that lead to thermodynamically accessible ionized and unionized
forms at physiological pH values. The ionized forms aid aqueous solubility, while
the non-ionized forms can diffuse more easily through lipophilic membranes. Conse-
quently, numerous pharmaceuticals have environmentally relevant pKa values, with
ionized and non-ionized species, being present under natural conditions. Each of
these species must be considered to fully anticipate the pharmaceutical’s aquatic
chemical behaviour. This situation is exemplified by a set of sulfa drugs, whose
photochemistry is strongly modulated by their speciation. The effect of speciation
of photochemical reaction rate applies not only to direct processes, but also to indi-
rect processes. For example, it is well documented, that single oxygen reacts quickly
with phenolate ions, but not with phenols (Petrovic and Barcelo (2007)).
Kummerer (2009) explains that antibiotics can be grouped by either their chemical
structure or mechanism of action. They are a diverse group of chemicals, that can
be divided into different sub-groups such as β-lactams, quinolones, tetracyclines,
macrolides, sulphonamides and others. They are often complex molecules which
may possess different functionalities within the same molecule. Therefore, under
different pH conditions antibiotics can be neutral, cationic, anionic, or zwitterionic
(figure 5.8a and b and figure 5.9a and b). Because of the different functionalities
within a single molecule, their physico-chemical and biological properties such as
logPow, sorption behavior, photo reactivity and antibiotic activity and toxicty may
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Figure 5.8.: Chemical structure of ciprofloxacin (a); at different pH ciprofloxacin car-
ries different electrical charges i.e., different chemical species are present
(b). From Kummerer (2009)
change with pH.
Ciprofloxacin (figure 5.8a), for example, possesses both basic and acidic function-
alities. The acid constants are 6.16 and 8.63. At a pH of 7.4, the iso-electric point
of ciprofloxacin, the molecule carries both a negative and a positive charge, i.e. it is
neutral as an entity despite these charges within the molecule (figure 5.9b). Solu-
bility, hydrophobictiy and hydrophilicity, and therefore logKow or the distribution
coefficient logKD, are all dependant upon pH.
Suarez et al. (2010) conclude that the main removal mechanisms for PPCPs only
(bio)transformation were significant for the majority of compounds. In the case
of musk fragrances, a significant fraction (7-18%) of compounds left the anoxic
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Figure 5.9.: Chemical structure of ceftazidime (a); ceftazidime forms an internal
zwitterion and can from additional chemical species as a function of pH
(b). From Kummerer (2009)
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reactor sorbed onto solids, whereas sorption was negligible in the case of the aerobic
plant, which was associated to the better settling characteristics of the nitrifying
biomass developed in that reactor. Volatilisation was only significant for ADBI
and contributed between 3 and 16% to the removal of this substance in the aerobic
system.
5.3. Source separations
In an interesting article Ternes et al. (2004b) explained that many PPCPs have lim-
ited biological degradability. Therefore, these compounds are only partially elimi-
nated when passing through WWTPs and end up in receiving waters or sorbed to
sludge that may be used for fertilizer. Source control and apportionment appear to
be the permanent, cost-effective solution for most compounds.
In particular:
• Separate treatment of HWWs. HWWs is heavily loaded with pharmaceuticals
and antibiotic-resistant bacteria. Separate treatment of HWWs, such as by
using a membrane bioreactor followed by ozonation of the eﬄuent, should be
considered. These measures could also be beneficial to the hospital. Treated
wastewater could be reused for flushing toilets and for gardening or it could
be directly discharged, reducing associated drinking-water fees and avoiding
wastewater fees.
• Labeling of PPCPs. Adding information about the environmental impacts of
a PPCP to its packaging could significantly reduce the use of harmful chem-
icals. For instance, Sweden has discussed introducing an environmental label
for pharmaceuticals, in cooperation with the chemical industry. This would
enable physicians and patients to select the most environmentally friendly
pharmaceuticals for a particular course of treatment (Ternes et al. (2004b)).
• Disposal of PPCPs. The disposal of PPCPs should be controlled and super-
vised. For example, as general practice, expired or superfluous products should
be collected and incinerated or possibly reused under controlled conditions.
• Urine separation. Pharmaceuticals are excreted to a great extent in urine
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as reported in Ternes et al. (2003). Larsen and Gujer (1996) shown that
separation and unique treatment of urine would significantly reduce the loading
of the wastewater and would allow recycling of the nutrients.
However, these four measures require political decisions, acceptance from the gen-
eral population, money for new infrastructure, and decades for their implementation.
Therefore, in the short term, a load reduction is easier to achieve within the WWTP.
Lienert et al. (2007a) concludes that the assumption that most pharmaceuticals
are excreted with urine could be verified to a certain extent. This statement is
valid for some pharmaceuticals and therapeutic groups, but is not all true for oth-
ers. Some of the detected inconsistency reflects biologically variability, but much
is caused by the large difference in physicochemical proprieties of the pharmaceuti-
cals. Moreover, just relying on mass balance does not necessarily correspond with
the ecotoxicological relevance.
In substance 70% of a pharmaceuticals was excreted via urine but Lienert et al.
(2007b) found that the environmental risk potential was estimated to be about equal
in urine and faeces. However they hypothesise that the PhCs in faeces, wich are
generally more lipophilic, might adsorb well to faecal matter and end up in the
sludge. If this is true, the fraction of micropollutants in faeces might be better
removable from WWs than the hydrophilic fraction in urine and a combination of
the two measures might prove to be very effective.
A solution for the final reduction of the PhCs diffusion into the environment is
for example the incineration. More countries, like for example Switzerland, use this
practice for the sludge deriving from WWTP.
5.4. Sustainable Technologies for HWWs
Essentially, hospitals are the main source of pharmaceutical compounds (PhCs) re-
leased into the environment. Generally, their discharges are co-treated with UWWs,
resulting in a decrement of the recalcitrant compounds concentrations in the final
eﬄuent due to water dilution. However, as many PhCs resist normal treatments,
pollutant load does not change.
HWWs are composed of the eﬄuents of three different services: (i) general services
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(kitchen, internal laundry, heating and cooling systems), (ii) diagnostic services (lab-
oratories, radiology departments, outpatients’ departments, transfusion centres) and
(iii) wards (general medicine, surgery, specialities, haemodialysis, etc.). In Italy and
in many other countries, by law, the eﬄuents from specific wards or services (such
as nuclear medicine or histological laboratories) that contain radioactive wastes or
anatomical parts cannot be discharged into the hospital sewage network, but must
be collected in adequate hermetic baskets and given to authorized disposal firms
(Emilia-Romagna (2009)).
By law, HWWs are often considered to be of the same pollutant nature as UWWs,
and so they are generally discharged into (municipal) sewer networks, collected at
a WWTP and treated along with UWWs. The only pre-treatment that could be
required before entering the sewer is a mild chlorination of the whole eﬄuent in
order to reduce its microbiological load.
WWTPs were originally built, and have more recently been upgraded, with the
aim of removing carbon, nitrogen and phosphorus compounds in addition to the
microbiological organisms which are the pollutants regularly arriving at the plant
in concentrations to the order of mg L−1 and at least 105 CFU/100 mL. HWWs
represent a unique kind of wastewater due to the nature and quantity of the micro-
pollutants which are typically present at µg L−1: active substances of medicines and
their metabolites, chemicals, heavy metals, disinfectants and sterilizers, radioactive
markers, (Emmanuel et al. (2001); Kummerer (2001); Altin et al. (2003); Jones et al.
(2005a)). Moreover, HWW flow rates generally amount to only a small percentage
of the total influent flow rate for co-treatment at a municipal WWTP. Consequently,
dilution of HWWs with UWWs usually results in a decrement of the PhCs content
in the final eﬄuent (from µg L−1 to ng L−1), but not in the total load, that is, the
quantity released daily into the receiving water body.
In cases where the hospital component represents a significant percentage (>
25%) of the WWs entering to the WWTP, and the receiving water, is intended for
irrigation or recreational uses, it would be take in consideration a good treatment
with chemical and biological degradation and separation, such as MBR, ozonation,
advanced oxidation systems.
The ability to degrade the more persistent substances depends on the availability
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of a sufficient number of specific microorganisms and their time of acclimatization.
Sufficiently high sludge age (at least 25-30 d) promote the occurrence of these con-
ditions, even if they are not always sufficient to complete degradation (Joss et al.
(2004)).
Some PhCs, as well as bacteria and viruses, tend to adsorb or absorbed on the
surface of solids within the biological reactor. Filtration through a UF membrane
due to the small pore size that characterizes this technology, can effectively stop all
the non solved contaminants. Therefore, the MBR system with UF membranes are
a suitable technology for the HWWs treatments for biological, chemical and physical
mechanisms that are activated inside the reactor tank.
Moreover, it is important to show that some PhCs are not retained by the mem-
brane system, for example those from more complex molecules or containing partic-
ular groups (Wen et al. (2004), Pauwels et al. (2006), Bouju et al. (2008)) because
they remain in the dissolved phase and are not retained by the membrane.
Jacobsen et al. (1993) found that removal by sorption was important for penta-
chioropbenol (but the same is for PhCs) and was up to 50% of the total removal at
short SRTs (< 3 days), decreasing to 5-10% at higher SRTs (> 14 days). There are
two reasons to expect that sorption in bioreactors with low SRTs will play a more
important role than for bioreactors with high SRTs: (i) at low SRT, the slow grow-
ing specific degraders will be washed out from the reactor system. Consequently,
biodegradation is stopped and the concentration level in the bioreactor increases,
which leads to an increased sorption and (ii) a higher mass-flow of wasted biomass
will contribute to an increased removal of pollutants in the sorbed phase.
Many studies like Ternes et al. (2004a), Pauwels and Verstraete (2006) and Jones
et al. (2005a) and the European project Poseidon (Ternes and Joss (2006)) made
by many Europeans research groups agree on the necessity to pay more attention to
the microbiological and chemical nature of the waste in question (the hospital).
Another important point is about the pollution load of this particular WWs,
difficult to treat for the qualitative and quantitative characteristics, especially in
view of the final point of discharge and mainly its intended use.
In conclusion for the most appropriate treatment for HWWs, there is a preferred
sequence to recommend and in general:
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• a separate treatment for HWWs is recommended in order to avoid dilution
due to mixing with urban sewage during co-treatment
• a biological treatment is necessary to remove organic load. Longer SRT
and high concentrations of the biomass in the biological tanks favour all the
biodegradation processes. UF membrane technology seems to be a promising
means for removal of pharmaceuticals; these treatments should be optimized
by modification of the membranes (variation of the materials and reduction of
molecular mass cut-off limits) and or by modification of the treatment process
(inoculation of specific microorganisms)
• ozonation and AOPs are at present considered promising techniques due to
the fact that they can react with many recalcitrant compounds, resulting in a
more biodegradable eﬄuent;
• GAC and PAC can enhance the removal of many PhCs.
Further studies and experimental investigations are required in order to evaluate
the capacity for removing the main PhCs from WWs by the different treatment steps
and to provide information about the most efficient ones from a technical and an
economic point of view.
As already stated, there is no specific treatment able to remove, at high percent-
age, all kinds of micro-pollutants typically found in HWWs due to their differing
behaviour during treatments. Many PhCs are resistant to conventional treatments.
According to Pauwels and Verstraete (2006) different operational configurations
should be developed and calibrated, thus generating the potential for practition-
ers to be informed about the financial aspects and overall risks associated with
putative treatments of HWWs.
Tsakona et al. (2007) proposed that the waste management strategy applied at
the hospital was observed and problematic areas were determined. All stages of
waste management presented problems, which mainly were due to human neglect.
To overcome these obstacles, the following actions were proposed for each stage of
waste management. These concept are explained in figure 5.10 where a schematic
representation of the waste categories and the proposed treatment and disposal
methods at the hospital were presented.
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Figure 5.10.: Schematic representation of the waste categories and the proposed
treatment and disposal methods at the hospital where research was
conducted. From Tsakona et al. (2007)
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Beier et al. (2011) report an experimental investigation about MBR on HWWs and
they conclude that MBR are a very attractive option for the treatment of these kind
of waters and elimination of PhCs in high density urban areas. The investigation
showed that, depending on the substance, between 19% and 94% of the level of
antibiotics found in the environment originate from hospitals. Because of their
ecotoxic potential, HWWs can have a significant impact on the environment. The
segregation of these WWs and their separate treatment at the source can reduce
the entry of drugs in waterways and enable water reuse after adequate polishing
treatment processes.
Beier et al. (2011) confirm the appropriateness of MBR for the treatment of HWWs
in high density urban areas. Based on a mass balance in an appropriate large-scale
case study, it was shown that the proportion of antibiotics found in UWWs originated
to at least 34% from the hospital. Because the pharmaceuticals concentration in the
MBR eﬄuent is often higher than the target value of 100 ng L−1, it is recommended
to add an advanced treatment technology, such as activated carbon adsorption,
ozone treatment or a further membrane step (nanofiltration or reverse osmosis) after
the MBR process. This also creates new opportunities for water reuse. It should be
mentioned that the residual streams emerging from the treatment of HWWs (such
as sludges and screenings) require thermal disposal. In new hospital buildings,
the streams containing pharmaceuticals should be segregated at the source and
separately treated, for example in MBRs. This would avoid the discharge of these
compounds in the sewer network and later on in the environment.
Interesting definitions about Source control and waste design are reported in
Larsen and Gujer (2001) and resumed in figure 5.11.
Referring to hospital eﬄuent management, many scientists agree in recommending
the avoidance of co-treatment with UWWs and of dedicating separated treatments
for HWWs (Pauwels and Verstraete (2006)). Heinzmann et al. (2008) suggested in
evaluating the feasibility of collecting in a separated sewage the eﬄuents from spe-
cific wards containing, for example, X-ray contrast media. Larsen et al. (2004) and
Ternes et al. (2004a) found that source separation of urine (see also section 5.3), con-
taining many of the pharmaceuticals and their transformation products from human
metabolism, may offer the most effective solution to the problem of pharmaceuticals
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Figure 5.11.: Source control waste design and discharge requirements relate to dif-
ferent interfaces between the relevant systems. From Larsen and Gujer
(2001)
in the environment. Due to the higher concentrations of micro-pollutants, biological
as well as physical processes are expected to be more efficient for urine than diluted
WWs. However, economic feasibility must be carefully evaluated.
Referring to the best available technologies in removing PhCs from WWs, recent
studies, generally investigating UWWs or synthetic ones, show that there is not a
unique treatment sequence able to remove all kinds of micro-pollutants, due to their
differing behaviours. Their main removal mechanisms are biodegradation favored by
a long sludge time (more than 30 d) and adsorption onto sludge flocks (Jones et al.
(2005a); Castiglioni et al. (2006); Lindberg et al. (2006); Pauwels and Verstraete
(2006); Matamoros et al. (2008); Miege et al. (2008)). Chemical-physical treat-
ments like coagulation-flocculation precipitation are not efficacious (Ternes and Joss
(2006)), while secondary biological treatments are considered to be an effective bar-
rier for most PhCs due to the metabolic and co-metabolic processes (Kreuzinger et al.
(2004); Daigger et al. (2005); Kimura et al. (2007); Radjenovic et al. (2009)) which
can take place in these systems. As many micro-pollutants tend to adsorb/absorb
into the biomass flocks, an efficient solid/liquid separation can greatly improve their
removal from wastewater and, at the same time, guarantee a constant and really
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good eﬄuent quality. Membrane biological reactors (MBRs) are suggested by many
authors (Daigger et al. (2005); Pauwels et al. (2006); Radjenovic et al. (2009)).
Ozonation and advanced oxidation processes (AOPs) are promising for an efficient
degradation of PhCs in water and wastewaters (Zwiener and Frimmel (2000); Chi-
ang et al. (2003); Huber et al. (2003); Balcioglu and Otker (2003); Ternes et al.
(2003); Machado et al. (2007); Zimmermann et al. (2008)).
Pauwels and Verstraete (2006) explain that HWWs urgently merit to be addressed
as critical discharge to the environment in both developing and industrialized coun-
tries. In view of the above mentioned features, it is clear that HWWs is a complex
matrix which warrants treatment before discharge to the environment.
About the HWWs, Boillot et al. (2008) conclude that hospital eﬄuents are still
rather poorly understood and in a context in which hazardous substances are ac-
cused, it appears necessary to carry out an in-depth characterization of this type
of eﬄuent. Hospitals are recognized for the specific substances they use: chemical
reactants, disinfectants, detergents, drug residues, etc. In his studies Boillot et al.
(2008) reports the global physicochemical parameters highlight moderate organic
pollution of the eﬄuents. However, a certain number of specific pollutants were
measured at non-negligible concentrations: AOX, glutaraldehyde, free chlorine, de-
tergents, Freon 113 and alcohols, acetone, formaldehyde, acetaldehyde, ammoniums,
phenols as well as several metals (copper, lead, zinc and arsenic). Generally, there
was very little bacterial flora in the eﬄuents. In addition, a battery of detail bioas-
says showed a considerable level of ecotoxicity with contributions made to toxicity
linked to TSS at certain periods. The study also showed that major fluctuations
of pollution occurred during the day. These physicochemical, microbiological and
ecotoxicological variations were correlated with hospital activities (change of shift,
cleaning and care activities, cleaning operating theatre units, progressive ending of
activities and night).
Liu et al. (2010) reports that of the 94 hospitals in Beijing, 89.6% use chlorine-
containing disinfectant for sewage treatment, in which liquid chlorine disinfection
accounted for 56.3% (figure 5.12); 84.6% of the 36 hospitals in Kunming use sodium
hypochlorite disinfectant in 2004; and 63% use liquid chlorine and 35.8% use chlorine
dioxide disinfection of the 106 hospitals in Hangzhou in 2004.
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Figure 5.12.: Disinfection types of 94 hospitals in Beijing. From Liu et al. (2010)
5.5. Experimental investigation
An experimental investigation was carried out during 2007 and 2008 on the eﬄuent
of a 300 bed hospital in Lagosanto near Ferrara and on the influent to the Lagosanto
municipal WWTP (5000 population equivalent, i.e.), in order to chemically charac-
terize these two kinds of WWs, as reported in section 4.2. The hospital has a wide
spectrum of wards (surgery, anaesthesiology and intensive care, orthopaedic and
traumatology, obstetrics and gynaecology, paediatrics, gastroenterology, cardiology,
urology, neurology, psychiatric) and services (first aid, radiology and diagnostic,
dialysis, clinical analysis) and thus may be considered representative of a general
hospital.
When a large hospital is built in the outskirts of a big town, it may be more con-
venient, from a technical and economic view point, to convey HWWs to the nearest
existing WWTP or to build a new one for hospital eﬄuent only. The existing WWTP
could have a small capacity. In these cases, advanced treatments are recommended
in order to protect and safeguard the environment, by reducing the pollutant load
discharged with the final eﬄuent. As reported, MBR technology seems to be, at
present, the most adequate one. For this reason, an MBR pilot plant (whose main
characteristics are reported in table 4.8) directly fed by Lagosanto Hospital eﬄuent
was tested. The chemical characteristics of the permeate are reported in Table 5.1.
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Table 5.1.: Samples number and chemical characteristics of the permeate during the
observation period
Parameter Samples Average
BOD5, mg L−1 20 9.2 ± 6
COD, mg L−1 20 20 ± 10
CODfiltered, mg L−1 20 15 ± 8
SS, mg L−1 20 2 ± 1
N-NH4, mg L−1 20 2 ± 1
Total P, mg L−1 20 4 ± 1
E. coli, CFU/100 mL 20 < 10
Very low concentrations were measured for all the monitored parameters, in par-
ticular for SS and E. coli. These good results are due to the combined actions of
biological degradation in the reactor and excellent solid-liquid separation due to UF
membrane filtration. In fact, MBR operates at a higher biomass content (10-12
kg m3) and with longer sludge retention times (SRT) of up to 30-50 days. In this
way, a more diverse microbial community can be established, including slow grow-
ing specialized bacteria with broader physiological capabilities; metabolic and co-
metabolic processes can be intensified which will also affect recalcitrant compounds
and a more complete mineralization can be possible in accordance with Clara et al.
(2005a); Daigger et al. (2005). These processes are the most important and efficient
biological systems for removing PhCs. Moreover, due to the small pore size (0.01
µm) of the UF membranes used, we expect that they are also able to retain the
viruses typically present in HWWs, reported below, whose dimensions vary in the
range of 0.02-0.16 µm.
HWWs characterization. Monitored parameters for HWWs have been: BOD5,
COD, SS, N-NH4, Total N, total P and E. coli. Instantaneous water samples were
withdrawn monthly from the internal hospital sewage network before immission
into public sewage. The hospital sewage network receives and conveys only black
waters from the different wards and services, as rain waters have a separate collec-
tion system. Water samples were collected in new 1 L plastic or glass bottles and
immediately analyzed for the different parameters.
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UWWs characterization. During the observation period, instantaneous samples
of water from the influent of the municipal WWTP of Lagosanto (5000 i.e.) were
withdrawn monthly and analyzed using the same parameters as HWWs. In addition,
historical data sets were used for its characterization. Samples were never taken
while it was raining, but about 24 h after the rain had stopped. This practice was
followed in order to avoid dilution of pollutant concentrations in wastewaters due to
the fact that this WWTP receives combined sewage (municipal wastewaters as well
as rain water).
The studied pilot plant. A submerged MBR pilot plant of 1.5 m3 active volume
equipped with ultrafiltration (UF) shallow fiber membranes, purchased from Pu-
ron, was installed at the Delta Hospital and fed by its eﬄuent. In this section is
considered also the UF technology because with a view to the new project of Cona
Hospital this seems the best technology to adopt.
The main characteristics of the studied pilot plant are reported in table 4.6 and
also in section 4.2. In particular this section refers to the UF MBR reported. The
biocenosis of the MBR was grown from inoculated sludge from the Lagosanto munic-
ipal WWTP (aeration basin) and cultivated over a period of approximately 45 days
to reach steady-state conditions. Continuous aeration was provided by means of a
sparger pipe situated at the bottom of the reaction vessel; the oxygen concentration
was kept between 1 and 2 mg L−1. The temperature inside the reactor was 23 ± 4
oC throughout sampling.
Twenty WWs samples were taken bearing in mind the HRT of the MBR process
for the influent to the pilot plant (corresponding to the raw hospital eﬄuent) and
the eﬄuent (permeate).
Analytical methodology. Analyses of chemical parameters were performed ac-
cording to the American Standard Methods for the Examination of water and
wastewater. Counting of E. coli was performed by the membrane filtration method,
as described in (IRSA-CNR (1994)), using the selective agar ECX GLUC AGAR at
an incubation temperature of 44.5 ± 0.2 oC for 18-24 hours. For other information
about the analytical methodology see appendix A.
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5.6. Adopted WWs treatment sequence in new
Ferrara Hospital
The new hospital complex in Ferrara is situated six kilometres from the town in the
first outskirts, in the small urban centre of Cona. It has a capacity of 900 beds and
a staff of 2400, including medical, administrative and technical services, in addition
to 250 university students and elderly people staying in the on-site accommodations.
Due to the building growth connected with the hospital construction, the nearby ur-
ban centres (Cona and Gualdo) are under expansion and their estimated residential
population is expected to climb to 1700 persons over the next years. In addition,
there are local businesses and industries, corresponding to 500 i.e.
Currently in this area, combined urban and industrial wastewaters (IWWs) are
conveyed to a small WWTP at Gualdo designed for 1000 i.e. Treatment includes
degritting, primary sedimentation, conventional activated sludge treatment and dis-
infection. This WWTP is not adequate to treat all the WWs coming from the
new hospital and the new urban development. A feasibility study has been carried
out to compare different scenarios with the aim of highlighting the advantages and
disadvantages of each design solution (figure 5.13).
a. Treat the HWWs on site by adopting the best available technology, and reuse
them for irrigation purposes (mainly for hospital parkland), convey UWWs
and IWWs to the small WWTP at Gualdo, upgrade it to the whole predicted
flow rate and treat together the two kinds of eﬄuents. Treat all the sludge
(including that from HWws treatments) at the WWTP at Gualdo (Figure 5.13
(a)).
b. Convey the HWWs by pipeline to the main WWTP in Ferrara, about 10-15 km
away from the new hospital, convey UWWs and IWWs to the small WWTP
at Gualdo, upgrade it to the whole predicted flow rate and treat together the
two kinds of eﬄuents (Figure 5.13 (b)).
c. Convey all the three WWs to the small WWTP of Gualdo, upgrade it for IWWs
and UWWs treatment and build a dedicated line for advanced treatment of
HWWs (Figure 5.13 (c)).
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d. Convey to and co-treat all three kinds of wastewaters at a new WWTP which,
once completed, will make the current WWTP of Gualdo obsolete (Figure 5.13
(d)).
The final eﬄuents of each scenario is in any case, in compliance with the (Italian)
legal limits for all conventional pollutants (BOD5, COD, SS, nitrogen compounds,
phosphorus compounds, E. coli, . . . ) corresponding to its final destination: dis-
charge into surface water body (D. Lgs 152/2006) or direct reuse for irrigation (DM
185/2003) (table 5.2). The choice of the most adequate scenario to adopt depends
on many technical, economical, legal, environmental, social, as well as political con-
straints. Figure 5.13 focuses on the main technical aspects concerning the manage-
ment and the treatment of a large hospital complex eﬄuent in a small urban centre.
In particular the different scenarios for HWWs management and treatments. Flow
rates for this case study: HWWs = 630 m3 d−1; UWWs = 300-500 m3 d−1 the range
is due to future urban development; IWWs = 50-70 m3 d−1; Ferrara UWWs = 20
000 m3 d−1
Table 5.2.: Main Italian legal requirements for eﬄuent discharge into surface water
body and for reuse
Parameter D. Lgs 152/2006 D.M. 185/2003Discharge Direct Reuse
COD, mg L−1 125 100
TSS, mg L−1 35 10
BOD5, mg L−1 25 20
N-NH4, mg L−1 15 2
Total P, mg L−1 10 2
E. coli, CFU/100 mL 5·103 10 as 80th percentile;
100 as the maximum value
The last option was selected for the treatment of hospital, urban and industrial
WWs in the study site for the following reasons:
• hospital flow rate will represent the greater part of the whole WWs flow rate
to be treated for the next 5-10 years, as the nearby urban centres will take
longer to be completed
• existing overflows along the network for urban and industrial sewage regulate
the flow inside the pipes and guarantee a maximum flow rate at the WWTP
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(a) (b)
Advantages: Different sequences of
treatment depending on the WWs,
more appropriate treatments for
HWWs; possibility of reusing the final
eﬄuent of the dedicated WWTP for
drip irrigating the hospital green area.
Drawbacks: Two WWTPs in operation
Advantages: Greater dilution of
HWws. Drawbacks: Storm water
overflows hamper biological processes
at the (large) WWTP
(c) (d)
Advantages: Just one WWTP, more
appropriate treatments for HWWs,
just one discharge point. Drawbacks:
Higher operational costs
Advantages: just one discharge point.
Drawbacks: Advanced treatments may
not be necessary for UWWs Combined
sewage must be previously drained in
case of MBR
Figure 5.13.: Different scenarios for HWWs management and treatments
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• the sewage systems of the urban centres under expansion are separated and
only black WWs will be conveyed to the WWTP. White WWs will be treated
separately.
The adopted sequence of treatments is reported in figure 5.14. Design param-
eters of the biological section result from the experimental investigation on the
hospital eﬄuent and on the MBR pilot plant previously described; those referring
to ozonation/UV irradiation derive from literature specific data (Ternes and Joss
(2006)). The average wastewater flow rate is about 60 m3 h−1. Hospital eﬄuent
and urban-industrial WWs are pumped separately, then subjected to a degritting
and a biological treatment (dephosphoration - nitrification - denitrification) by an
MBR (SRT = 30 d; biomass concentration of 8-10 kg m−3, UF membranes with
pores size of 0.05 µm, a surface flux of 15-25 L m−2 h−1). The permeate is subjected
to an AOP by means of O3 (7.5-10 mg O3 L−1, contact time of 16 min) and UV
(irradiation of 100 mJ cm−2, exposure time of about 4-7 s).
Figure 5.14 Flow scheme of the new WWTP for HWWs, UWWs and IWWs.
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Figure 5.14.: Flow scheme of the new WWTP for HWWs, UWWs and IWWs
For the sludge, technologies able to greatly reduce its production and disposal
frequency have been adopted: first, an aerobic digestion; second, an ozonation (50
g O3 kg−1 TSS−1 treated) of the digested sludge, which reduces the excess sludge
amount and favours oxidation of the PhCs absorbed into the solid phase, increas-
ing the content of readily biodegradable COD, and third, a mechanical thickener
completes the treatment.
Average influent concentrations were obtained by assuming that HWWs contribute
60% of the total influent flow rate and UWWs the remaining 40%, and by weighting
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their corresponding (average) values from the second column in table 4.6. Concen-
trations in the MBR permeate are prudently taken as equal to those reported in
Table 5.1, resulting from our experimental investigation, with the exception that
total P as a specific chemical treatment is included (Table 5.3). The final eﬄuent,
after AOP treatment, will have a better quality in terms of macro-pollutants as
well as of PhCs (antibiotics, analgesics and anti - inflammatories) due to the com-
bined action of ozone and UV on recalcitrant compounds and less biodegradable
organic matter still present in the water. According to literature data (Bouju et al.
(2008); Kasprzyk-Hordern et al. (2009); Radjenovic et al. (2009)), their removal
range is from 50-90%. At present, these seem to be the best available technologies
for removing different kinds of micro - pollutants.
This produces an eﬄuent of really high and constant quality, which is also able to
meet the strict Italian limits for discharge into surface water bodies and with an ad-
equate dose of ozone and radiation, legal limits for direct reuse will also be satisfied.
Its receiving surface water body is a narrow canal with a modest autodepurative
capacity belonging to the local network, usually used for agricultural needs. The
ability to guarantee a WWTP eﬄuent of excellent quality reduces its impact on the
environment.
These reasons supported the adoption of biological and chemical advanced tech-
nologies for the treatment of hospital, urban and industrial WWs. Moreover due
to the small size (60 m3 d−1), this new WWTP could be used as a test plant for
further experimental investigations in order to optimize removal of micro-pollutants
and evaluate the economic-technical feasibility of these kinds of technologies in other
sites.
Table 5.3.: Main design parameters and final permeate quality
Parameter Influent Eﬄuent
COD, mg L−1 355 20
SS, mg L−1 137 2
BOD5, mg L−1 164 9
N-NH4, mg L−1 25 2
Total P, mg L−1 5 1
E. coli, CFU/100 mL 5·105 5
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5.6.1. Footprint and costs
Joss et al. (2008) explain that activated sludge treatment allows only for a partial
removal of micropollutants, mainly via sorption and biological degradation. Ozona-
tion and activated carbon filtration are processes bearing the potential to drastically
reduce the micropollutant load discharged to the environment after (centralized) bi-
ological treatment. The estimated total costs between 0.05 and 0.20 Euro m3 treated
water (depending on plant size and eﬄuent DOC content) represent only a small
fraction of the total costs for UWWs management and are therefore considered fea-
sible.
Ternes et al. (2003) report that, for large-scale installation (investment + 10 g m3
ozone) the costs for the ozone treatment, are approximately < 0.04 Euro m3 and for
ozone/UV (400 J m−2) < 0.05 Euro m3.
The new WWTP for the new Ferrara’s Hospital covers an area of 1 000 m2,
resulting in a specific area of 0.25 m2 i.e.−1.
Specific construction costs amount to 460 Euro i.e.−1 and 3.6 Euro m−3 for treated
WW.
In total the energy consumption amounts to 830 MWh yr−1, this cause an annual
cost of 100 000 Euro.
The final treatment of the excess sludge production (100 tn yr−1) will be with
ozone and this will involve in a gross economic output of 59-88 Euro ton−1 of sludge
not disposed.
5.7. Discussion
Informed scientists agree that urgent measures must be taken in order to set guide-
lines for the treatment of HWWs, both with respect to attainable efficiency and
costs per m3 of water treated. Experimental studies are also necessary, because
there is a remarkable paucity of data, concerning the possible impacts of HWWs on
the environment.
The case study presented and discussed here shows how the delicate problem of
the treatment of the eﬄuent of a new large hospital built in a small urban centre
has been faced. Different operational configurations were evaluated and compared,
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thus generating the potential for administrators and practitioners to be informed
on financial aspects and technical solutions for the different treatment options of
HWWs. The sequence adopted for the treatment of the eﬄuent of the new large
hospital in Ferrara results from an experimental investigation. It represents, up to
now, the best available technology for removing macro - pollutants as well as PhCs,
as it combines advanced biological and chemical treatments, resulting in a reduced
impact of the final eﬄuent on the environment.
Moreover also the footprint and the costs are considered and the final treatment
sequence was chose on the basis of literature data and experimental investigation in
order to reduce the final impact of this new hospital into the environment.
The adopted treatment (reported in the scheme in figure 5.14) represents the best
balance between cost and possibility to built this new treatment plant. Obviously
a dedicate WWTP treating only HWWs were done the best treatment for this
particular kind of WWs, but the demand to treat also the local UWWs in the same
WWTP require to built only one treatment plant with the best technologies.
Ort et al. (2010) show that if, for whatever motivation, HWWs shall be treated
separately onsite, it must be noted, that for many substances no major overall
reduction can be achieved, since many PhCs are taken on a regular basis at home.
With the current trend to shorter hospitalisations and treatments (diagnostics) of
outpatients, this also holds true for compounds mainly administered in hospitals.
Beier et al. (2011) explain that German Ministry of the Environment set a limit
of 100 ng L−1 for the discharge of PhCs into the environment and the measured
eliminations correspond to a large extend values cited in the litterature for membrane
bioreactors (see Ternes (1998), Joss et al. (2006)). The sludge age in the MBR
treating HWWs exceeded 100 days. The elimination of PhCs in the MBR is based
on adsorption of the compounds on the activated sludge matrix and on biological
degradation or transformation.
Considering that for many pharmaceutical compounds, the concentration in the
MBR eﬄuent is often higher than the target value of 100 ng L−1, it is recommended
to add an advanced treatment technology, such as activated carbon adsorption,
ozone treatment or a further membrane step (nanofiltration or reverse osmosis)
after the MBR process.
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Joss et al. (2008) conclude speaking about the advanced treatment of wastewater
that is probably one of the simplest measures on a short term. On a longer term,
more efficient source control measures for impeding environmental contamination
with micropollutant may be implemented.
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CHAPTER 6
Conclusions
The aim of this work was the definition and the characterization of HWWs with
particular attention to the possible differences between these eﬄuents and the urban
ones.
The presence of a hospital structure in an urban area represents a source of impact
for many pollutants (mainly the common monitored macroparameter) and for new
emerging contaminants (antibiotics, hormones, surfactants, detergents, fragrances,
heavy metals. . . ).
Emerging contaminants are represented by different categories of drugs and, among
them, antibiotics are the main common into the HWWs as reported in this study
and confirmed by the literature data.
The starting point of this research was the critical analysis of the current man-
agement of hospital eﬄuents, generally immitted into the public sewage and the
co-treatment to a municipal WWTP. In this context, quali - quantitative analysis of
hospital and urban raw eﬄuents were carried out and evaluation of the efficiency of
conventional and advanced technologies were done in order to focus and understand
the best treatment for hospital eﬄuents which minimizes the environmental impact.
This work started in chapter 2 from the analysis of 73 emerging contaminants
from surface, ground waters and drinking waters deriving from Po River and Ferrara
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waters work. These analysis were done in order to obtain some informations about
the diffusion into the environment of these particular pollutants. A comparison with
literature data were done.
An important consideration is about the concept that all the discussion and the
mass balance done during this thesis referring to the analysed compounds (73 in
Ferrara for example) and not to all the possible compounds present in the waters
or discharged. This concept is to take in consideration because perhaps some com-
pounds not analysed in this study could change some balance mainly in surface
waters. So, all the consideration here reported refers to the big number of analysed
compounds, but not to all the possible compounds.
Table 2.5 compares the analytical results reporting that the drinking water pro-
cesses improve the water quality also towards PhCs. Referring to the GW analysis
(table C.3) it is clear that all the high concentration of these PhCs is due only to 4
different compounds: Indomethacine, Ketoprofen, Mevastatin and Doxycycline. If
summed, they represent more than 70% of the total concentration. In general, the
accumulation of the PhCs in GWs is possible but, the aerobic, anoxic or anaerobic
conditions in this particular sites can differ a lot and can vary from point to point
influencing the stability and the accumulation of these substances.
The detected compounds decrease from the GWs (36 compounds) to the Po River
waters (27 compounds) till the wells waters (10 compound detected).
Next chapter (chapter 3) analyses the hospital eﬄuent, studying the macrochar-
acteristics of these waters. This chapter take in consideration the common man-
agement of hospital eﬄuent, with a general point of view and conclude with some
important aspects about hospital structures:
• Pollutant load. Referring to this topic table 3.4 shows the ratio about
macroparameters in the two eﬄuents, and table 3.8 shows the ratio in the
different classes of micropollutant compounds. It is evident that the hospital
pollutants load is really higher than those in UWWs. The ratio can be also 3
times higher for the common BOD5, COD, SS and 4, 10, till 150 for the re-
ported micropollutant. For example hospital structures represent, potentially,
a consistent antibiotic input sources into the sewage and consequently into
the environment, for the main use of antibiotics in these structures, so they
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can do a really important contribution to the proliferation of drug-resistant
microorganisms.
• Hydraulic contribution. Figures 3.3 and 3.4 show the water consumption
per day and per bed with respect to hospital size, and the flow rates for hospital
and urban centres of different size. Daily HWWs flow rates range between 600-
900 L bed−1 d−1 and so they are 2-5 times higher than urban flow rates, which
refer to one inhabitant equivalent (typically included in the interval 120-250 L
i.e.−1 d−1).
Moreover this chapter reports the analysis done in the eﬄuent of the two studied
hospital, Ferrara and Lagosanto. About these hospital some important consideration
are:
• HWWs are subject to seasonal variations (see table 3.15) and, in fact, the
experimental campaign results from summer and winter are considered sepa-
rately in table 3.16.
• In terms of detected compounds, Lagosanto shows a higher value, if compared
both with Ferrara summer analysis than with Ferrara winter analysis. In
particular, in Lagosanto WWs were found 59 compounds. In Ferrara WWs
there were a large variability from summer (47 compounds) to winter (57
compounds).
• The more detected compounds are the two antibiotics Ciprofloxacin and Oflo-
xacin and the diuretic Furosemide. Moreover in Ferrara Hospital was detected
also a hight concentration of the antibiotic Clarithromycin. These compounds
were detected in a low concentration in Lagosanto Hospital than in Ferrara
Hospital.
• Table 3.16 shows the pro capita contribute of the PhCs. The small hospital
of Lagosanto presents a really highest pro capita load (expressed as ng L−1
patient−1) if compared with that of Ferrara. The 5.8 ng L−1 patient−1 are
really a high contribute compared with the Ferrara summer values of 0.8 ng
L−1 patient−1. In total, referring to the reported analytical results, the sum
of PhCs for patient are 305 ng L−1 patient−1 in Lagosanto Hospital and only
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38 (or 127) in Ferrara Hospital in summer (or in winter season). This is also
due to the lowest water consumption in Lagosanto Hospital (670 L bed−1 d−1)
respect Ferrara Hospital (800 L bed−1 d−1).
• This problem put the attention on the characteristics of the WWs derived from
a small hospital structure (Lagosanto for example) that, in terms of pollutant
load, may represent an environmental problem, if does not adequately treated
before the discharge in a surface water body.
Lagosanto’s WWs are collected in a public sewage and co-treated with UWWs
in a CAS system (5000 i.e.). The final discharge point is an irrigational channel
with a dominant flow derived from the WWTP for almost 8 month for year.
Ferrara WWs are also collected in a public sewage but co-treated with the
UWWs derived from all the town (130 000 i.e.) and mixed, before the discharge
in the final water body, with the industrial treated WWs derived from the
nearest petrochemical site (100 000 i.e.). Then, in this case, the dilution with
other kind of waters, plays a really important role in the final concentration
before the discharge. So the impact of this WWTP on the final discharge is
really low in terms of PhCs concentration.
A lot of experimental investigation were carried out during this research years
and almost 6 different pilot plants were tested in order to investigate and focus the
problem under studying. To see all the experimental investigations and the pilot
plants tested, a rapid focus is presented in appendix B.
The analysis done about the simple disinfection of raw hospital eﬄuents shown
that:
• PAA is able to reach higher removal rate for TC than E. coli (0.5-1 log unit
of difference on average at the same applied dose c x t) (Figure 4.3).
• On the contrary, NaClO is a bit more effective with E. coli than TC (Figure
4.4).
• Experimental data are quite spread due to the different characteristics of the
raw WW, influent to the pilot plant, in particular suspended solids that varied
in a wide range (table 4.4). About this table some considerations are according
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to literature data, a concentration of SS up to 100 mg L−1 does not influence
the biocidal action of PAA. Greater concentrations can reduce it.
The disinfection of raw HWWs with PAA or NaClO represents a good technical
solution for those situation, where is not present a WWTP able to treat this specific
WWs and in order to reduce the health risk the disinfection is recommended.
The experimental section about the two tested MBRs in Lagosanto (section 4.2)
reported the results about the typical pollutant substances (macroparameters) and
not about PhCs. The results of these experimental sections confirm that an UF
membrane is able to reduce the final impact of the hospital eﬄuents due to the
excellent water quality obtained.
Other studies (from section 4.3 to section 4.6) focus the attention of CAS, MBR,
O3 and CW technologies in removing PhCs in order to see the capacity of conven-
tional, advanced biological and oxidation processes and a natural polishing system
in removing the investigated micropollutants.
The main results confirmed that a multibarrier system (obtained in different ways:
an MBR + O3 and a CAS + CW) can improve the water quality by guaranteeing
a higher removal efficiency mainly for those pollutants that are present in low con-
centration in WWs.
A typical CAS treatment (SRT = 5 d) is able to remove the carbonaceous fraction
(COD, BOD5) and the nutrients (N and P) present in WWs but not all the pollutants
detectable in concentration with from µg L−1 to ng L−1. This because the typical
biological treatment needs time and quantity to develop bacterial and biomasses,
able to degrade and transform also the micro-compounds.
The results about the natural treatments put in evidence that the persistent mass
loading due to PhCs of a secondary eﬄuent can be reduced by a polishing treatment,
able to favour different removal pathways, which become necessary due to the great
variability of the contaminants of interest.
CW requires high surface i.e.−1 ratio, so these natural polishing treatments rep-
resent adequate solution for small communities or the last treatment step for the
dedicated treatment of specific users, such as hospital structures where the concen-
trations of micropollutants should be more carefully removed. The natural treatment
can improve the final efficiency because the coexistence of several microenvironments
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in CWs allows both the thermodynamic feasibility of chemical reactions and the de-
velopment of a great variety of microbiological communities able to guarantee the
enzymatic capacity necessary to achieve the target biogeochemical reactions. This is
true for the low concentrations of PhCs detected in the first experimental investiga-
tion (section 4.5) but also for the second one (section 4.6) where the concentration of
three antibiotics were artificially increased in order to simulate a peak concentration
and to stress the natural system.
The problem of the adequate treatment for the hospital eﬄuents must be taken in
consideration from the scientific community in order to set guidelines and to verify
if the final water body receptor is able to receive the pollution load deriving from
WWTP. In fact, if the receiving river is an eﬄuent dominant (the hight percentage
of water derived from WWTP), it becomes necessary to improve the quality of the
discharge, in order to reduce the long term environmental impact.
The case studies presented and discussed in this thesis show how the delicate
problem of the eﬄuent’s treatments of a new large hospital built in a small urban
centre, has been faced. Different operational configurations were evaluated and
compared, thus generating the potential for administrators and practitioners, to
be informed on financial aspects and technical solutions for the different treatment
options of HWWs. The possible adopted sequences are shown in figure 5.13.
Recently many Authors (among them Ort et al. (2010) and Beier et al. (2011))
explain that it is recommended to add an advanced treatment technology, such as
activated carbon adsorption, ozone treatment or a further membrane step (nanofil-
tration or reverse osmosis) after the MBR process, confirming that, in order to
reduce the high load pollution derived from hospital structure, it is necessary a se-
quence of different consequent treatments. In these cases the adopted technology
(such as nanofiltration or RO) represents the BAT but not the BATNEC. To obtain
relevant results in removing PhCs from WWs, literature shows that it is possible to:
• make a reduction at the source of antibiotics. In substances the concept is to
adopt other antibiotics, if possible, more degradable,
• make a source separation of the liquid part of the eﬄuents with the solid phase.
In fact, as reported, more PhCs tend to stay in urine rather than in faces. So
an adequate liquid treatment can reduce the final environmental impact.
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These two concepts represents some possible management ways that in some cases
are quite expensive and difficult to respect and to implement.
The adopted treatment (reported in figure 5.14) represents, up to now, the best
available technology in removing macro - pollutants as well as PhCs, as it combines
advanced biological and chemical treatments, resulting in a reduced impact of the
final eﬄuent on the environment.
It is important to underline that today the dilution of HWWs plays an important
role in the treatment. For example, a co-treatment of a large hospital in a densely
populated catchment are causes a dilution in the total (urban + hospital) influent
raw flow rate and consequently also in the final eﬄuent, but it is appropriate to pay
attention on the discharged load resulting from the contribute of the hospital and
the urban center.
Table 3.17 put in evidence that the contact between UWWs and HWWs in Ferrara
sewage generates a dilution of the concentration: from 1443 ng L−1 in Ferrara raw
Hospital to 378 ng L−1 at the influent of Ferrara’s WWTP.
Considering the 900 beds in Ferrara Hospital and the pro capite water consump-
tion for bed in Ferrara (more or less 800 L bed−1 d−1), it is easy to obtain the total
flow per day in the hospital (720 m3 d−1). This value represents only the 2% of the
total water conveyed at the Ferrara WWTP (more or less 35 000 m3 d−1).
Starting from the analytical results obtained in this thesis, considering the dilution
factor (QHospital
QTotal
) and comparing the hospital load with the urban ones, the percentage
concentration of the hospital in the urban sewage represents 9% of the total load.
This means that the hospital water load represents the 2% of the total water influent
at Ferrara’s WWTP, but the concentration load represent the 9% of the total PhCs
in the municipal sewage. This is another important reason to consider hospital
eﬄuent quite different from the urban ones. The load percentage for the different
classes are reported in table 3.17.
Another treated aspect confirms that a multibarrier system can really improve
the final eﬄuent quality in terms of quantity of detected pollutant and also in terms
of load. In fact, a passage through a natural system working as polishing step, is
able to reduce the concentration and the quantity of detected PhCs.
In a correct management of hospital structures, it is appropriate to consider their
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eﬄuent with all the problems that they can cause:
• hydraulic problems, due to their high water consumption. This represent an
important key design to understand the future impact of an hospital structure
into the sewage network,
• loading problems of the high concentration in macro and micro pollutants.
This aspect represents a relevant problem mainly in small and old WWTPs
that discharge in eﬄuent dominant surface water body of the local surface
network often used for irrigation purposes as it can occur in many countries,
• treatments problems for the difficult in defining the best sequence treatment
due to the variety of behavior of the molecules of pharmaceuticals. Litera-
ture explains, and this study confirms, that the use of only one technology to
treat this eﬄuent is inadequate. CAS treatment treating only hospital eﬄu-
ents could be insufficient if the objective is the removing of high percentage
of micropollutants. MBR represents a good technology, able to remove some
micropollutants, but a multibarrier system is desirable. Advanced treatment,
such as ozonation or natural polishing steps, are the best technologies that can
activates chemical reactions and a great variety of microbiological communi-
ties, able to guarantee different biogeochemical reactions,
• discharge problems connected to the residual content of pharmaceuticals in
the final treated WWs which can exhibits ecotoxicological effects. A correct
evaluation of the final water receptor’s characteristics (flow rate, dilution ca-
pacity, chemical characteristics, final destination, legal constrains) is really an
important step in the planning of the building of a new hospital structure. The
discharge problem is not a secondary question, because if the final discharge is
in a large river, the resulting dilution and the natural processes (photodegra-
dation) which can occur can contribute in the (natural) decrement of the
pollutant concentrations and mitigate the consequent environmental impact,
but, if the final eﬄuent is a small channel, a continuous (bio-)accumulation of
the pollutants can cause relevant environmental problems.
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6.1. Suggestions for future work
In the last years the international literature developed numerous scientific publica-
tions about the PPCPs, PhCs, EDCs and micropollutants in general. There is no
doubt that the problem of hospital eﬄuents is relevant and the scientific community,
mainly in the last years, is studying this aspect.
The definition of some markers for HWWs could be of great interest. For example
in the UWWs treatment with three or four parameter (COD, SS, N. . . ) it is possible
to characterize the kind of eﬄuent, but in the HWWs the high concentration of
PhCs and the difference in the behaviour of these substances cause problem in the
individuation of marker.
In general, scientists put the attention on Carbamazepine, Diclofenac, Sulfamethox-
azole and Iopromide as markers of PhCs pollution in WWs. Referring to Carba-
mazepine it is considered as an anthropological marker and not a typical hospital
substance, because it is commonly prescribed to outside patients for long periods
and for many pathologies. Probably antibiotics could be markers for HWWs, but
further studies are necessaries to define which kind.
An idea to characterize hospital eﬄuents may be an analysis of toxicity of these
WWs compared with the urban ones.
Another idea may be the study of an index of different parameter (macro and
micro) in order to compare by the use of an aggregate function the different load of
hospital and urban eﬄuents.
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APPENDIX A
Analytical methods
This Ph.D thesis does not deal with the analytical chemistry and this part of my
thesis derives directly from my experience in the Barcelona CSIC Laboratory. I
think that an analytical chemist, that will read this chapter could consider this part
really a basic report, but the aim of this thesis was evaluate the PPCPs problem
from an engineering point of view, so the analytical aspects (certainly important)
are not the real core of this dissertation.
Analysis of conventional WWs parameters including COD, SS, NH4 and total
phosphorus, were performed according to the American Standard Methods for the
Examination of water and wastewater APHA (2001). Counting of E. coli was per-
formed by the membrane filtration method, as described in Ref. IRSA-CNR (1994).
Analysis on PhCs were conducted using the specific analytical method performed
in Gros et al. (2009) described below.
For the pharmaceuticals analysis, water and WWs samples were collected in dif-
ferent forms by using clean plastic bottle in adequate volume:
• samples deriving from surface waters, ground waters and potable waters were
collected in instantaneous samples
• samples taken from HWWs were collected directly from the final septic tank
with an autosamples in order to have a 24 hours composite sample for each
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point
• samples from Ferrara WWTP and from the CW studied before this plant.
Each one of this samples was 4 hours composite sample
A.1. PhCs in environmental samples
The prerequisite for a proper risk assessment and monitoring of the quality of sur-
face, drinking and waste water is the availability of multi-residue methods, that
permit measurement at low ng L−1 level or even below that. A single method for
the analysis of various pharmaceuticals belonging to different compound classes has
several advantages, such as shorter analysis time, reduced field sampling and overall
cost reduction. In the need to monitor pharmaceutical residues in the environment
numerous sensitive, accurate and reliable analytical methods have been developed for
determination of pharmaceuticals and their metabolites in aqueous solutions. The
pharmaceuticals more frequently included in such multi-residue methods are anal-
gesics and anti-inflammatory drugs, antibiotics, lipid regulators, psychiatric drugs,
and β-blockers. These drugs have very high consumption worldwide and are the
most ubiquitous in both surface and WWs. Solid-phase extraction (SPE) methods
combined with gas chromatography-mass spectrometry (GC-MS) and GC with tan-
dem MS (GC-MS2) (Halling-Sorensen et al. (1998)) or liquid chromatography (LC)
with tandem MS (LC-MS2) (Stolker et al. (2004), Gros et al. (2006)) are the usual
methods of choice for identification and quantitation. Furthermore, in the last few
years, analytical methodologies using high performance LC (HPLC) or ultra perfor-
mance LC (UPLC) coupled to advanced chromatographic techniques and detection
systems such as quadrupole-time of flight (QqToF), ion trap (IT), quadrupole-linear
ion trap (Q-LIT), linear ion trap-Fourier transform-ion cyclotron resonance (LIT-
FT-ICR) and LTQ Orbitrap have been developed (Radjenovic (2009)).
Optimisation of the sample preparation step is one of the most important step in
the development of an analytical method, since it will greatly influence the sensitivity
and selectivity of the method. Target compounds are isolated and preconcentrated
from the aqueous phase in the SPE enrichment step. Newly developed polymeric sor-
bents with improved wetting characteristics and mass transfer, and with additional
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possibilities for interaction of functional groups of analytes have allowed high pre-
concentration factors. One of the major advantages is the possibility of carrying out
a multi-residue method working at neutral pH (Gomez et al. (2006)), which greatly
simplifies the sample handling procedure. Due to the high retention capabilities
of these sorbents, acidic compounds can be extracted from water samples without
previous acidification. This is of great importance when performing a multi-residue
analysis, because the risk of acidic hydrolysis of other compounds is not enhanced.
Furthermore, no clean-up step is needed for the removal of humic and fluvic acid, and
also there is a possibility of online extraction using large sample volumes (Farre et al.
(2007)). SPE and solid-phase microextraction (SPME) are the two most widely used
methods for sample extraction. SPME has several advantages over SPE when the
analysis is performed by GC-MS, since less sample volume is required; it is solvent-
free and easily automated, which allows high enrichment factors in the concentration
of organic compounds in aqueous matrices (Rodriguez et al. (2004)). The Oasis HLB
sorbent (polystyrene-divinylbenzene-N-vinylpyrrolidone terpolymer), which exhibits
both hydrophilic and lipophilic retention characteristics, has often been used for si-
multaneous extraction of neutral and acidic pharmaceutical residues. This materials
has excellent wetting properties, thus providing the advantage of no negative run-
ning dry effects on the analyte recovery. Neutral and acidic compounds are retained
on a solid phase by Van der Waals and H-donor-H-acceptor interactions. The less
common SPE cartridges employed are RP-C18, Lichrolut ENV+, Oasis MCX and
StrataX that generally need pH adjustment and sometimes special elution condi-
tions. When performing a single group analysis, molecularly imprinted polymers
(MIPs) and immunosorbents could be useful tools to provide high selectivity for
target analytes. In a recent study by Gros et al. (2006), MIPs provided lower de-
tection limits for waste water analysis than Oasis HLB, due to their specificity for
target β-blockers and closely related compounds (Radjenovic (2009)).
A.2. Analytical techniques
Liquid chromatography-mass spectrometry (LC-MS, or alternatively HPLC-MS) is
an analytical chemistry technique that combines the physical separation capabilities
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of liquid chromatography (or HPLC) with the mass analysis capabilities of mass
spectrometry.
LC-MS is a powerful technique used for many applications, which has very high
sensitivity and specificity.
Liquid chromatography combined with mass spectrometry (LC-MS) and related
techniques, such as ultra performance LC-MS (UPLC-MS), have become robust,
sensitive techniques for detecting parent compounds at ultra-trace levels in environ-
mental samples.
Unlike, gas chromatography (GC)-MS, LC-MS can determine polar analytes with-
out need for previous derivatization. This advantage of LC-MS, is particularly at-
tractive when simultaneously analysing compounds belonging to structurally distinct
groups whose determination by GC-MS would involve more than one derivatization
reaction.
With the advent and availability of recent analytical instrumentation that aids
compound identification [e.g., LC coupled to ion-trap (IT)-MS or time-of-flight
(ToF)-MS], more degradates and metabolites are being identified. These two MS
techniques, provide complementary data that facilitate structural elucidation of un-
known compounds. For example, the ability to conduct multiple stages of frag-
mentation in an IT-MS system can generate spectra with considerable amounts of
structural information, that identifies an unknown degradate. Further confirmation
of the proposed identity or chemical formula of new degradation products, can be
achieved by accurate mass measurements using a ToF-MS system or other high res-
olution mass analyzers. Current bench top ToF-MS instruments, can now achieve
a low femtomole (fmol)-level sensitivity, high resolving power and mass accuracy.
Even more powerful in terms of confirmatory analysis are hybrid triple-quadrupole
ToF-MS (QqToF-MS) systems that acquire product ion spectra with accurate mass
measurements of product ions (precision in the low ppm range). An alternative to
ToF instruments is the recently launched LTQ Orbitrap that combines a conven-
tional linear IT (LIT-MS) with an Orbitrap mass analyzer. This system provides
outstanding mass accuracy, mass resolution and reliable high sensitivity MSn per-
formance.
Using LC-MS, there has been a vast number of analytical methods for determina-
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tion of emerging pollutants and studies of their occurrence in the environment pub-
lished (e.g., pharmaceuticals, hormones, endocrine-disrupting compounds, PFCs,
drinking-water DBPs, sunscreens and ultraviolet (UV) filters, brominated flame re-
tardants and benzotriazoles).
Recently, several articles focused on degradation products of emerging products
and their toxicological effects. In this sense, in recent years, different review pa-
pers have been published on analytical methods for emerging contaminants, and
the occurrence of these compounds in the environment. However, this is the first
review article devoted to the fate and the ecotoxicology of emerging pollutants and
especially focusing on their metabolites and TPs in the aquatic environment (Farre
et al. (2008)).
The efforts to develop and refine an interface for introducing a flowing liquid
high performance liquid chromatography (HPLC) system into a high vacuum mass
spectrometry environment, were fueled by a strong notion, that combination would
be unique and would provide powerful advantages for analysis.
From an applications standpoint, the partnership of HPLC and mass spectrometry
benefited greatly from the tradition of HPLC, within the pharmaceutical industry
and from the growing trend, to obtain structural and quantitative information during
earlier stages of drug development. Ultimately, it has been the power of HPLC to
resolve, and the ability of mass spectrometry to identify that enabled LC-MS to
integrate effectively with drug development and to solve problems.
The integrated LC-MS format provides the pharmaceutical industry with a highly
efficient platform to conduct a series of online steps to purify the sample and amplify
the signal (Lee (2002)).
A.2.1. Samples preparations
Water samples were filtered through 1 µm glass fiber filters followed by 0.45 µm
nylon membrane filters water samples were spiked, prior to the extraction, with
appropriate concentrations of standard mixtures containing target analytes. For
the preconcentration of water samples, a Baker vacuum system (J.T. Baker, The
Netherlands) was used. In all cases, 500 mL of surface waters, 200 mL of eﬄuent,
and 100 mL of influent wastewaterswere loaded onto the cartridges at a flow rate of
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approximately 5 mL min−1.
All standards used were of high purity grade (>90%). Isotopically labelled com-
pounds, used as internal standards, were 13Cphenacetin, fluoxetine - d5 and flume-
quine from Sigma - Aldrich (Steinham, Germany), sulfathiazole - d4 from Toronto
Research Chemicals, diazepam - d5 and phenobarbital - d5 from Cerilliant (Texas,
USA), atenolol - d7, carba - mazepine - d10, ibuprofen - d3 from CDN isotopes
(Quebec, CAN) and mecoprop - d3 from Dr. Ehrenstorfer (Augsburg, Germany).
Both individual stock standard and isotopically labelled internal standard solutions
were prepared on a weight basis in methanol, except fluoroquinolones, which were
dissolved in water: methanol mixture (1:1) containing 0.2% v/v hydrochloric acid
(Golet et al. (2002)). After preparation, standards were stored at -20 oC. Fresh
stock solutions of antibiotics were prepared monthly due to their limited stability
while stock solutions for the rest of substances was renewed every three months. A
mixture of all pharmaceuticals was prepared by appropriate dilution of individual
stock solutions in methanol-water (25:75, v/v). Working standard solutions, also
prepared in methanol-water (25:75, v/v) mixture, were renewed before each ana-
lytical run. A separate mixture of isotopically labelled internal standards, used for
internal standard calibration, was prepared in methanol and further dilutions also
in methanol-water (25:75, v/v) mixture.
A.2.2. HPLC-MS analysis
LC analysis was performer using an Agilent HP 1100 HPLC (Palo Alto, CA, U.S.A.),
equipped with an autosampler and connected in series with a 4000 QTRAP hy-
brid triple quadrupole-linear ion trap mass spectrometer equipped with a Turbo
Ion Spray source (Applied Biosystems-Sciex, Foster City, CA, U.S.A.). Chromato-
graphic separation was achieved with a Purospher Star RP-18 endcapped column
(125 mm 0 2.0 mm, particle size 5 µm) preceded by a C18 guard column (4 x 4, 5
µm), both supplied by Merck (Darmstadt, Germany). For the analysis in NI mode,
eluent A was a mixture of acetonitrile/methanol (1:1, v/v) and eluent B was HPLC
grade water at a flow rate of 0.2 mL/min. The elution gradient started with 20%
eluent A, increasing to 80% in 20 min, raising to 90% in 4 min and then, back to
initial conditions within 3 min. The column was re-equilibrated for 15 min before
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another injection with a total time for chromatographic analysis of 42 min. The
analysis in PI mode was performed using aceto nitrile as eluent A and HPLC grade
water with 0.1% formic acid as eluent B. The elution gradient started with 5% eluent
A, increasing to 95% in 25 min, raising to 100% in the following 5 min. Initial condi-
tions were reached in 5 min and reequilibration time was 10 min. Chromatographic
analysis lasted 45 min.
The sample injection volume was set at 20 µL in all chromatographic methods.
The optimization of compound dependent MS parameters (declustering potential
(DP), entrance potential (EP), collision energy (CE) and cell exit potential (CXP))
for each transition was performed by infusing standards of each individual compound
at 100 µg L−1 to the mass spectrometer. It should be remarked that all transitions
were recorded in one single retention time window, without losing sensitivity, setting
appropriate values for the dwell time and pause between mass ranges. Therefore, a
value of 10 (PI) and 50 ms (NI) was set for dwell time, and 2 (PI) and 5 ms (NI)
for the pause between mass ranges (Gros et al. (2009), Gros et al. (2010)).
Given the polar nature of pharmaceuticals, LC-MS was the analytical method of
choice (Gros et al. (2006)). All analyses were performed in the ESI+ and ESI- mode,
depending on the nature of the predominant charge carrier of a certain compound
in the solution. The ESI cone-jet interface involves application of a high electrical
potential to a liquid sample flowing through a capillary, evaporating it and transmit-
ting the single solvated gas phase ions to the inlet aperture of the MS for separation
based on their m/z ratio, followed by detection. The LC analysis was performed
using a Waters 2690 HPLC system (Milford, MA, US) coupled to a Waters Micro-
mass Quattro QqQ-MS, equipped with a Z-spray ESI interface (Manchester, UK).
Chromatographic separation was achieved with a Purospher Star RP-18 endcapped
column (125mm x 2.0 mm, particle size 5µm) and a C18 guard column, both sup-
plied by Merck (Darmstadt, Germany). For the analysis in NI mode, eluent A was
methanol and eluent B was water at a flow rate of 0.2 mL min−1. The elution gra-
dient started with 20 % of eluent A, increasing to 80 % in 20 min, raising to 90 % in
a 4 min gradient and then, back to initial conditions within 3 min. The column was
re-equilibrated for 15 min before another injection. The analysis in PI mode was
performed using as eluent A a mixture of acetonitrile-methanol (2:1) and as eluent
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B a buffer consisting in NH4Ac 5 mM/HAc at pH 4.7, also at a flow rate of 0.2
mL min−1. The elution gradient started with 15 % of eluent A, keeping isocratic
conditions for three minutes. Then, eluent A increased to 95 % in 22 min and was
held for 7 min. Finally, initial conditions were reached again in five minutes, with a
re-equilibration time of 15 min in order to restore the column. The sample injection
volume was set at 10 µL. MS parameters for the analysis were the following: ESI
source block and desolvation temperature: 150 and 350 oC, respectively; capillary
voltage: 2.8 kV; argon collision gas 2.5 x 10-3 mbar; cone nitrogen and desolvation
gas flow: 43 and 636 L h−1. After the selection of the precursor ions for each ana-
lyte, product ions were obtained with a combination of collision energies and cone
voltages, parameters that were previously optimized. Instrument control, peak de-
tection and integration were carried out using Masslynx NT software (version 3.4).
For increased sensitivity and selectivity, data acquisition was performed working in
MRM.
To confirm the presence of a compound in environmental samples when using
LC-MS two transitions between precursor and product ions should be monitored
working in MRM, earning 4 IPs. Other criteria used are the MRM ratio (calculated
as the ratio between the abundances of both transitions) and the LC retention time.
If there is poor fragmentation of some compounds, their confirmation can be per-
formed by matching their LC retention times with the ones obtained in standards
(Gros et al. (2006), Gros et al. (2009), Gros et al. (2010)). This shift between com-
pared retention times should not exceed 2.5% in order to consider the confirmation
accurate enough. In the method optimized by Gros et al. (2006) and Gros et al.
(2009) transitions between a precursor ion and the two most abundant fragment
ions, were chosen for each analyte when working in MRM mode, earning 4 iden-
tification points (IPs), enough to accomplish the EU directive aforementioned. In
the cases where compounds showed poor fragmentation only one transition could be
monitored. However, it only happened for five compounds (ibuprofen, gemfibrozil,
pravastatin, ofloxacin and glibenclamide), and since the shifts in their LC renetion
times in the samples and standards was less than 2 %, confirmation was considered
accurate enough. For internal standards, only one transition was selected, as they
are isotopically labelled compounds which are not likely to be found in environmen-
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tal samples.
From table A.1 to table A.7 are reported the physico-chemical proprieties of the
73 analysed compounds (data obtained from EPIsuite v4.00, Ternes and Joss (2006),
Petrovic and Barcelo (2007)). In particular in those tables the letter A. . . L means:
A = Analgesics / anti-inflammatories G = Beta-blockers
B = Antibiotics H = Diuretic
C = Antidiabetic I = Lipid regulator
D = Antihypertensive J = Psichiatric drugs
E = Barbitures K = Receptor antagonist
F = Beta-agonists L = Antineoplastic
These data are from Jelicic and Ahel (2003); Roberts and Thomas (2006); Rad-
jenovic et al. (2009); Kasprzyk-Hordern et al. (2009); Rosal et al. (2010); Sipma
et al. (2010); Sui et al. (2010); Verlicchi et al. (2010a)
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A. Analytical methods
Another important table referring to the optimized QqLIT-MS/MS parameters by
SRM Negative and Positive Ionization Mode and all those data are reported in table
A.11 for the negative ionization mode and in table A.12 for the positive ionization
mode.
Table A.11.: Target Compounds and Their Optimized QqLIT-MS/MS Parameters
by SRM Negative Ionization Mode
Compounds 
precursor ion 
(m/z) 
SRM 1 
Collision 
Energy 1 
SRM 2 
Collision 
Energy 2 
Rt (min) 
IS used for 
quantification 
Acetaminophen 150 107 22 
  
3.6 mecoprop-d3 
Salicylic acid 137 93 20 66 38 4.1 mecoprop-d3 
Hydrochlorothiazide 296 78 28 
  
6.1 mecoprop-d3 
Clofibric acid 213 127 26 85 14 12.9 mecoprop-d3 
Furosemide 329 205 22 285 32 13.3 ibuprofen-d3 
Naproxen 229 185 10 169 38 14.3 mecoprop-d3 
Mecoprop-d3 (IS) 218 146 24 
  
14.8 
 
Ketoprofen 253 209 12 197 6 14.9 mecoprop-d3 
Phenobarbital-d5 (IS) 236 193 16 
  
14.2 
 
Phenobarbital 231 188 14 
  
14.2 phenobarbital-d5 
Chloramphenicol 323 152 22 194 18 15.1 ibuprofen-d3 
Butalbital 223 180 16 85 18 16.6 ibuprofen-d3 
Bezafibrate 360 274 26 154 38 16.7 ibuprofen-d3 
Pentobarbital 225 182 18 85 18 18.6 ibuprofen-d3 
Ibuprofen-d3 (IS) 208 164 10 
  
19.1 
 
Ibuprofen 205 161 10 
  
19.2 ibuprofen-d3 
Diclofenac 294 250 16 214 30 19.9 ibuprofen-d3 
Indomethacine 356 312 12 297 24 20.6 ibuprofen-d3 
Mefenamic acid 240 196 20 180 38 21.1 ibuprofen-d3 
Gemfibrozil 249 121 20 127 14 24.3 ibuprofen-d3 
!
A.3. La Spezia analysis
All the water analysis in the WWs derived from the experimental investigation in
La Spezia were analysed in the Department of Environmental Health Science Mario
Negri Institute for Pharmacological Research in Milan by Professor Zuccato and his
work team with the method reported below and also explained in Zuccato et al.
(2010)
Standards were dissolved in methanol to a concentration of 1mg mL−1 and subse-
quently diluted to 10 ng µL−1 (stock solution) and 1-0.1 ng µL−1 (working solutions).
The stock solutions of amoxicillin, ciprofloxacin, ofloxacin, oxytetracycline and sul-
phamethoxazole were renewed monthly because of their limited stability. The I.S.
were dissolved in methanol (1 mg mL−1) and subsequently diluted to 10 and 1 ng
µL−1. All stock and I.S. solutions were stored at -20 OC in the dark.
The cartridges used for solid phase extraction were: 3 mL disposable OASIS MCX
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A.3. La Spezia analysis
Table A.12.: Target Compounds and Their Optimized QqLIT-MS/MS Parameters
by SRM Positive Ionization Mode
Compounds 
precursor ion 
(m/z) 
SRM 1 
Collision 
Energy 1 
SRM 2 
Collision 
Energy 2 
Rt (min) 
IS used for 
quantification 
Salbutamol 240 148 25 166 20 5.7 atenolol-d7 
Metronidazole 172 172 21 82 37 5.8 13C-Phenacetin 
Sotalol 273 213 25 255 25 6.1 atenolol-d7 
Atenolol 267 145 35 190 35 6.2 atenolol-d7 
Atenolol-d7 (IS) 274 145 37 
  
6.2 
 
Cimetidine 253 95 30 159 23 6.3 atenolol-d7 
Famotidine 338 189 27 259 20 6.3 atenolol-d7 
Ranitidine 315 176 25 130 39 6.5 atenolol-d7 
Sulfadiazine 253 156 25 92 43 7.3 sulfathiazol-d4 
Codeine 300 152 85 115 105 7.4 
 
Lisinopril 406 84 75 
  
8.1 atenolol-d7 
Sulfathiazol-d4 (IS) 260 160 23 
  
8.2 
 
Nadolol 310 254 30 201 35 8.5 atenolol-d7 
Trimethoprim 291 230 33 261 31 8.8 
 
Pindolol 249 116 30 98 30 8.8 atenolol-d7 
Enoxacin 321 303 30 234 33 8.9 flumequine 
Ooxacin 362 261 39 
  
9.2 flumequine 
Oxytetracycline 461 426 25 201 51 9.2 13C-Phenacetin 
Norfloxacin 320 302 35 
  
9.3 flumequine 
Ciprooxacin 332 288 25 231 51 9.4 flumequine 
Sulfamethazine 279 186 25 124 33 9.5 sulfathiazol-d4 
Danooxacin 358 340 35 314 27 9.7 flumequine 
Doxycycline 445 410 29 154 41 9.7 13C-Phenacetin 
Phenazone 189 56 40 147 33 9.8 carbamazepine-d10 
Timolol 317 261 30 244 30 9.8 atenolol-d7 
Enrofloxacin 360 316 29 245 39 9.9 flumequine 
Metoprolol 268 121 35 133 35 10.2 atenolol-d7 
Clenbuterol 277 203 23 132 33 10.3 atenolol-d7 
Spiramycin 843 174 53 540 43 10.7 carbamazepine-d10 
Azithromycin 749 591 43 573 50 10.9 carbamazepine-d10 
Chlortetracycline 479 462 29 444 29 11.4 13C-Phenacetin 
Carazolol 299 116 35 222 35 11.8 atenolol-d7 
Tetracycline 445 428 20 
  
11.8 13C-Phenacetin 
Tilmicosin 869 696 61 174 55 11.8 carbamazepine-d10 
Sulfamethoxazole 254 156 25 92 41 12.5 sulfathiazol-d4 
Enalapril 377 234 29 303 35 12.5 diazepam-d5 
Propranolol 260 116 35 183 30 12.5 atenolol-d7 
13C-Phenacetin (IS) 181 139 23 
  
12.7 
 
Nifuroxazide 276 121 25 65 73 12.8 13C-Phenacetin 
Betaxolol 308 116 40 121 40 12.9 atenolol-d7 
Erithromycin 734 158 41 576 35 13.4 carbamazepine-d10 
Tylosin A 916 174 63 773 41 14.1 carbamazepine-d10 
Pravastatin 447 327 29 
  
14.2 carbamazepine-d10 
Paroxetine 330 192 31 123 45 14.4 fluoxetine-d5 
Carbamazepine-d10 (IS) 247 204 31 
  
14.5 
 
Clarithromycin 748 591 35 158 40 14.6 carbamazepine-d10 
Carbamazepine 237 194 29 
  
14.7 carbamazepine-d10 
Roxithromycin 838 158 49 679 31 15.1 carbamazepine-d10 
Fluoxetine 310 44 93 148 13 15.1 fluoxetine-d5 
Fluoxetine-d5 (IS) 315 153 13 
  
15.3 
 
Propyphenazone 231 56 57 189 35 15.3 carbamazepine-d10 
Flumequine (IS) 262 202 47 
  
15.4 
 
Josamycin 828 174 45 600 37 15.6 carbamazepine-d10 
Lorazepam 323 174 45 229 45 15.7 diazepam-d5 
Loratadine 383 337 33 267 47 17.5 carbamazepine-d10 
Diazepam 285 193 45 154 50 17.6 diazepam-d5 
Diazepam-d5 (IS) 290 198 43 
  
17.6 
 
Tamoxifen 372 72 43 327 35 19.4 carbamazepine-d10 
Atorvastatin 559 440 27 250 63 19.8 carbamazepine-d10 
Glibenclamide 494 369 23 169 55 20.7 carbamazepine-d10 
Phenylbutazone 309 77 77 160 29 20.7 carbamazepine-d10 
Mevastatin 391 185 19 159 39 21.5 carbamazepine-d10 
Fenofibrate 361 139 43 
  
25.2 diazepam-d5 
!
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(60 mg, Waters Corp., Milford, MA) and 3 mL disposable Lichrolut EN (200 mg,
Merck, Darmstadt, Germany). All the solvents were of reagent grade or higher.
Acetone, methanol, ethyl acetate were for pesticide analysis (Carlo Erba Reagents,
Italy), acetonitrile for LC-MS (Riedel de Haen, Seelze, Germany). Ammonium
hydroxide solution (25%), formic acid (98-100%) and triethylamine (99.5%) were
from Fluka (Steinheim, Germany). Hydrochloric acid (37%) was from Carlo Erba
(Milan, Italy). HPLC grade Milli-Q water was obtained with a MILLI-RO PLUS
90 apparatus (MILLIPORE, Molshelm, France).
A.3.1. Solid phase extraction
Waste and surface water samples were extracted as described in Castiglioni et al.
(2006), where detailed information on recoveries and performance of the methods
are reported. Briefly, water samples were filtered on glass microfiber filters GF/A
1.6 µm (Whatman, Kent, UK) and spiked with internal standards before extrac-
tion. The extraction was done on two SPE columns, an Oasis MCX at pH 2.0 for
amoxicillin, ciprofloxacin, l-floxacin/ofloxacin, lincomycin, sulphamethoxazole, van-
comycin, oleandomycin, oxytetracycline and tilmicosin, and a Lichrolut EN at pH
7.0 for clarithromycin, erythromycin, erythromycin-H2O, spiramycin and tylosin.
Wastewater and river water samples, respectively 50 and 500 mL aliquots, were
spiked with 20 ng of internal standards (salbutamol-D3 and ibuprofen-D3). The Oa-
sis MCX cartridges were conditioned before use with 6 mL methanol, 3 mL Milli-Q
water and 3 mL water acidified to pH 2. Samples were then passed through the car-
tridges under vacuum, and the cartridges were vacuum-dried for 5 min. Elution was
with 3 mL methanol, and 3 mL 2% ammonia solution in methanol. The Lichrolut
EN cartridges were conditioned before use with 6 mL methanol and 6 mL Milli-Q
water. Cartridges were vacuum-dried for 10 min and eluted with 3 mL methanol
and 3 mL ethyl acetate. All the eluates were pooled and dried under a nitrogen
stream. An ultrasonic solvent extraction (USE) was used for sludge samples ex-
traction as previously described for particulate (Castiglioni et al. (2006)). Sludge
(5 g) was extracted three times with 20 mL methanol, and after each extraction
step, the samples were centrifuged for 10 min at 6000 rpm. The supernatants were
finally pooled, dried under an air stream, redissolved in 100 µL Milli-Q water and
220
A.3. La Spezia analysis
filtered before analysis. The instrumental limits of quantification (IQL) were in the
hundreds pg/injected range, and the limits of quantification (LOQ) of the method
were in the low ng L−1 range (0.5-2 ng L−1).
A.3.2. HPLC-MS-MS analysis
Samples were analysed by reversed-phase liquid chromatography-tandem mass spec-
trometry (HPLC-MS-MS). Samples were analysed with an HPLC system consisting
of two Perkin-Elmer Series 200 pumps and a Perkin-Elmer Series 200 auto sampler,
and an API 3000 triple quadrupole (Q1q2Q3) mass spectrometer equipped with
a turbo ion spray source (Applied Biosystems-Sciex, Thornhill, Ontario, Canada).
A Luna C8 column 50mm× 2mm i.d., 3 µm particle size (Phenomenex, Torrance,
CA, USA) was used for chromatographic separation at a flow rate of 200 µL min−1.
Mass spectrometric analysis was done in the multiple reaction monitoring mode
(MRM), in negative (sulphamethoxazole) and positive ionisation modes (all the
other compounds). Quantification was by isotope dilution using ibuprofen-D3 for
sulphamethoxazole and salbutamol-D3 for the other antibiotics.
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APPENDIX B
Experimental campaigns carried out
This simple appendix was made in order to explain in only one table (see table B)
all the experimental investigation carried out in this Ph.D. research.
In fact, more than 6 experimental investigations weredeveloped in these years of
study and also in reading all the thesis perhaps some point results unclear, this may
be done from the frequent overlap of the experimentation periods.
It is possible to say that all the experimental section started in the final part
of 2007 with a first screening of Lagosanto HWWs. In this first experimentation
mainly macroparameters were analysed in order to understand the effective nature
of HWWs. In this phase also a focus on the main PhCs were done.
The subsequent step in the experimentation were obtained with the help of a lot
of partners that financed and helped all the different managing aspect. I want to
thank one more time all these different assistants.
Summarizing table B shown the site, the treatment step, the kind of waters and
the period of observation for the general aspect of each phase. Moreover it reports
all the searched and detected compounds for the PhCs analysis, all the samples
analysed and the kind of sample taken. At the end of the table, the last columns
shown all the partners involved in each specific research and the section where each
experimentation is explained in this thesis. In order to avoid a repetition of the
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different data table yet presented during the text, in this table are reported the
table number and page where we find the different analytical data, referring to the
specific experimentation.
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APPENDIX C
Analytical results on PhCs
This appendix shows all the analytical results on PhCs analysis done in the different
water matrix during the experimental section. For simplicity table C.1 resumes all
the kind of water where is possible to find some information about the specific topic.
Table C.1.: Summary of the total analytical data
Water Analytical data (page) Section (page)
Po River C.2 (228) 2.5.1 (35)
GW C.3 (229) 2.5.2 (37)
Wells C.4 (231) 2.5.2 (37)
Step of Ferrara water works C.5 (232) 2.5.3 (42)
Lagosanto HWWs C.6 (233) 3.6.1 (81)
Ferrara HWWs C.7 (235) 3.6.2 (84)
La Spezia WWs C.8 (237) 4.3 (114)
Ferrara WWTP Influent C.9 (238) 4.4 (121)
Ferrara WWTP Eﬄuent C.10 (240) 4.5 (127)or CW Influent
Ferrara CW Eﬄuent C.11 (242) 4.5 (127)
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Table C.2.: Po River waters (ng L−1)
Compounds 1st sample 2nd sample 3th sample
Acetaminophen 11 11 11
Atenolol 31 28 30
Butalbital – – 12
Carbamazepine 31 30 28
Clenbuterol 16 18 12
Diclofenac 34 33 57
Enoxacin 26 – 16
Erithromycin 22 – –
Hydrochlorothiazide 77 94 118
Ibuprofen 10 13 13
Lorazepam 28 24 14
Mefenamic acid 10 11 9
Metoprolol 16 18 12
Mevastatin 10 23 10
Naproxen 13 13 16
Norfloxacin 55 37 45
Paroxetine 32 16 20
Phenobarbital 14 – 23
Phenylbutazone 41 – –
Pravastatin 25 11 27
Propyphenazone 18 – –
Ranitidine 88 46 49
Salbutamol 15 18 12
Salicylic acid 30 41 39
Sotalol 70 80 84
Sulfadiazine 21 18 12
Sulfamethoxazole 12 10 19
Average 29 28 29
Sum 756 593 688
228
Table C.3.: GWs (ng L−1)
Compounds S1A S1B S2A S2B S3A S3B
Acetaminophen 34 44 28 52 49 65
Atenolol – – 112 – – 22
Butalbital 42 – – – – –
Carbamazepine – – – – 34 –
Chloramphenicol – – – – 20 –
Chlortetracycline – – 12 15 36 41
Ciprofloxacin – – – – – 21
Diclofenac 13 – – – – –
Doxycycline – – – 85 165 149
Enoxacin – – – – 11 12
Erithromycin 15 14 20 48 10 58
Fluoxetine 31 – 12 – 21 17
Indomethacine 1983 836 611 120 615 269
Ketoprofen 374 447 397 197 547 887
Lorazepam – – – 25 24 10
Mefenamic acid 162 135 88 70 103 38
Metoprolol 16 13 21 18 55 33
Metronidazole 38 36 19 13 61 64
Mevastatin 164 217 182 277 263 120
Naproxen 48 70 68 55 124 186
Nifuroxazide 11 63 24 25 23 92
Norfloxacin 10 – – – – 11
Ofloxacin 11 – 13 – 17 23
Oxytetracycline 32 18 13 47 70 93
Pentobarbital – 11 – 28 34 33
Phenobarbital 49 – – – – 15
Phenylbutazone – 11 52 – 21 20
Pravastatin 18 – 59 16 – 32
Propyphenazone – – – – – 13
Salicylic acid 30 33 37 42 37 39
Sotalol – – 15 – – –
Sulfadiazine – – – – 13 –
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Sulfamethazine – – 77 70 63 74
Sulfamethoxazole – – – – 10 12
Tetracycline – – – 21 28 99
Timolol – – – 10 21 18
Average 162 139 93 62 92 86
Sum 3080 1948 1858 1233 2477 2566
230
Table C.4.: Wells mixture waters (ng L−1)
Compounds Wells mixture
Carbamazepine 46
Erithromycin 19
Hydrochlorothiazide 41
Lorazepam 19
Norfloxacin 31
Paroxetine 27
Pravastatin 11
Ranitidine 63
Salicylic acid 35
Sulfamethazine 51
Average 34
Sum 344
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Table C.5.: DWs (ng L−1)
Compounds Lag. Clarifl. Ozon. AC filtr. DW
Atenolol 23 – – – –
Carbamazepine 31 24 – – –
Clenbuterol 30 17 – – –
Diclofenac 22 13 – – –
Enoxacin 12 10 – – –
Erithromycin 19 18 – – –
Hydrochlorothiazide 67 47 50 – –
Ibuprofen 13 – – – –
Lorazepam 17 16 11 – –
Metoprolol 30 17 – – –
Naproxen 16 – – – –
Norfloxacin 21 15 12 – –
Paroxetine 28 20 19 14 14
Phenobarbital 13 11 – – –
Phenylbutazone 29 – – – –
Pravastatin 19 – – – –
Ranitidine 173 21 12 18 –
Salbutamol 15 – – – –
Salicylic acid 31 32 40 44 28
Sotalol 71 62 – – –
Sulfamethoxazole 14 15 – – –
Average 33 23 24 25 21
Sum 694 339 145 76 42
232
Table C.6.: Lagosanto HWWs (ng L−1)
Compounds
Samples
1st 2nd 3th 4th
Acetaminophen 5906 5161 3722 3344
Atenolol 5044 3511 5767 6200
Atorvastatin 95 73 103 62
Azithromycin 11 108 – –
Betaxolol 13 12 – 20
Bezafibrate 2944 562 221 57
Butalbital 38 15 14 –
Carbamazepine 867 659 767 641
Chlortetracycline 50 20 20 63
Cimetidine 32 26 26 19
Ciprofloxacin 10510 11862 14723 9977
Clarithromycin 38 137 38 24
Clofibric acid 43 14 – 11
Codeine 258 358 432 396
Diclofenac 457 290 301 169
Doxycycline 193 136 97 266
Enalapril 269 151 199 186
Enoxacin 434 335 395 475
Erithromycin 164 114 319 62
Famotidine 90 183 290 87
Fenofibrate 11 – – 26
Fluoxetine – 18 – –
Furosemide 17667 15889 13367 10589
Gemfibrozil 19 18 18 20
Glibenclamide 69 48 97 85
Hydrochlorothiazide 1339 1409 2114 2127
Ibuprofen 1633 1526 2518 1017
Indomethacine 4064 2265 311 3199
Ketoprofen 9840 2553 5473 2240
Lisinopril 185 609 78 139
Loratadine 14 – – –
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Lorazepam 636 621 628 789
Mefenamic acid 178 497 364 301
Metoprolol 870 864 990 581
Metronidazole 483 433 328 1642
Mevastatin 717 971 383 1961
Naproxen 1213 2122 2831 3195
Nifuroxazide 2302 98 635 2556
Norfloxacin 45 63 103 55
Ofloxacin 12948 22244 20973 18257
Oxytetracycline 889 296 621 1319
Pentobarbital 74 22 11 33
Phenobarbital 29 27 – –
Phenylbutazone 38 10 47 54
Pindolol 263 78 112 32
Pravastatin 190 674 594 1039
Propranolol – 40 51 –
Propyphenazone 20 12 13 –
Ranitidine 244 1750 2200 1678
Salbutamol 103 50 51 42
Salicylic acid 1244 1983 1156 897
Sotalol 3798 4689 5940 4579
Spiramycin – 40 – –
Sulfadiazine 33 33 34 29
Sulfamethazine – 14 13 –
Sulfamethoxazole 3253 4250 6452 3004
Tetracycline 21 – 10 26
Tilmicosin 73 58 67 51
Trimethoprim 817 1322 1828 801
Average 1687 1631 1918 1688
Sum 92777 91326 97842 84420
234
Table C.7.: Ferrara HWWs (ng L−1)
Compounds
Samples
1st 2nd 3th 4th 5th
Acetaminophen 4658 3450 3390 1426 2793
Atenolol 2586 2208 6550 5650 5050
Atorvastatin 173 80 244 252 308
Azithromycin 46 50 577 769 1044
Bezafibrate – – 44 42 510
Butalbital 52 11 247 477 342
Carbamazepine 1183 758 1083 1008 748
Chlortetracycline 93 62 – – –
Cimetidine – – 37 33 265
Ciprofloxacin 1889 1379 14944 26167 23056
Clarithromycin 50 64 13500 9330 10000
Clenbuterol – – 1193 1108 862
Clofibric acid – – 12 14 –
Codeine 636 422 2080 3167 410
Diazepam – – 38 33 21
Diclofenac 271 176 527 527 476
Doxycycline 97 56 – – –
Enalapril 176 85 244 404 284
Enoxacin 105 58 189 181 448
Erithromycin 79 86 154 227 91
Famotidine 48 35 75 134 97
Fluoxetine 24 33 35 63 69
Furosemide 7717 6389 5297 6281 5719
Gemfibrozil – – 64 14 19
Glibenclamide 71 66 103 113 72
Hydrochlorothiazide 816 536 2331 2388 1838
Ibuprofen 813 380 3220 2419 2230
Indomethacine 895 3409 607 403 590
Ketoprofen 1417 829 1370 1765 1066
Lisinopril 337 89 – – –
Loratadine – – 20 15 26
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Lorazepam 198 167 640 698 464
Mefenamic acid 104 131 748 564 331
Metoprolol 970 507 1193 1108 862
Metronidazole 392 261 958 1057 853
Mevastatin 531 449 68 189 204
Naproxen 339 485 10867 2767 1077
Nifuroxazide 158 103 334 222 326
Norfloxacin 23 44 305 224 513
Ofloxacin 4049 3262 31769 36538 24538
Oxytetracycline 74 104 – – –
Paroxetine – – 76 69 56
Pentobarbital 14 24 149 122 110
Phenobarbital 27 13 358 256 131
Phenylbutazone 48 77 123 170 118
Pindolol – – 48 – 42
Pravastatin 64 77 269 154 81
Propranolol 94 76 61 37 30
Propyphenazone – – 98 – –
Ranitidine 1511 1077 1407 3586 4107
Roxithromycin – – 136 77 23
Salbutamol 27 27 99 140 123
Salicylic acid 1053 989 2413 2360 1906
Sotalol 352 613 6723 5193 3306
Spiramycin – – 62 108 34
Sulfadiazine 119 77 329 271 383
Sulfamethazine – – 27 13 30
Sulfamethoxazole 2670 900 3364 1733 936
Tilmicosin 14 16 123 318 348
Timolol – – 22 39 38
Trimethoprim 860 449 359 117 68
Average 807 652 2128 2228 1809
Sum 37923 30639 121306 122541 99473
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C. Analytical results on PhCs
Table C.9.: Ferrara WWTP influent (ng L−1)
Compounds
Samples
1st 2nd 3th 4th
Acetaminophen 498 839 763 1153
Atenolol 2100 1777 2080 2367
Atorvastatin 12 21 16 –
Azithromycin 330 20 92 –
Bezafibrate 115 71 63 111
Butalbital 72 251 101 110
Carbamazepine 300 488 1167 369
Chloramphenicol 22 16 13 24
Cimetidine 29 59 39 61
Ciprofloxacin 2100 1946 3700 1100
Clarithromycin 186 158 782 105
Clenbuterol 220 289 265 247
Codeine 86 92 100 150
Diazepam – 16 – –
Diclofenac 362 481 478 436
Enalapril 75 71 82 99
Enoxacin 81 108 130 90
Erithromycin 40 63 72 –
Famotidine 11 22 – 18
Fenofibrate – – 18 –
Fluoxetine 108 188 73 55
Furosemide 386 441 391 475
Gemfibrozil 281 169 156 197
Glibenclamide 96 81 85 88
Hydrochlorothiazide 1381 1673 5509 2323
Ibuprofen 959 928 1036 1181
Indomethacine 204 176 201 59
Ketoprofen 192 184 132 163
Loratadine – 20 18 –
Lorazepam 214 239 173 249
Mefenamic acid 1024 557 1138 894
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Metoprolol 220 289 265 247
Metronidazole 56 35 28 48
Mevastatin 161 275 133 122
Naproxen 828 906 782 814
Nifuroxazide 57 76 55 19
Norfloxacin 307 159 149 198
Ofloxacin 766 454 2222 574
Paroxetine 80 41 22 20
Pentobarbital 23 21 36 43
Phenobarbital 182 106 273 269
Phenylbutazone 129 130 98 67
Pindolol – – 11 –
Pravastatin 120 135 122 80
Propranolol 45 27 15 14
Propyphenazone 62 38 74 38
Ranitidine 116 93 128 108
Roxithromycin 139 49 62 –
Salbutamol 11 11 19 13
Salicylic acid 291 452 207 1044
Sotalol 369 614 517 637
Spiramycin 147 70 26 –
Sulfadiazine 13 25 26 24
Sulfamethazine 12 33 18 –
Sulfamethoxazole 385 278 735 375
Tilmicosin 218 304 460 21
Timolol 13 16 16 10
Trimethoprim 61 62 72 39
Average 302 288 454 353
Sum 16298 16138 25443 16946
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Table C.10.: Ferrara WWTP eﬄuent or CW influent (ng L−1)
Compounds
Samples
1st 2nd 3th 4th
Acetaminophen 58 23 27 12
Atenolol 711 976 703 546
Atorvastatin – – 14 –
Azithromycin 132 177 148 69
Bezafibrate 43 42 48 11
Butalbital 90 125 95 95
Carbamazepine 440 378 392 276
Cimetidine 29 49 32 12
Ciprofloxacin 623 516 1120 294
Clarithromycin 275 315 289 258
Clenbuterol 214 202 181 130
Codeine 70 82 61 52
Diclofenac 277 327 315 218
Enoxacin 97 31 65 50
Erithromycin – 13 33 –
Fenofibrate – – 13 –
Fluoxetine 63 – 47 62
Furosemide 342 326 346 83
Gemfibrozil 111 175 106 42
Glibenclamide 54 74 77 14
Hydrochlorothiazide 971 1418 1222 1049
Ibuprofen 106 117 91 –
Indomethacine 129 60 85 118
Ketoprofen 94 106 84 56
Lorazepam 136 119 142 82
Mefenamic acid 906 396 664 688
Metoprolol 214 202 181 130
Metronidazole 27 41 29 13
Mevastatin 127 40 136 27
Naproxen 199 208 205 100
Nifuroxazide 23 – 12 –
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Norfloxacin 159 165 149 137
Ofloxacin 359 523 479 215
Paroxetine 11 15 18 –
Pentobarbital 28 17 18 –
Phenobarbital 114 141 174 123
Phenylbutazone 59 37 60 51
Pravastatin 50 38 70 59
Propranolol 13 26 18 16
Propyphenazone 30 45 24 68
Ranitidine 74 104 90 44
Roxithromycin 17 34 53 13
Salbutamol 17 14 – 11
Salicylic acid 121 113 110 127
Sotalol 350 473 259 211
Spiramycin 22 50 31 19
Sulfadiazine 21 19 19 10
Sulfamethazine 15 11 11 –
Sulfamethoxazole 238 204 244 169
Tilmicosin 81 36 27 –
Timolol – 12 – –
Trimethoprim 37 51 36 37
Average 174 180 177 138
Sum 8374 8664 8853 5796
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Table C.11.: Ferrara CW eﬄuent (ng L−1)
Compounds
Samples
1st 2nd 3th 4th
Acetaminophen 21 18 – –
Atenolol 386 573 369 204
Azithromycin – – – 19
Bezafibrate 23 25 30 –
Butalbital 79 81 31 44
Carbamazepine 324 392 458 374
Cimetidine 21 38 23 11
Ciprofloxacin 292 147 302 91
Clarithromycin 266 311 299 185
Clenbuterol 159 180 179 129
Codeine 34 35 27 18
Diclofenac 284 278 332 190
Enoxacin 75 21 36 19
Fluoxetine 30 15 43 88
Furosemide 228 207 230 53
Gemfibrozil 110 128 76 24
Glibenclamide 42 52 53 22
Hydrochlorothiazide 634 309 520 267
Ibuprofen 53 48 74 –
Indomethacine 76 41 57 41
Ketoprofen 70 80 76 52
Lorazepam 104 114 132 72
Mefenamic acid 626 366 549 590
Metoprolol 159 180 179 129
Mevastatin 19 35 56 47
Naproxen 140 107 179 29
Norfloxacin 72 54 98 70
Ofloxacin 67 40 76 74
Pentobarbital – – 11 13
Phenobarbital 106 115 158 78
Phenylbutazone 13 22 24 34
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Pravastatin 15 17 37 36
Propranolol 11 – – –
Propyphenazone 69 35 45 –
Ranitidine 67 53 50 14
Roxithromycin 13 15 83 57
Salicylic acid 107 107 108 117
Sotalol 320 452 273 178
Spiramycin – 14 – 11
Sulfadiazine 13 23 26 18
Sulfamethoxazole 148 153 248 170
Trimethoprim 27 26 32 14
Average 136 123 144 97
Sum 5304 4925 5607 3581
Table C.12.: Sulfamethoxazole, Ciprofloxacin, Trimethoprim concentration (µg L−1)
in Ferrara CW during the final experimental campaign
Date Sul Cipro Trim
In Out In Out In Out
30 March 2010 43 62 3.55 0.52
01 April 2010 59 65 1.96 0.42
02 April 2010 283 65 4.02 0.54
06 April 2010 45 98 2.04 0.34
07 June 2010 48 64 1.57 0.3
08 June 2010 355 44 1.26 0.32
19 May 2010 29 33 4.09 0.17 8 3
20 May 2010 31 10 0.97 0.11 7 3
21 May 2010 14 18 0.49 0.18 4 2
22 May 2010 24 14 0.44 0.1 12 3
26 June 2010 26 16 0.47 0.11 20 6
27 June 2010 36 104 0.26 0.07 16 6
Average 83 49 1.76 0.27 11 4
Sum 993 593 21.12 3.18 67 23
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APPENDIX D
Publications
This appendix reports all the scientific publications made in these research years.
Not all the work done in these years were about PhCs because other research ac-
tivities were open in the Sanitary and Environmental Engineering group at the
Department of Engineering of Ferrara.
In particular some paper were about the concept of water reuse using natural
treatment and other paper treated specifically concept like PhCs and hospital, the
real aim of this thesis.
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Abstract
The availability of freshwater to meet different water needs has raised serious concerns in the last decades all
around the world. Water scarcity, deterioration of quality and increasing demand have led to the development and
use of alternative sources of water. Reclamation and recycling are now considered as key components of water and
wastewater management policies around the world. In this context, the adoption of soft wastewater treatments with
a minimum use of chemical agents and having minimum environmental impact is widely encouraged.
An experimental campaign was carried out on a pilot plant which consisted of a two-stage disinfection system
for a secondary biological effluent. Disinfection consisting of a chemical step (mild chlorination) followed by a
natural one (filtration through a horizontal subsurface flow (HSF) bed) was tested in order to evaluate the possi-
bility of producing a final effluent adequate for agricultural reuse.
The investigation has shown that this combined system, with low doses of NaClO (2 mg L!1 of disinfectant
and a retention time of 30 min, corresponding to an applied dose of 2 " 30 = 60 mg L!1 min!1) and a well
designed final subsurface flow system (at least 1 m2 EI!1) is able to obtain an effluent complying with reuse qual-
ity limits, in particular for microbiological parameters.
For HSF design parameters, neither filling material, aspect ratio nor vegetation type (Phragmites australis and
turf) caused significant differences in the average levels of COD, suspended solids, NH4, total phosphorus and
Escherichia coli concentrations in the effluent.
Finally in order to protect HSF bed from substrate clogging and to prolong its working life, a rapid sand filter was
placed before the bed and its impact analyzed. It was demonstrated that the filter was able to retain occasional but
unavoidable activated sludge carry-overs from the secondary clarifier which otherwise would rapidly accumulate in
the front region of the bed resulting in poor performance (overflows and medium clogging) in quite short time.
Keywords: Disinfection; Experimental investigation; Polishing chemical and natural treatment; Reuse; Clogging
prevention
*Corresponding author.
0011-9164/09/$– See front matter ! 2009 Elsevier B.V.
doi:10.1016/j.desal.2009.03.004
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Figure D.1.: Verlicchi, P., Galletti, A., Masotti, L.: A promising practice to reclaim
treated wastewater for reuse: Chemical disinfection followed by natural
systems. Desalination 247 (2009), 490-508
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Management of hospital wastewaters: the case of the
effluent of a large hospital situated in a small town
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Hospitals are the main source of pharmaceutical compounds (PhCs) released into the
environment. Generally, their discharges are co-treated with domestic wastewaters, resulting
in a decrement of the recalcitrant compound concentrations in the final effluent due to water
dilution. However, as many PhCs resist normal treatments, pollutant load does not change.
This paper compares the chemical characteristics of hospital and domestic wastewaters on
the basis of an experimental investigation for macro-pollutants and literature data for PhCs.
A membrane biological reactor pilot plant fed by a hospital effluent is tested in order to evaluate
the feasibility of treating these kinds of wastewaters with membrane systems. The paper then
presents the possible scenarios in the management of the effluent of a large hospital situated in
a small town. In particular, it reports on a case study of designing a (new) treatment plant for the
effluent of the 900 bed hospital in Ferrara, Northern Italy, located on the outskirts of the town.
Finally, costs for the intervention are given.
Key words | best technologies, costs analysis, domestic wastewaters, experimental investigation,
hospital wastewater, pharmaceutical compounds
INTRODUCTION
Hospital wastewaters (HWws) are composed of the
effluents of three different services: (i) general services
(kitchen, internal laundry, heating and cooling systems),
(ii) diagnostic services (laboratories, radiology departments,
outpatient departments, transfusion centres) and (iii) wards
(general medicine, surgery, specialities, haemodialysis, etc.).
In Italy and in many other countries, by law, the effluents
from specific wards or services (such as nuclear medicine or
histological laboratories) that contain radioactive wastes or
anatomical parts cannot be discharged into the hospital
sewage network, but must be collected in adequate hermetic
baskets and given to authorized disposal firms (Emilia
Romagna Region Guidelines 2009).
By law, HWws are often considered to be of the same
pollutant nature as domestic wastewaters (DWws), and so
they are generally discharged into (municipal) sewer net-
works, collected at a wastewater treatment plant (WWTP)
and treated along with DWws. The only pre-treatment
that could be required before entering the sewer is a
mild chlorination of the whole effluent in order to reduce
its microbiological load.
WWTPs were originally built, and have more recently
been upgraded, with the aim of removing carbon, nitrogen
and phosphorus compounds in addition to the microbiolo-
gical organisms which are the pollutants regularly arriving
at the plant in concentrations to the order of mg/L and at
least 105CFU/100ml. HWws represent a unique kind of
wastewater due to the nature and quantity of the micro-
pollutants which are typically present at mg/L: active
substances of medicines and their metabolites, chemicals,
heavy metals, disinfectants and sterilizers, radioactive
markers, (Emmanuel et al. 2001; Kummerer 2001; Altin
et al. 2003; Jones et al. 2005). Moreover, HWw flow
rates generally amount to only a small percentage of the
doi: 10.2166/wst.2010.138
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Figure D.2.: Verlicchi, P., Galletti, A., Masotti, L., Management of Hospital
Wastewaters. The case study of the Eﬄuent of a Large Hospital Sit-
uated in a Small Town, Water Science and Technology, 61.10 (2010),
2507-2519
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s u m m a r y
Hospital wastewaters contain a variety of toxic or persistent substances such as pharmaceuticals, radio-
nuclides, solvents and disinfectants for medical purposes in a wide range of concentrations due to labo-
ratory and research activities or medicine excretion. Most of these compounds belong to the so called
emerging contaminants; quite often unregulated pollutants which may be candidates for future regulation
depending on research on their potential health effects and monitoring of their occurrence. Their main
characteristic is that they do not need to persist in the environment to cause negative effects since their
high transformation/removal rates can be compensated for by their continuous introduction into the
environment.
Some of these compounds, most of them pharmaceuticals and personal care products may also be pres-
ent in urban wastewaters. Their concentrations in the effluents may vary from ng L!1 to lg L!1.
In this paper, hospital effluents and urban wastewaters are compared in terms of quali–quantitative
characteristics. On the basis of an in-depth survey: (i) hospital average specific daily water consumptions
(L patient!1 day!1) are evaluated and compared to urban ones (L person!1 day!1), (ii) conventional
parameters concentrations in hospital effluents are compared to urban ones and (iii) main pharmaceuti-
cals and other emerging compounds contents are compared in the two wastewaters. Finally, an overview
of the removal capacity of the different treatments is reported.
! 2010 Elsevier B.V. All rights reserved.
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This study investigated the accumulation and removal of Cu, Ni and Zn in two horizontal subsurface ﬂow
constructed wetlands for domestic wastewater treatment, which differ by shape, presence of macrophytes
and water depth. Between March and December 2007, the three metals were measured in the inﬂuent and
efﬂuents of the two systems. Average percentage removal rates were extremely low for Cu (3% and 9% in the
two beds) and higher for Zn and Ni (between 25 and 35%). Under higher Zn inﬂuent concentrations, it was
found to be between 78–87%, which is in agreement with other literature data.
During the peak standing crop season (August), biomasses of the different parts of Phragmites australis
(stems, leaves and ﬂowers, roots and rhizomes) were analysed in terms of weight and heavy metal
concentration in order to assess heavy metal distribution among the tissues. It was found that the plants
contribute to total heavy metal removal to a lesser extent than the ﬁlling medium. Aboveground tissues
remove 34% of Cu, 1.8% of Ni and 6.2% of Zn % and, once harvested, their disposal does not appear to pose a
problem for the environment. If heavy metals are present at high concentrations in the horizontal subsurface
ﬂow bed inﬂuent, over time, their accumulation in the ﬁlling medium could necessitate special care in the
bed's management to avoid release into the surrounding environment.
© 2010 Elsevier B.V. All rights reserved.
1. Introduction
Constructed wetlands with a horizontal subsurface ﬂow (H-SSF)
are commonly used for domestic wastewater treatment, but there are
further applications for other types of wastewaters such as efﬂuents
from food processing, abattoirs, pulp and paper production, and
textile industries as well as municipal solid wastes (MSW) landﬁll
leachate. In general, H-SSF systems are extensively monitored for
macropollutants, including BOD5, COD, suspended solids, nitrogen
and phosphorus compounds and bacteria (Kadlec and Knights, 1996;
Vymazal et al., 1998; Sundaravadivel and Vigneswaran, 2001).
Fewer studies have looked at trace elements in H-SSF systems,
although lately there has been a growing interest in evaluating such
systems ability and reliability in removing micropollutants, particu-
larly heavy metals (HMs), from domestic and industrial wastewaters
(Scholz and Xu, 2002; Vymazal and Krasa, 2003; Ranieri, 2004), MSW
landﬁll leachate (Peverly et al., 1995; Yalcuk and Ugurlu, 2009), and
acid mine drainage (Mays and Edwards, 2001; Deng et al., 2004).
In recent years, some studies have investigated the behaviour of
plants in the presence of HMs. Among them, Miretzky et al. (2004)
and Hassan et al. (2007) examined the removal rates of some
elements, Drost et al. (2007) investigated the toxicity of HMs on
plants, Dunbabin and Bowmer (1992) analysed the use of these plants
as bioﬁlters for polluted waters, Cardwell et al. (2002) evaluated
biomonitoring of metals, Deng et al. (2004) and Mishra et al. (2008)
investigated HMs uptake by duckweed (Lemnaminor), water hyacinth
(Eichoria crassipes), Salix, cattail (Typha latifolia) and common reed
(Phragmites australis).
The HM concentration ranges vary depending on the origin of the
wastewaters. Table 1 shows the observed ranges of HMs concentra-
tions in raw domestic and industrial wastewaters (mainly reﬁnery,
chemical and plastic factories), in different types of surface runoff
(parking areas, roofs, roads), MSW landﬁll leachate, and acid mine
drainage.
The main difﬁculty in treating wastewaters containing HMs is due
to the fact that they cannot be destroyed or degraded. HMs can
accumulate in binding sites within the ﬁlling medium or precipitate
during their passage through the plant.
H-SSF beds are dynamic micro-systems in which many physical,
chemical and biological mechanismsmay occur simultaneously. These
mechanisms are strictly correlated to ﬁlling medium conditions (i.e.:
structure, chemical composition, bioﬁlm and sediments character-
istics), environmental conditions (mainly aerobic/anaerobic/anoxic
conditions, temperature and pH), and operational conditions (mainly
water chemical characteristics and ﬂow rate) which may change over
time.
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Abstract A new index, the Wastewater Polishing
Index (WWPI), has been defined for the rapid
assessment of the quality achieved by different
polishing treatments for water discharged into sur-
face water bodies and for reuse purposes. The
index is defined by a weighted average of six pa-
rameters (SS, BOD5 COD, ammonia, total phos-
phorus, and E. scherichia coli), each transformed
onto a sub-index scaled from 0 to 100. E. coli
has been assigned a greater weight than the other
indicators. The index is equal to 0 if none of the
six pollutants are present in the effluent and to 100
when all six parameters equal their corresponding
Italian legal limits for discharge into surface water
bodies. When all six of them equal their corre-
sponding Italian legal limits for reuse, the WWPI
is 36. The index has been validated and tested on a
pilot plant including a rapid sand filtration, a slow
filtration through a horizontal subsurface flow sys-
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tem and a lagooning, in addition to their com-
binations. The experimental investigation showed
that the index is a good tool for (1) rapidly com-
paring the water quality achieved by different
treatment sequences, particularly natural systems;
(2) rapidly evaluating whether the proposed se-
quence is able to produce an effluent adequate
for reuse; and (3) rapidly evaluating the water
quality improvement achieved by different sys-
tems. The proposed index could be of great help
for managers and decision makers when planning
for water resources, in particular, for comparing
the quality level achieved by different wastewater
treatment sequences.
Keywords Experimental validation ·
Natural treatments · Polishing treatments ·
Reuse · Sensitivity analysis ·
Water quality index
Introduction
A water quality index is a unitless number that
ascribes a quality value to an aggregate set of mea-
sured chemical, physical, and microbiological pa-
rameters. Generally, water quality indices consist
of sub-index scores assigned to each parameter
by comparing its measurement with a parameter-
specific rating curve, optionally weighted and
Author's personal copy
Figure D.5.: Verlicchi P., Masotti L., Galletti A., Wastewater Polishing Index: a tool
for a rapid quality assessment of reclaimed wastewater, Environmental,
Monitoring and assessment, 173 (2011) 267-277
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